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CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Chronic obstructive pulmonary disease (COPD) is a common, preventable and 
treatable disease characterised by relentless respiratory symptoms and airflow 
limitation that is due to airway and/or alveolar aberrations usually triggered by 
significant exposure to noxious gases.
1
 Diagnosis of COPD should be considered in 
subjects with respiratory symptoms such as difficulty in breathing (dyspnoea), chronic 
cough, excessive sputum production and history of tobacco use,
2
 although 
occupational and indoor air pollution also contributes to the disease onset.
3
 There is 
accumulating evidence that early-life exposures and impaired lung development play 
a central role in the pathophysiology of the disease in a significant proportion of 
patients.
4
 COPD is a leading cause of morbidity and mortality worldwide. It was the 
third leading cause of disability-adjusted life years among non-communicable 
diseases, according to the Global Burden of Disease Study 2017.
5
 COPD is projected 
to hold an equal position among the leading causes of death worldwide in 2030.
6,7
 It 
also places a very high burden on the health system.
11
 Additionally, the disease is 
associated with tremendous social and economic impact.
8
 In the European Union, 
COPD accounts for 38.9 billion euros and 52.4 billion dollars in direct and indirect 
costs annually in the United States (U.S).
9,10
  
 
DIAGNOSIS AND CLASSIFICATION OF COPD 
 
Spirometry is the current tool for COPD diagnosis. Post-bronchodilator forced 
expiratory volume-one second/forced vital capacity (FEV1/FVC) <0.70 confirms the 
presence of airflow limitation and the diagnosis of COPD in symptomatic individuals.
1
 
The severity of airflow limitation is classified according to the FEV1 as percentage of 
predicted. The Global Initiative for Obstructive Lung Disease (GOLD) categorises 4 
spirometric stages: 
 GOLD 1 - mild: FEV1 ≥  80% predicted  
 GOLD 2 - moderate: 50% ≤ FEV1 < 80% predicted  
 GOLD 3 - severe: 30% ≤ FEV1 < 50% predicted  
 GOLD 4 - very severe: FEV1 < 30% predicted.1  
It is well recognised that the degree of airflow limitation is a poor predictor of 
patient-related outcomes in COPD. There is a substantial overlap in dyspnoea, health 
status and exercise capacity between patients in different spirometric GOLD stages.
12
 
Thus, the burden of disease cannot be predicted from the severity of lung impairment 
alone.
1
 To provide a more integrated diagnosis of the disease, the GOLD strategy 
adopted a composite COPD assessment approach to group patients based on 
symptoms and previous history of exacerbations or hospitalisations. Symptoms are 
assessed using the Modified British Medical Research Council (mMRC) or COPD 
assessment test (CAT) scale.
1
 The mMRC is a simple measure of breathlessness 
resulting in a score from 0-4, while CAT is an eight-item measure of health status 
impairment in COPD patients and ranges from 0 to 40.
1
 According to symptoms and 
risk of exacerbations, patients are classified as: 
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 Group A: low risk (0-1 exacerbation per year, not requiring 
hospitalisation) and fewer symptoms (mMRC 0-1 or CAT <10)  
 Group B: low risk (0-1 exacerbation per year, not requiring 
hospitalisation) and more symptoms (mMRC≥ 2 or CAT≥ 10)  
 Group C: high risk (≥2 exacerbations per year, or one or more requiring 
hospitalisation) and fewer symptoms (mMRC 0-1 or CAT <10)  
 Group D: high risk (≥2 exacerbations per year, or one or more requiring 
hospitalisation) and more symptoms (mMRC≥ 2 or CAT≥ 10).1 
EXACERBATIONS 
 
The natural course of COPD is characterised by acute events, referred to as 
exacerbations, which are defined as the acute worsening of a patient’s symptoms 
beyond normal day-to-day variations that require additional pharmacotherapy.
1
 
Exacerbations of respiratory symptoms are frequently triggered by bacterial or viral 
infections,
13
 although in recent years different biological exacerbation clusters have 
been identified.
14
 During exacerbations, there is an increased hyperinflation and gas 
trapping with reduced expiratory flow, thus resulting in increased dyspnoea.
15
 
Exacerbations of COPD have a considerable impact on health status,
16
 lung 
function,
17
 and exercise capacity.
18
 Also, they are associated with substantial mortality 
and economic impact. Mortality rates of 22 to 43% after 1 year and 36 to 49% after 2 
years following hospitalisation for COPD have been reported.
19
 Exacerbations are 
responsible for approximately 1.5 million emergency department visits and 700,000 
medical admissions annually in the U.S.
20
 Given the central role of exacerbations in 
the pathophysiology of the disease, prevention of exacerbations is one of the 
fundamental treatment goals in COPD management. To prevent these events, it is 
important to understand the demographic, biochemical, clinical and other factors that 
predict exacerbations in individual patients. Smoking, air pollution, severe airflow 
limitation, a history of prior exacerbations and comorbidities are well-recognised risk 
factors and triggers for exacerbations
21
 but are insufficient to predict which individuals 
with COPD will have exacerbations and when. 
 
PHARMACOLOGIC MANAGEMENT OF STABLE COPD  
 
The goal of management of patients with COPD is to reduce symptoms, improve 
exercise tolerance, health status and decrease the frequency and severity of 
exacerbations.
1
 There is currently no evidence from clinical trials has shown any 
existing drug treatment capable of modifying lung function decline in the long-term or 
reducing mortality risk.
22–24
 Various classes of drugs are used in the treatment of 
COPD, including bronchodilators, inhaled corticosteroids (ICS), oral glucocorticoids, 
phosphodiesterase-4 (PDE-4) inhibitors, methylxanthines, and antibiotics.
1
 Most drugs 
used in the treatment of COPD are administered as inhalers. GOLD 2017 proposed a 
model for the initiation and subsequent escalation and de-escalation of pharmacologic 
management based on the assessment of patient symptoms and exacerbations risk.
25
 
However, with the introduction of GOLD 2019, this treatment scheme has now 
changed.
1
 
Bronchodilators include short-acting beta2-receptor agonists (SABAs) and 
(ultra) long-acting beta2-receptor agonists, (LABAs or ultra-LABAs) act by binding to 
Chapter 1 
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the beta2-receptors in the airways subsequently increasing cyclic-AMP resulting in 
bronchorelaxation.
1
 They are recommended for the treatment of COPD patients with 
mild or moderate disease. Antimuscarinic agents act by blocking the brochoconstrictor 
effect of acetylcholine on the M3 muscarinic receptors resulting in relaxation of the 
airway smooth muscles.
26
 There are also short (e.g. ipratropium) and long acting (e.g. 
tiotropium and aclidinium) antimuscarinic agents (SAMAs and LAMAs). Short acting 
bronchodilators usually have a duration of action of 4 to 8 hours,
27
 and are used as 
needed to improve patients symptoms and lung function.
28
 Long-acting 
bronchodilators are the mainstay of pharmacological treatment of patients with 
COPD,
25
 either as monotherapy or in combination of LABAs and LAMAs. These 
medications bring about bronchodilation by different mechanisms and provide 
synergistic benefits.
2
 The efficacy of these drugs in improving lung function, quality of 
life, and exercise tolerance as well as in reducing COPD exacerbations is well 
established.
1
 
Traditionally, ICS and systemically administered glucocorticoids (GCs) have 
played a central role in COPD management. Although the exact mechanism of action 
of ICS is still debated,
29
 it is well established that they possess an anti-inflammatory 
effect.
30
 It is recommended that ICS therapy be combined with LABAs or LAMAs, in 
response to uncontrolled exacerbations.
21
 The use of ICS alone was found to have no 
effect on long-term FEV1 decline or mortality in COPD patients.
31
 However, in patients 
with moderate to severe exacerbations ICS combined with LABAs were found to be 
more effective than either of the agents alone in reducing exacerbations and lung 
function decline.
32
 In addition to clinical benefits, ICS has been associated with 
significant adverse effects, including the risk of fractures,
33
 skin bruising and oral 
candidiasis.
34
 The Pharmacovigilance Risk Assessment of the European Medicines 
Agency (EMA) acknowledged that ICS treatment further increased the risk of 
pneumonia among COPD patients.
35
 Targeting patients who will benefit from 
corticosteroid therapy is important, as it may help in reducing ICS-related side effects 
and treatment costs.
36
 The main factors known to increase the risk of pneumonia 
among patients treated with ICS include older age (>55 years), a body mass index 
(BMI) (<25kg/m
2
), greater severity in airflow limitation, prior history of exacerbation 
and low blood eosinophil counts.
37
 Despite recommendations in clinical guidelines, 
ICS are still overprescribed among COPD patients.
37
 
During exacerbations of the disease, systemic GCs are prescribed in order to 
shorten recovery time and improve lung function. They also improve oxygenation and 
reduce the risk of early relapse, treatment failure and the length of hospitalisation.
1
 
Systemic GCs are not recommended in the treatment of stable COPD, and exposure 
is known to be associated with high risks of systemic adverse effects,
1
 including the 
risk of skin bruising and oral candidiasis.
33
 Other studies have reported an increased 
risk of fractures with corticosteroid use.
38,39
 Van Staa et al conducted a retrospective 
cohort study, which included over 200,000 patients exposed to oral corticosteroids 
and an equal number of controls with a mean age of 57, years and discovered that 
patients exposed to higher daily and cumulative doses of oral corticosteroid had an 
increased risk of vertebral, forearm hip and non-vertebral fractures.
40
 Three dose 
categories were assessed: low dose (less than 2.5 mg/day), medium (2.5-7.5 
mg/day), and high dose (7.5 mg/day or more).  However, these dose stratification 
does not provide a clear insight into the effect of GCs among patients with COPD 
considering that a dose of 40mg daily for 5 days is recommended in the treatment of 
severe exacerbations.
41
 While the effects of oral GCs on fracture risks in COPD are 
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well documented,
42
 only one study has explored high-dose intermittent use of GCs 
and risk of fractures among COPD patients
43
 prior to this Ph.D. thesis. Consequently, 
more studies are required among COPD patients to further understand the impact of 
intermittent use of corticosteroids using appropriate comparator groups. 
In recent years, other pharmacological treatments aimed at reducing 
exacerbations have been introduced in COPD management, including roflumilast (a 
PDE-4 inhibitor) for patients with severe disease and a bronchitic phenotype,
44
 and 
macrolide antibiotics for non-smoking patients with refractory exacerbations despite 
inhaler therapies.
45–47
  
 
BIOMARKERS 
 
A biomarker is defined as a measure of any molecule or material, which could be 
either cells or tissues that reflects a disease process.
48
 The essential roles of 
biomarkers in health include; enhancing disease diagnosis, monitoring of disease 
prognosis, and guiding therapy, with the aim of improving patient outcomes and 
reducing potential side effects of treatments.
49,50
 For biomarkers to play a vital role in 
improving the management of patients, they must possess several properties: 1) a 
biological role in the pathogenesis of the disease, 2) easy to accurately measure, 3) 
sensitive to changes in order to enable repeatability, 4) modifiable by therapeutic 
interventions, 5) retain a long half-life, 6) and associated with outcome.
51
 Additionally, 
they have to be relevant, sensitive and specific to the disease or condition, reliable to 
be used in different settings, clinically interpretable, simple and cost-effective to 
deploy.
52,53
 
Over the last decades, there has been increasing interest in the potential role 
of biomarkers in COPD. For example, the Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate End-points (ECLIPSE) study, which was a 3-year multi-
centre study, aimed to measure biomarkers in blood, urine, sputum and breath 
condensate in order to identify clinically relevant COPD subtypes and relate these 
biomarkers to markers of disease progression.
54
 Among the biomarkers assessed, C-
reactive protein (CRP), fibrinogen, and serum interleukin-6, met the validation 
criteria.
55
 A review of the current state of biomarkers in COPD reported that changes 
in biomarker levels indeed predicted important outcomes such as exacerbations and 
mortality.
56
 Fibrinogen was one of the most promising biomarkers reported to be 
associated with the risk of COPD, disease progression and death.
57
 However, early 
investigations observed no significant relationship between plasma fibrinogen and 
decline in lung function.
58
 Furthermore, researchers found a weak association 
between fibrinogen and mortality, on the other parameters fibrinogen was 
outperformed by other biomarkers.
58
 Findings on fibrinogen as a diagnostic biomarker 
for exacerbations have been mixed and variable. In addition, the high variation around 
the mean values have suggested that fibrinogen is probably not a suitable biomarker 
for COPD management.
60
 
More recently, a number of studies have investigated blood eosinophil counts 
as a potential biomarker of interest in COPD management.
61–65
 Eosinophils are 
derived from progenitor stem cells in the bone marrow and released into the blood 
upon maturity. They play a central role in homeostasis and disease pathogenesis in 
various tissues, including the lungs.
61
 Blood eosinophil concentration is reported as an 
absolute count (cells/µL) or as a percentage of total leukocytes.
61
 The interest in its 
potential use was heightened by a large cohort study, which showed that elevated 
Chapter 1 
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blood eosinophil count was associated with an increased risk of exacerbations.
62
 Also 
post-hoc analyses from the TRial of Inhaled STeroids ANd long-acting beta2-agonists 
(TRISTAN) and Investigating New Standards for Prophylaxis in Reducing 
Exacerbations (INSPIRE) trials (n=2,672) showed that COPD patients with blood 
eosinophil counts ≥2% had a reduced exacerbation risk compared to patients with 
blood eosinophil counts <2% when treated with ICS containing treatments compared 
to patient without ICS therapy.
63
 However, in the SCO30002 study no significant 
difference was found between patients with blood eosinophil counts ≥2% versus 
<2%.
63
 Post-hoc analyses of the WISDOM trial showed that withdrawal of ICS 
resulted in increased risk of exacerbations at blood eosinophil counts of ≥4% or ≥300 
cells/µL.
64
 Other researchers have also reported that COPD patients with elevated 
blood eosinophil counts had lower risk of exacerbations when treated with ICS 
compared to patients without elevated eosinophil counts.
65
 However, a randomized, 
double-blind trial which included over 2000 COPD patients with mean age of 64 
years, followed for 52 weeks, found that ICS/LABA combination was inferior to 
LABA/LAMA combination in exacerbation reduction, even among patients with 
elevated blood eosinophil counts.
66
 With these conflicting findings, it is important to 
further explore the role of blood eosinophil counts as a biomarker in a general practice 
setting. This will ensure directing ICS therapy to patients who will potentially benefit 
from its use, reducing the possibility of adverse side effects, especially within general 
practice. Researchers have questioned what exact blood eosinophil cut-off value 
should be used to predict patients who will potentially benefit from ICS therapy.
64
 
Further, for blood eosinophils to be recognised as a reliable biomarker for ICS therapy 
among COPD patients, it is critical that the stability of this biomarker is established.  
While the role of blood eosinophil counts for biomarker-guided use of ICS 
among COPD patients is mounting, C-reactive protein (CRP) is another biomarker of 
significant interest in COPD management. It is produced in the liver and is known to 
bind to the receptors of the phagocytes and plays a role in apoptosis and necrosis.
67
 
CRP is generally indicated as a biomarker for systemic inflammation, which is 
considered a risk factor for morbidity and mortality. In stable COPD, increased CRP is 
found to be independent of other risk factors for COPD such as smoking.
68
 Elevated 
CRP level has been associated with an increased risk of exacerbations requiring 
hospitalisation and with an increased risk of COPD mortality.
51
 The use of CRP as a 
biomarker of response to treatment and the impact of pharmacotherapies on CRP 
levels is controversial. A randomised placebo-controlled trial conducted among COPD 
patients previously exposed to ICS found that withdrawal from ICS resulted in 
increased CRP levels by 71%, whereas after 2 weeks of ICS therapy, CRP levels 
reduced by 50%, but no change was observed in the placebo arm.
69
 A double-blind 
placebo-controlled study showed that exposure to inhaled fluticasone suppressed the 
levels of CRP and withdrawal of therapy increased CRP levels.
70
 Additionally, Pinto et 
al,
68
 employing cross-sectional analysis of a cohort study showed that CRP levels 
were lower in COPD patients treated with ICS. The role of biomarkers including blood 
eosinophils and CRP in the management of COPD needs to be systematically 
evaluated before they can be implemented in personalised disease management. The 
use of a single biomarker to help in guiding therapy is deemed a “one-eyed” 
approach, as such evaluating several biomarkers has the potential of increased 
precision-guided treatment decisions among patients with COPD.
71
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AIM OF THIS THESIS 
 
From this introduction, it is clear that COPD is a multicomponent and unpredictable 
disease. Disease classification is no longer based on the severity of airflow limitation 
only, but also on symptoms and risk of exacerbations. However, current disease 
management is limited by the inability to predict the course of the disease, and 
response to pharmacological treatments. Biomarkers can contribute to personalised 
disease management by stratifying patients according to risk profiles, and predicting 
response to therapy. Indeed, several biomarkers have been proposed in COPD 
management, but have not been extensively investigated in a real-life setting. Since 
exacerbations play a pivotal role in the burden of COPD, and for the wider society, 
thus they are considered crucial outcomes of disease management. Therefore, the 
aim of the current thesis was to evaluate the potential role of blood eosinophils and 
CRP as biomarkers for predicting exacerbations response to ICS among patients with 
COPD in the general population. 
 
 
OUTLINE OF THIS THESIS 
 
Chapter 2 explores trends in moderate and severe exacerbations among COPD 
patients in the UK from 2005 to 2013. 
Chapter 3 provides insight on the stability of blood eosinophil counts among COPD 
patients and the impact of age, sex, smoking status and baseline blood eosinophil 
counts within the UK general practice. 
Chapter 4 evaluates the risk of moderate-to-severe exacerbations, severe 
exacerbations and all-cause mortality among COPD patients exposed to ICS, 
stratified by CRP tertiles. 
Chapter 5 explores the risk of acute exacerbations, hospitalisations/accident and 
emergency visits, and all-cause mortality among COPD patients with specific absolute 
or relative blood eosinophil counts cut-offs. 
Chapter 6 investigates the impact of blood eosinophil counts on the withdrawal of ICS 
and the risk of moderate-to-severe exacerbations, severe exacerbations, and all-
cause mortality among COPD patients and the impact of blood eosinophil counts. 
Chapter 7 evaluates the impact of intermittent high-dose glucocorticoid use on 
fracture risk among patients with COPD, the impact of proxy indicators of disease 
severity and the effect of dose in the Danish population. 
Chapter 8 discusses previous chapters, methodological considerations, the future 
direction for research and clinical practice. 
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ABSTRACT  
 
Introduction: Exacerbations of chronic obstructive pulmonary disease (COPD) is 
characterised by increased symptoms such as dyspnoea, cough and sputum 
production and/or purulence, leading to greater risk of hospitalisation and mortality. 
Very few studies have measured long term trends in the incidence of exacerbations of 
COPD. We therefore investigated the incidence of moderate and severe 
exacerbations in the United Kingdom (UK) general population. 
 
Methods: A population based-study including Clinical Practice Research Datalink 
(CPRD) patients ≥ 40 years with a current diagnosis of COPD within the UK from 
2004 to 2013 was conducted. Individuals with a history of asthma were excluded from 
main analyses. We calculated the incidence rates for any, moderate, and severe 
exacerbations. The incidence rates for any, moderate and severe exacerbations for 
COPD in each calendar year were calculated as follows: the sum of any or moderate 
or severe exacerbations for COPD in that year divided by the total duration of follow-
up in the same calendar year from 2005 through to 2013.  We then analysed these 
rates by gender and age categories (40-59 years, 60-79 years and ≥80 years).  
 
Results: Among 213,561 patients with an incident COPD diagnosis, 86,300 patients 
were included in the study. From 2005 to 2013, the incidence rate of any 
exacerbations increased from 89 to 98 per 1000 person-years (PYs) (p=0.005). 
Women had significantly higher incidence rates of any exacerbation for each calendar 
year when compared to men (p<0.0001). The incidence rate of any and moderate 
exacerbations increased with age from 2005 to 2007. For severe exacerbations 
incidence decreased from 2005 to 2007 before increasing from 2008 until the end of 
follow-up (43 per 1000 PYs (95% confidence interval, 42-45/1000PYs) in 2013). 
Incidence rates of severe exacerbations were similar by gender and patients aged 
80+ years had higher incidence rates of severe exacerbations from 2005 to 2008 after 
which their incidence rates dropped in subsequent years. 
 
Conclusion: This is the first study that reports the long-term changes in the incidence 
rates of moderate and severe exacerbations within the UK general practice. Women 
showed a substantially higher risk of any COPD exacerbations, and their risk is 
increasing. The incidence rates of any exacerbations increased during the study 
period, while severe exacerbations were variable. Furthermore, incidence rates varied 
substantially by age group. 
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INTRODUCTION 
 
Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as acute 
episodes of increased respiratory symptoms necessitating additional therapy.
1
 Main 
symptoms are increased dyspnoea, cough and sputum production and/or purulence. 
Exacerbations of COPD negatively impact on lung function
2
 health status
3
 and muscle 
function.
4
 Also, they are important drivers of hospitalisations
5
 and are associated with 
high mortality risk.
6
 Hence, prevention of exacerbations of COPD is one of the main 
goals of pharmacologic treatment of the disease and multiple options for drug therapy 
are available.
7
 In the United Kingdom (UK), £253 million British Pounds (GBP) is 
spent yearly on COPD management, with more than 50% of the costs attributed to 
exacerbations.
8
 Also, COPD-related mortality has increased from 2004-2012 (̴29,000 
died in 2012) while incidence of COPD decreased and then remained stable over the 
same period (̴115,000 new diagnosed COPD in 2012). There are over a million bed 
days and 140,000 hospital admissions each year in the UK due to COPD (1.7% of all 
hospital admissions and bed days).
9
   
The role of demographic characteristics in shaping the trends in 
exacerbations and related hospitalisations over time has not been adequately 
described in a UK population. Understanding trends in acute exacerbations and 
related hospitalisations can help redirect healthcare policies and interventions to 
subgroups most affected by exacerbations, allow comparison between countries to 
aid healthcare planning, predict future healthcare challenges, and provide a basis for 
improving future management. Thus, there is a need to understand the constantly 
changing trends and to subsequently target health planning and policies towards 
groups who are at high risk of exacerbations of COPD.
10
 Management of patients with 
COPD in the UK is performed mainly within the primary care setting.
11
 Therefore, this 
study aims to describe the incidence rates of moderate and severe exacerbations for 
COPD by age and gender within the UK primary care setting from 2005-2013. 
 
METHODS  
 
Data source 
This study was conducted with data from the Clinical Practice Research Datalink 
(CPRD), formerly known as the General Practice Research Database (GPRD). CPRD 
contains computerized medical records of 674 primary care practices in the UK. Data 
collection started in January 1987 and over 11 million persons are currently included, 
corresponding with 7% of the UK population.
12,13
 The introduction of the Quality and 
Outcomes Framework (QOF) in April 2004, was aimed at facilitating quality reporting 
of various diseases by GPs, including COPD and its related outcomes.
14
 The quality 
management system uses indicators recorded by GPs to monitor effectiveness in 
COPD reporting and to reduce the rate of misdiagnosis. Indeed, a high positive 
predictive value in identifying patients with COPD based on these read codes has 
been reported,
12
 and the CPRD has been used in various studies on COPD.
15–17
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Using CPRD ensured that our results are generalizable within the UK population. The 
independent scientific advisory committee of the Medicines and Healthcare product 
Regulatory Agency (MHRA) database research approved this study. (ISAC protocol 
No: 18_046R). 
 
Study population 
We selected all patients aged 40 years with a diagnosis of COPD as recorded by 
read codes within the CPRD. The study period was from 1 January 2004 until 31 
December 2013 corresponding to the period since the introduction of the Quality and 
Outcomes Framework (QOF). However, we calculated the incidence rates from 2005 
through to 2013. For the main analyses, we excluded all patients with a history of 
asthma from the study and COPD diagnosis prior to 2004. Follow-up ended at the 
earliest of the study end date (31 December 2013), or the patient’s death or transfer 
out of the practice. The primary endpoint was the first acute exacerbation of COPD in 
a given calendar year, identified using validated read codes for exacerbations of 
COPD
18
 from the referral and/or clinical files. We defined this as any exacerbations of 
COPD. The secondary outcomes were defined as follows: (i) exacerbations of COPD 
without hospitalisations/accident and emergency (AE) visits evaluated using validated 
read codes for exacerbations of COPD from the clinical file only. This was defined as 
moderate exacerbations of COPD. (ii) COPD-related hospitalisations/AE visit 
evaluated using read codes for hospitalisations/AE visits for COPD from both clinical 
and/or referral file in addition with validated read codes for exacerbations of COPD 
from the referral file. This was defined as severe exacerbations of COPD. Referral 
files contains referral details recorded by GPs while the clinical file contains all the 
medical history data entered by the GP.
19
 
 
Statistical analysis 
For our main analyses, we only counted the first outcome of interest within a given 
calendar year (i.e. patients with an outcome only contributed time at risk from January 
1 up to the date of the first outcome within each year). The incidence rates for 
moderate/severe, moderate and severe exacerbations for COPD in each calendar 
year was calculated as follows: the sum of any or moderate or severe exacerbations 
for COPD in that year divided by the total duration of follow-up in the same calendar 
year. We only calculated incidence rates from 2005 through to 2013. The incidence 
rates were expressed as the number of exacerbations per 1000 person-years (PY). 
We then analysed these rates by gender and age categories (40-59 years, 60-79 
years and 80 years). The incidence rates are accompanied by 95% confidence 
intervals (CI). Using chi-square test, we compared the changes in trends with 
statistically significant difference determined at p<0.05 between calendar year, gender 
and age categories. All analyses were carried out using SAS 9.4 (SAS Institute, Cary, 
NC). 
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Sensitivity analysis 
We performed two sensitivity analyses. As far as we know, there are no established 
methods to estimate incidence rates of moderate and severe exacerbations among 
COPD patients. In the first sensitivity analysis we no longer counted the first event 
within a given calendar year, but we added up all exacerbations that occurred in a 
calendar year. To overcome the problem of potentially counting the same event more 
than once, we stipulated a gap of at least 30 days between consecutive events of any 
exacerbations of COPD. This sensitivity analysis was carried out to depict the overall 
trend of any exacerbations of COPD using validated read codes form referral or/and 
clinical files.  In the second sensitivity analysis, we included patients with a history of 
asthma and estimated the incidence rates of any exacerbations taking only the first 
exacerbation into consideration.  
 
RESULTS 
We identified 213,561 patients with COPD diagnosis within the CPRD of whom 
86,300 met the inclusion criteria. The mean age of patients in our study was 68 years 
and 45.5% (n=39,241) were women (see supplementary Table S.2.1). 
 
Trends of any exacerbations for COPD 
We observed 30,996 any exacerbation for COPD during the study period. Table 2.1 
shows the overall incidence rates of any exacerbations for COPD. From 2005 to 
2007, the incidence rates of the primary outcome any exacerbations remained stable 
at around 88 per 1000PYs. A rise in incidence rates of any exacerbations was noted 
from 2008 to 2012 (112 per 1000PYs (95%CI, 109-114/1000PYs)). However, we 
observed a decrease in the incidence rates of any exacerbations to 98 per 1000 PYs 
in 2013. Overall, there was a 10% increase in the incidence rates of any 
exacerbations from 2005 to 2013, which was statistically significant (p=0.005).  
 
Table 2.1. Incidence rates
a
 of any exacerbations for COPD from 2005-2013
b
. 
Year 
No. of any exacerbations 
PY at risk IR /1000 PY (95% CI) 
n=30,996 
2005 1,110 12514.4 89 (84-95) 
2006 1,678 18981.8 88 (84-93) 
2007 2,194 24905.1 88 (85-92) 
2008 2,838 30441.4 93 (90-97) 
2009 3,356 35161.5 95 (92-99) 
2010 4,315 40319.5 107 (104-110) 
2011 4,839 44777.5 108 (105-111) 
2012 5,500 49260.1 112 (109-114) 
2013 5,166 52893.7 98 (95-100) 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; AE, accident 
and emergency; PY, person-years; CI, confidence interval. 
a
Only one event per calendar year was counted. 
b
using validated read codes for AECOPD from clinical and/or referral files. 
 
 
Gender specific incidence rates are shown in Figure 2.1a. In both men and women, 
any exacerbations incidence rates followed a somewhat similar pattern of year-to-year 
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change. The incidence rates for both men and women increased from 84 and 95 in 
2005 to 90 and 107 per 1000 PYs in 2013 respectively. Women had greater incidence 
rates of any exacerbations in each calendar year compared to men (p<0.0001). 
Figure 2.2a shows the incidence rates of any exacerbations by age. There 
was an increase in incidence rates of any exacerbations with increasing age group 
from 2005 to 2007, which disappeared from 2009 to 2013. In 2008 the incidence rates 
of any exacerbations were the same among patients 40-59 and 60-79 years old.  We 
observed a decrease in year-to-year incidence rates of any exacerbations for 80+ 
year-old patients. In contrast, any exacerbation rates increased across the study 
period for patients in the 40-59 and the 60-79 year old age groups.  
 
Trends of moderate exacerbations for COPD 
From 2005 until 2013, a total of 30,973 moderate exacerbations were observed in our 
study population. Table 2.2 shows the annual incidence rates of moderate 
exacerbations for COPD. The general trend of moderate exacerbation was similar to 
that of any exacerbations for COPD by age and gender. From 2005 to 2007, the 
incidence rate of the moderate exacerbations remained stable at around 88 per 
1000PYs before increasing to 112 per 1000 PYs (95%CI, 109-114/1000PYs) in 2012. 
We found a significant increase in moderate exacerbations for COPD by 10% from 
2005 to 2013 (p=0.005). 
 
Trends of severe exacerbations for COPD 
Between 2005 and 2013 we found 8,032 severe COPD exacerbations. From 2005 to 
2007 we found a decline in the incidence rates of severe exacerbations for COPD 
from 18 to 11 per 1000 PYs. However, there was a steady increase from 2008 until 
the end of the study period. In 2013, the incidence rate was 43 per 1000 PYs. Figure 
2.1b shows the incidence rates of severe exacerbations by gender (Table 2.3). Similar 
to the overall trend, both men and women showed a flattened ‘U’ shaped decrease in 
incidence rates of severe exacerbations before an increase from 2008 to their peak 
rates in 2013.  Women and men had similar incidence rates in each calendar year of 
the study (p=0.747).  
Figure 2.2b shows the incidence rates of severe exacerbations for COPD by 
age. We noticed an increasing incidence rate of severe exacerbations for COPD by 
age from 2005 to 2008. In 2012 and 2013 patients age 60-79 years had a significantly 
higher incidence rate compared to other age groups (p<0.0001). For each age group, 
the incidence rates for severe exacerbations decreased from 2005 to 2007 before 
increasing from 2008 to 2013 (Figure 2.2b). For all age groups, the rates in 2009 were 
similar. 
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Table 2.2. Incidence rates
a
 of moderate exacerbations for COPD from 2005-2013
b
. 
Year 
No. of moderate 
exacerbations 
n=30,973
 a
 
PY at risk IR /1000 PY (95% CI) 
2005 1,110 12514.8 89 (84-94) 
2006 1,676 18983.3 88 (84-92) 
2007 2,193 24905.2 88 (85-92) 
2008 2,835 30443.4 93 (90-96) 
2009 3,352 35164.4 95 (92-98) 
2010 4,313 40320.7 107 (104-110) 
2011 4,835 44779.7 108 (105-111) 
2012 5,496 49261.5 112 (109-114) 
2013 5,163 52895.7 98 (95-100) 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; AE, accident 
and emergency; PY, person-years; CI, confidence interval. 
a
Only one event per calendar year was counted. 
b
using validated read codes for AECOPD from clinical file only. 
 
 
Table 2.3. Incidence rates of severe exacerbations for COPD from 2005-2013
b
. 
Year 
No. of  severe exacerbations
 a
 
n=8,032 
PY at risk IR /1000 PY (95% CI) 
2005 229 12896 18  (16-20) 
2006 248 19646.9 13 (11-14) 
2007 277 25792.1 11 (10-12) 
2008 455 31421.6 14 (13-16) 
2009 556 36382.1 15 (14-17) 
2010 821 41713.3 20 (18-21) 
2011 1,224 46192.4 26 (25-28) 
2012 1,902 50388.8 38 (36-39) 
2013 2,320 53691 43 (42-45) 
 Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; AE, 
accident and emergency; PY, person-years; CI, confidence interval. 
a
Only one event per calendar year was counted. 
b
using read codes for hospitalisation/AE visits for COPD from clinical and/or referral files in addition with validated read codes for 
AECOPD from referral file. 
 
Sensitivity analysis of trends of any exacerbations of COPD.  
For the first sensitivity analysis, we considered multiple events in a given calendar 
year. A total of 37,160 any exacerbations of COPD were observed during the study 
period. The trends were similar to that observed for moderate/severe exacerbations of 
COPD when we evaluated only one event in a calendar year. However, we found a 
non-significant increase of 3% in the incidence rates of any COPD exacerbations from 
2005 to 2013. (see supplementary Table S.2.2). In the second sensitivity analysis we 
included patients with a history of asthma. The incidence rates declined gradually until 
2007 and remained the same from 2008 to 2009. The incidence rates dropped from 
119 to 103 per 1000 PYs from 2011 to 2013. Overall, there was a 2% decrease in the 
incidence rates of any COPD exacerbations, which was not statistically significant 
(p=0.577). (see supplementary Table S.2.3) 
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Figure 2.1.  Incidence rates of (a) any exacerbations
a
  or (b) severe exacerbations
b
  for COPD by 
gender. 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; AE, accident 
and emergency; PY, person-years. 
a
using validated read codes for AECOPD from clinical and/or referral files. 
b
using read codes for hospitalisation/AE visits for COPD from clinical and/or referral files in 
addition with validated read codes for AECOPD from referral file. 
 
a 
b 
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Figure 2.2.  Incidence rates of (a) any exacerbations
a
 or (b) severe exacerbations
b
  for COPD 
by age. 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; AE, 
accident and emergency; PY, person-years. 
a
using validated read codes for AECOPD from clinical and/or referral files. 
b
using read codes for hospitalisation/AE visits for COPD from clinical and/or referral files 
in addition with validated read codes for AECOPD from referral file. 
 
 
 
 
a 
b 
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DISCUSSION  
 
Summary of main findings 
Using the world’s largest primary care database, this study showed a significant 
increase in the incidence rates from 2005 to 2013 for the primary endpoint, any 
exacerbations of COPD. For severe exacerbations, incidence rates increased from 
2008 to 2013. Women had higher incidence rates of any exacerbations compared to 
men throughout the study period but they had similar incidence rates of severe 
exacerbations for COPD from 2005 to 2013. The incidence rate of any exacerbations 
for COPD was higher in patients 80+ years from 2005 to 2008, after which this trend 
was not observed.  
 
Comparison with existing literature 
To the best of our knowledge there has been no previous large-scale 
population based studies on the trends of moderate to severe exacerbations of COPD 
in the UK.  Previous studies have focused mainly on prevalence rates of COPD,
20–22
 
with no emphasis on the trends of acute exacerbations of COPD. Using the Health 
Improvement Network database, Snell et al,
9
 reported a 27% increase in the 
prevalence of COPD in the UK from 2004 to 2012. This increase in prevalence of 
COPD is correlated with the increase in incidence of moderate and severe 
exacerbations of COPD in our study. 
A study conducted among 423 COPD patients within the Dutch general 
practice from 1980 to 2006 reported a reduction in overall annual exacerbation rates 
which is contrary to our findings.
10
 The study also observed that the decreasing trends 
was independent of age and sex.
10
 It is difficult to draw a definite conclusion for the 
declining trends of acute exacerbations of COPD in their study, but it might be related 
to changes in treatment guidelines for COPD and increased emphasis on vaccination 
during the study period.
10
 In our study, we also found that the incidence rates of acute 
exacerbations increased with increasing age in certain years. This might be due to 
disease progression and severity of the disease state. Investigators have reported a 
relationship between old age and underreporting of acute exacerbations,
23
 which 
means that the incidence rates might be underestimated among older patients.  
Although, few studies have focused on incidence rates of moderate 
exacerbations of COPD more have focused on COPD exacerbation requiring 
hospitalisations (severe exacerbations). Fuhrman et al,
24
 examined the temporal 
trends in acute exacerbations related hospitalisations from 1998 to 2007 in France, 
and found that admission rates increased significantly, especially among females. 
Although, our study also reported an increase in severe exacerbations there were 
only slight differences by gender for all years. Another study conducted in Brazil found 
no changes in hospitalisation rates from 1998 to 2009.
25
 The Hospital Episode 
Statistics published by the UK department of health from 1998 to 2003 showed an 
increase in the number of admissions for COPD,
26
 with 140,000 hospital admissions 
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each year.
9
 It has been reported that 30% of patients hospitalised for exacerbations 
will be seen again and possibly admitted with another exacerbation within 8 weeks.
26
 
Contrary to our findings, a study investigating the incidence of COPD which defined 
COPD diagnosis based on AE visit and hospitalisation in Canada reported a reduction 
in the incidence of COPD from 1996 to 2007.
20
 Similarly, Kinnula et al,
27
 reported a 
decrease in the rates of hospitalisations associated with COPD in Finland from 1998 
to 2007. The exact reason for the low incidence rates of severe exacerbations in our 
study is not completely understood. However, this might be related to the fact that 
most COPD patients die from various fatal comorbidities associated with COPD 
severity before they could be hospitalised for an acute exacerbations of COPD.
28
 
Another explanation is that many patients have problems in identifying symptom 
aggravation and fail to report exacerbations to health experts,
29,30
 resulting in 
spontaneous hospitalisations and AE visits. Additionally, GPs often record COPD 
hospitalisation using less specific read codes.
31
 Merinopoulou et al,
32
 reported that the 
rates of COPD-related hospitalisations from 2011 to 2013 were higher in patients with 
more severe disease state, with most severe patients  (GOLD D) having 3 times the 
number of exacerbations compare to least severe groups (GOLD A). The lack of 
information on disease stage in our study made it impossible to corroborate their 
finding. 
Whilst emphasis has been on adherence to treatment guidelines among 
COPD patients in different Global Initiative for Obstructive Lung Disease (GOLD) 
recommendations as a means of reducing the prevalence of COPD-related 
exacerbations, a significant dissociation has been reported between adherence to 
guidelines and actual management of COPD patients.
33
 A study conducted among 
24,957 COPD patients in the UK showed that the patients were not managed in 
accordance to GOLD and National Institute for Health and Care Excellence 
recommendations, with substantial amount of patients not receiving appropriate 
medications.
34
 Despite current developments with LAMA/LABA and ICS in treatment 
of COPD patients we found no objective reduction in exacerbations in our study. 
Although, low adherence to therapy,
35
 and improper inhaler technique among COPD 
patients
7
 may have contributed to the observed trends. Furthermore, variation in the 
incidence of exacerbations seems to follow the incidence of influenza A during the 
study period, suggesting that this might have had an impact our study.
36
 It is also 
important to note that the use of long-acting agents was low in our study cohort. 
 
Strengths and limitations 
A major strength of this study was the inclusion of patients from one of the world’s 
largest primary care databases, thus providing a very large sample size. Second, we 
were able to assess the incidence rates of moderate and severe exacerbations over a 
long period. Third, we considered periods since the introduction of the QOF ensuring 
greater quality and validity of data recording. Fourth, we used validated read codes for 
acute exacerbations of COPD. Lastly, a validity study of COPD patients in the CPRD 
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concluded that patients with COPD can be identified easily using specific read 
codes.
37
 
Despite the numerous strengths, this study had some limitations. The use of 
the read codes for acute exacerbation may have underestimated the true incidence 
rates of COPD exacerbations. However, the read codes used have been reported to 
have a high positive predictive value (PPV) of 96% in identifying patients with COPD 
exacerbation in the CPRD,
18
 and we explored both clinical and referral files to ensure 
all exacerbations were identified. Nevertheless, we may have missed a considerable 
amount of exacerbations that may be miscoded e.g. as respiratory tract infections or 
pneumonia. Although we excluded asthma patients from the main analyses, it was 
impossible to rule out the inclusion of patients with reversible airflow limitation in this 
study.
38
 Furthermore, the PPV of approximately 50.2% and a sensitivity of 5.4% in 
identifying hospitalisations for COPD within the CPRD is arguably low, which may 
have resulted from GPs recording hospitalisation for COPD by generic hospitalisation 
codes and/or acute exacerbation read codes.
31
 As such the incidence rate for severe 
exacerbations is likely to an underestimate of the true incidence in the UK. While the 
method of diagnosis of COPD has not changed since 2005, GPs ability to identify 
exacerbations of COPD might have changed over time,
32
 which may have had an 
effect on our findings. 
 
Implication for future research and clinical practice 
The introduction of QOF in 2004 was aimed at ensuring quality recording of diagnosis 
and treatment of COPD and other chronic diseases.
39
 Although, approximately equal 
numbers of patients were diagnosed with COPD annually during the study period. The 
higher incidence rates of any exacerbations among women and among older patients 
suggests emphasis be placed on adherence to treatment guidelines and other 
interventions among these patient groups. The increased incidence of any 
exacerbations in our study since the introduction of QOF, is concerning. This 
coincides with sceptics questioning the relevance of QOF in aiding holistic clinical 
care,
39
 although it cannot be denied that its introduction has resulted in a modest 
reduction in overall emergency admission rates for long-term conditions.
39
 ECLIPSE 
investigators, suggest that patients with two or more exacerbations in a year 
represent a distinct “frequent exacerbators” phenotype, and have increased risk of 
future exacerbation events.
40
 Though these group of patients could not be identified in 
our study.  Fundamentally, it is important for GPs to identify these patients by carefully 
exploring patient’s history and targeting interventions based on recommendations 
from clinical guidelines. Also, greater emphasis should be made on treatment 
adherence by COPD patients, as “frequent exacerbators” and patients with history of 
hospitalisation have been reported to be less likely to adhere to therapy.
35
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Conclusion 
This is the first study that reports the long-term changes in the incidence rates of 
moderate and severe exacerbations as recorded by UK general practitioners. Women 
showed a substantially higher risk of any COPD exacerbations, and their risk is 
increasing. The incidence rates of any exacerbations increased during the study 
period, while severe exacerbations were variable. Furthermore, incidence rates varied 
substantially by age group. In addition, these findings have the potential to help 
redirect health policies, planning and interventions to target subgroups more 
effectively, and may provide a basis for improving overall COPD management in the 
future. 
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Supplementary Material 
 
 
S.2.1. Baseline characteristics of COPD patients.  
 n=86,300 % 
Females 39,241 45.5 
Mean age (years, SD) 68.1 11.3 
Age category (years)   
  40-59 19,475 22.6 
  60-79 51,982 60.2 
  80+ 14,843 17.2 
BMI (kg/m
2
) in the past 6 months   
   Underweight (BMI < 18.5 kg/m
2
) 4,784 5.5 
   Normal weight (BMI 18.5-24.9 kg/ m
2
) 29,808 34.5 
   Overweight (BMI 25.0-30.0kg/ m
2
) 26,529 30.7 
   Obese (BMI > 30,0 kg/ m
2
) 20,938 24.4 
   Missing 4,241 4.9 
Smoking status at index date   
   Never 9,005 10.4 
   Current 38,207 44.3 
Former  38,662 44.8 
Missing 426 0.5 
Drug use (in the past 6 months)   
SABAs 48,624 56.3 
LABAs 7,542 8.7 
SAMAs 7,576 8.8 
LAMAs 15,102 17.5 
Xanthine derivatives 770 0.3 
Antidepressants 17,063 19.8 
History of co-morbidities    
Diabetes Mellitus 9,619 11.1 
Anxiety 12,267 14.2 
Osteoporosis 15,063 5.9 
Malignancies excluding non-melanoma skin cancer 12,357 14.3 
Chronic liver disease 292 0.3 
Ischaemic heart disease 12,493 14.5 
Abbreviations: SD, standard deviation; COPD, chronic obstructive pulmonary disease; BMI, body mass index; SABAs, short-acting beta-
2 agonists; LABAs, long-acting beta-2 agonists; SAMAs, short-acting muscarinic antagonists; LAMAs, long-acting muscarinic 
antagonists; ICS, inhaled corticosteroids. 
 
 
 
 
S.2.2. Incidence rates
a
 of any exacerbations for COPD from 2005-2013
b
. 
Year 
No. of any exacerbations 
PY at risk IR /1000 PY (95% CI) 
n=30996 
2005 1,471 13350.9 110 (105-116) 
2006 2,260 20607.8 109 (105-114) 
2007 3,034 27540.5 110 (107-114) 
2008 3,934 34209.7 114 (112-118) 
2009 4,760 40181.9 118 (115-122) 
2010 6,247 46885.5 133 (130-136) 
2011 7,137 52995.1 134 (132-138) 
2012 8,090 59217.2 137 (134-139) 
2013 7,250 64304.4 113 (110-115) 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; AE, accident 
and emergency; PY, person-years; CI, confidence interval. 
a
We counted all events occurring 30 days between consecutive events within a calendar year. 
b
using validated read codes for AECOPD from clinical and/or referral files. 
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S.2.3. Incidence rates
a
 of any exacerbations for COPD from 2005-2013 among COPD patients with history of asthma
b
. 
Year 
No. of any exacerbations 
PY at risk IR /1000 PY (95% CI) 
n=53,514 
 2005 2,098 19984.5 105 (101-109) 
2006 3,100 30311.7 102 (99-106) 
2007 4,082 39632.7 103 (100-106) 
2008 5,106 48203.1 106 (103-109) 
2009 5,858 55284.1 106 (103-109) 
2010 7,390 63121.3 117 (115-120) 
2011 8,273 69617.8 119 (116-121) 
2012 9,204 76043.7 121 (119-123) 
2013 8,403 81196.9 103 (101-106) 
 Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; HR, hazard ratio; AE, accident 
and emergency; PY, person-years; CI, confidence interval. 
a
Only one event per calendar year was counted. 
b
using validated read codes for AECOPD from clinical and/or referral files. 
 
 
 
S.2.4. Incidence rates of any exacerbations of COPD from 2005-2013 by gender
a
. 
                 Men               Women 
Year 
No of any exacerbations 
PY at risk IR /1000 PY 
No of any exacerbations 
PY at risk IR /1000 PY n=15,609 n=15,387 
  
2005 579 6902.9 84 (78-91) 531 5611.5 95 (87-103) 
2006 856 10465.5 82 (77-87) 822 8516.2 97 (90-103) 
2007 1,132 13676.2 83 (78-88) 1,062 11228.9 95 (89-100) 
2008 1,487 16628.7 89 (85-93) 1,351 13812.7 98 (93-103) 
2009 1,698 19195.5 88 (85-93) 1,658 15966.0 104 (99-109) 
2010 2,154 21933.4 98 (94-102) 2,161 18386.1 118 (113-122) 
2011 2,451 24244.7 101 (97-105) 2,388 20532.8 116 (112-121) 
2012 2,700 26598.9 102 (98-105) 2,800 22661.1 124 (119-128) 
2013 2,552 28494.1 90 (86-93) 2,614 24399.5 107 (103-111) 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; PY, person-years. 
a
using validated read codes for AECOPD from clinical and/or referral files 
 
 
 
 
S.2.5. Incidence rates of moderate exacerbations of COPD from 2005-2013 by gender
a
. 
 
Men Women 
Year 
No of moderate 
exacerbations PY at risk IR /1000 PY 
No of moderate 
exacerbations PY at risk IR /1000 PY 
n=15,599 n=15,374 
2005 579 6903.4 84 (78-91) 531 5611.5 95 (87-103) 
2006 856 10465.6 82 (77-87) 820 8517.7 96 (90-103) 
2007 1,132 13676.2 83 (78-88) 1,061 11229.1 94 (89-100) 
2008 1,485 16630.6 89 (85-94) 1,350 13812.8 98 (93-103) 
2009 1,697 19195.8 88 (84-93) 1,655 15968.5 104 (99-108) 
2010 2,152 21934.6 98 (94-102) 2,161 18386.1 118 (113-122) 
2011 2,450 24245.1 101(97-105) 2,385 20534.6 116 (112-121) 
2012 2,698 26599.4 101 (98-105) 2,798 22662.1 124 (119-128) 
2013 2,550 28495.4 90 (86-93) 2,613 24400.3 107 (103-111) 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; PY, person-years. 
a
using validated read codes for AECOPD from clinical file only 
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S.2.6. Incidence rates of severe exacerbations of COPD from 2005-2013 by gender
a
. 
  Men Women 
Year 
No of severe 
exacerbations PY at risk IR /1000 PY 
No of   severe 
exacerbations PY at risk IR /1000 PY 
n=4,318 n=3,714 
2005 119 7108.1 17  (14-20) 110 5787.9 19 (16-23) 
2006 115 10811.4 11 (9-13) 133 8835.5 15 (13-18) 
2007 149 14116.3 11 (9-12) 128 11675.8 11 (9-13) 
2008 238 17150.8 14 (12-16) 216 14270.9 15 (13-17) 
2009 299 19806.7 15 (13-17) 258 16575.4 16 (14-18) 
2010 467 22577.2 21 (19-23) 354 19136.1 18 (17-21) 
2011 656 24941.7 26 (24-28) 568 21250.8 27 (25-29) 
2012 1,029 27054.8 38 (36-40) 873 23334.1 37 (35-40) 
2013 1,246 28788.9 43 (41-46) 1,074 24902.7 43 (41-46) 
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; IR, incidence rate; PY, person-years. 
a
using read codes for hospitalisation/AE visits for COPD from clinical and/or referral files in addition with validated read codes for 
AECOPD from referral file. 
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ABSTRACT  
 
Background: Increasing data supports the role of blood eosinophils as a biomarker 
for identifying steroid-responsive patients with chronic obstructive pulmonary disease 
(COPD). The objective of this study was to investigate the stability of blood eosinophil 
counts over time in patients with COPD and non-COPD controls, and the impact of 
gender, age, smoking and baseline counts. 
 
Methods: The study was conducted with data obtained from the Clinical Practice 
Research Datalink (CPRD) in the United Kingdom (UK). Patients aged 40 years and 
older diagnosed with COPD were matched with up to two non-COPD controls by 
gender, year of birth and medical practice. The primary outcome of interest was 
persistence of blood eosinophils counts <2% or ≥2% throughout follow-up before and 
after stratification for possible confounders. 
 
Results: The stability of blood eosinophil counts was significantly lower in COPD 
patients versus non-COPD (chi-square test (x
2
)=66·48; p<0·001). In patients with 
COPD, stability decreased from 90% at 6 months to 79% at 1-year and subsequently 
dropped to 51% in 4 years. When stratified by baseline eosinophil count, patients with 
counts greater than 6% showed the greatest stability while patients with eosinophil 
levels lower than 2% showed the least stability. Stability of blood eosinophil counts 
decreased with increasing age, was significantly higher in males as compared to 
females (x
2
=40·57; p<0·001), and was higher in smokers compared to non-smokers 
(x
2
 = 6·35; p <0·001). 
 
Conclusions: While the clinical impact of gender and smoking is probably low, age 
and baseline eosinophil levels had more impact on long-term stability of blood 
eosinophil counts. 
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INTRODUCTION  
 
Chronic obstructive pulmonary disease (COPD) is a major cause of worldwide 
morbidity and mortality.
1,2
 It is currently responsible for 2·75 million deaths annually, 
and it is projected to be the third leading cause of death globally by the year 2030.
3
 
Although COPD is defined by the presence of persistent airflow limitation, it is well 
known that exacerbations play a central role in the progression, and the clinical and 
societal burden of the diseases.
3
 
One of the major goals of pharmacological management is the prevention of 
exacerbations.
4
 Various respiratory drug classes are known to reduce the number of 
exacerbations, including long-acting beta-agonists (LABAs),
5
 long-acting 
anticholinergics (LAMAs),
3
 and inhaled corticosteroids (ICS).
6 
While it is traditionally 
recommended that patients with severe COPD and repeated exacerbations are 
treated with ICS containing regimens, alternative approaches were introduced in 
recent years.
6
 This is based on the growing recognition of the heterogeneity of 
exacerbations,
7
 the lack of efficacy of ICS in a large proportion of patients, and the 
concerns of side effects of ICS.
8,9
 However, it is also recognized that a proportion of 
patients respond very well to ICS,
6
 and there is increasing data supporting the role of 
serum eosinophils to identify these steroid-responsive patients.
10
 Patients with high 
blood eosinophil counts seem to benefit more from ICS in terms of exacerbation rate 
reduction,
11
 while ICS could be withdrawn without increases in exacerbation rates in 
patients with low blood eosinophil counts.
12
 However, the optimal cut-off in blood 
eosinophils remains to be established. Moreover, little is known about the long-term 
stability of blood eosinophils as a biomarker in both patients with COPD as well as 
non-COPD subjects in the general population, and the impact of patient 
characteristics and environmental factors such as age, gender, smoking and baseline 
eosinophil counts remain unclear.
12
  
Therefore, the aim of this study was to determine the stability of blood 
eosinophil counts over time in patients with COPD and non-COPD controls derived 
from the general population. We also examined the influence of gender, age, smoking 
status and eosinophil counts at baseline on eosinophil stability.  
 
METHODS  
 
Data source 
This study was conducted with data obtained from the Clinical Practice Research 
Datalink (CPRD), formerly known as the General Practice Research Database 
(GPRD). CPRD contains computerized medical records of 674 primary care practices 
in the United Kingdom (UK). Data collection started in January 1987 and over 11 
million persons are currently included, corresponding with 7% of the UK population.
13
 
For this study the period of valid data collection has been limited to 1 January 2005 
and later, corresponding to the introduction of the Quality and Outcomes Framework 
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(QOF) in April 2004, which facilitates quality reporting of various diseases, including 
COPD.
14
 The quality management system, uses indicators recorded by general 
practitioners (GPs) to monitor effectiveness in COPD reporting and to reduce the rate 
of misdiagnosis. Indeed, a high positive predictive value in identifying patients with 
COPD based on these read codes has been reported
15
 and CPRD has been used in 
various studies on COPD.
16–18
 (ISAC protocol  No:16_131R). 
  
Study population 
The study population consisted of all individuals aged 40 years and older with a 
diagnosis of COPD recorded by a read code during the period of valid data collection 
(1 January 2005 to 31 January 2015). Each patient with COPD was matched with up 
to two non-COPD controls by gender, year of birth and medical practice. Patients 
were followed from the date of the first blood eosinophil count up to the last valid 
eosinophil count during the period of valid data collection or end of study (31 January 
2015). Only patients with at least two blood eosinophil counts on different dates were 
included.  Patients with a history of asthma or COPD exacerbations within 30 days 
before the start of follow-up were excluded from both groups. All patients using 
maintenance systemic corticosteroid therapy 30 days before start of follow-up, 
irrespective of the medical indication, were excluded in further analysis. 
 
Outcomes 
The primary outcome of interest was stability of blood eosinophils, defined as blood 
eosinophil count, which persistently remained <2% or ≥2% throughout follow-up. 
Blood eosinophil counts which did not persistently remain <2% or ≥2% during the 
period of patient follow-up were considered unstable. As a secondary outcome, we 
redefined instability as an absolute change of ≥2% in blood eosinophil counts 
between two consecutive readings taken on different days, regardless of the index 
value. The percentage eosinophil count was obtained by dividing the absolute 
eosinophil counts by total white blood cell counts both in 10
9
cells/L multiplied by one 
hundred. If a patient had multiple measurements on the same day, the first 
measurement was used. 
 
 Statistical analysis 
 Kaplan-Meier survival curves were plotted to describe the stability of blood eosinophil 
counts for COPD patients and matched controls (using the LIFETEST procedure SAS 
9.4 [SAS Institute, Cary, NC]). All patients were categorised according to eosinophil 
count at baseline (<2.0%, 2.0-3.9%, 4.0-5.9%, ≥6.0%), age (40-59 years, 60-79 years 
and 80+ years), gender and smoking status (current smoking ‘yes’ or ‘no’). The 
comparison of eosinophil stability between the various strata was deduced using 
survival plots and chi-square (x
2
) test with statistically significant differences 
determined between groups at p<0.05. 
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Proportions of patients with stable blood eosinophil counts were determined at various 
periods in time.  
 
Sensitivity analyses. 
In the sensitivity analysis, we defined stability as blood eosinophil counts persistently 
<0.34 x 10
9
 cells/L or ≥0.34 x 109 cells/L throughout follow up. Blood eosinophil 
counts that did not persistently <0.34 x 10
9
 cells/L or ≥0.34 x109 cells/L during follow-
up were considered unstable (see supplementary Table S.3.1). 
 
RESULTS 
 
From the inception cohort of 677,147 patients, 226,352 had a diagnosis of COPD and 
were matched with up to two non-COPD controls (450,795) starting January 2005. A 
total of 39,824 patients with COPD and 90,772 without COPD (non-COPD) met the 
various inclusion criteria for this study population (Figure 3.1).  Table 3.1 displays the 
baseline characteristics of all subjects in the analyses. The mean age (± SD) at index 
date in COPD patients was 69·4 ± 10·6 years and 69·9 ± 10·6 years for matched non-
COPD controls. The mean duration of follow-up was 3·0 ± 2·3 years for COPD 
patients and 2.9 ± 2·1 years for non-COPD controls. The mean number of blood 
eosinophil reading from each patient with COPD was 6·2 ± 1·2 and 5·1 ± 1·3 for non-
COPD controls. The mean eosinophil count was 3·0 ± 3·2% versus 2·9 ± 3·0% for 
patients with COPD and matched controls, respectively. The percentage of COPD 
patients with an eosinophil count <2% was 36·4% at baseline compared with 36·9% 
of non-COPD controls. With regard to prior medication use, COPD patients had 
higher utilisation of all measured medications in the 6-months prior to index date, with 
higher use of SABAs compared to controls (55·8% vs. 2·6%). The prevalence of 
cardiovascular diseases, osteoporosis and anxiety disorder was higher in patients 
with COPD, compared to non-COPD controls. The mean absolute eosinophil counts 
were (0·23 ± 0.26) x 10
9
 cells/L for COPD patients and (0·21 ± 0·35) x10
9
 cells/L for 
non-COPD controls (p<0.001). 
Figure 3.2 shows that the 10-year stability of blood eosinophil count was 
significantly different in COPD patients versus non-COPD (x
2
=66·48; p<0.001). The 
stability of blood eosinophil counts increased with baseline counts in both COPD as 
well as non-COPD controls, with eosinophil counts greater than 6% showing the 
greatest stability while patients with eosinophil levels lower than 2% having the least 
stability (COPD: x
2
=2246·82; p<0·001; non-COPD: x
2
=5749·03; p<0·001, Figure 3.3). 
In addition, the stability of blood eosinophil counts in patients with COPD was highest 
in individuals aged 40-59 years and decreased with increasing age category 
(x
2
=203·39; p<0·001, Figure 3.4a). Figure 3.4b depicts the stability in non-COPD 
patients by age (x
2
=621·17; p<0·001). 
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Table 3.1. Baseline characteristics of patients with COPD and controls without COPD. 
 COPD Patients Non-COPD Controls 
   
 n = 39,824 % n = 90,772 % 
Follow-up time, years, mean (SD) 3.0 2.3 2.9 2.1 
Number of females 18,284 45.9 44,468 48.9 
Age, years, mean (SD) 69.4 10.6 69.9 10.6 
Age category     
   40–59 years 7,159 18.0 15,001 16.5 
   60–79 years 25,358 63.7 57,899 63.8 
   >80 years 7,307 18.3 17,872 19.7 
Index blood eosinophil count  
   Absolute, 3 x 10
9 
cells/L, mean (SD) 0.23 0.26 0.21 0.35 
   Percentage, mean (SD) 3.0 3.2 2.9 3.0 
Index blood eosinophil count category     
   Low (<2.0%) 14,492 36.4 33,486 36.9 
   Moderate (2.0–3.9%) 15,231 38.3 35,755 39.4 
   High (4.0–5.9%) 6,496 16.3 14,644 16.1 
   Very high (>6.0%) 3,605 9.0 6,887 7.6 
Smoking status, n (%)     
   Never 4,412 11.1 46,581 51.3 
   Current 16,107 40.5 13,298 14.7 
   Former 19,286 48.3 30,849 33.9 
   Missing 19 0.1 44 0.1 
Drug use 6 months before     
   SABAs 22,202 55.8 2,317 2.6 
   LABAs 3,728 9.4 181 0.2 
   SAMAs 3,473 8.7 275 0.2 
   LAMAs 6,879 17.3 193 0.2 
   ICSs 11,667 28.2 1,270 1.4 
   Xanthine derivatives 314 0.8 27 0.0 
History of comorbidities     
   Cardiovascular diseases 9,397 23.6 18,334 28.5 
   Stroke 2,993 7.5 5,720 6.3 
   Rheumatoid arthritis 1,402 3.5 2,434 2.7 
   Anxiety 6,005 15.1 11,065 12.2 
   Osteoporosis 2,609 6.6 4,730 5.2 
   Any cancer (excluding non-melanoma skin cancer) 6,227 15.6 14,426 15.9 
   Chronic liver disease 122 0.3 174 0.2 
   Pulmonary fibrosis 332 0.8 160 0.2 
Abbreviations: COPD = chronic obstructive pulmonary disease; ICSs = inhaled corticosteroids; LABAs = long-acting b2-agonists; LAMAs = 
long-acting muscarinic antagonists; SABAs = short-acting b2-agonists; SAMAs = short-acting muscarinic antagonists. 
 
 
 
Stability was also significantly different between genders; with males having 
significantly higher stability in blood eosinophil counts (x
2
=40·57; p<0·001, Figure 
3.5a). Figure 3.5b displays eosinophil stability among matched controls, by gender, 
with significant difference between males and females (x
2
=155·02; p<0·001). When 
patients with COPD were stratified by smoking status (Figure 3.6) smokers had a 
higher stability in blood eosinophil counts compared to non-smokers (x
2
=6·35; 
p<0·001). In an additional analysis, we reanalysed the data using our secondary 
outcome of blood eosinophil counts stability. The results obtained were similar to 
those from our primary analysis except for the stability by blood eosinophil counts at 
baseline. 
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Table 3.2 shows the proportion of COPD patients with stable blood eosinophil 
counts after stratification by baseline blood eosinophil count, age, gender and 
smoking status over periods of follow-up based on our primary outcome definition. In 
patients with COPD the stability decreased from 90% at 6 months to 79% at 1-year, 
and subsequently dropped to 51% in 4 years. By blood eosinophil counts at baseline 
we observed an increase in stability with increasing counts at each time point. 
Stability in blood eosinophils decreased with increasing age. As shown in Table 3.2, 
the clinical impact of gender and smoking status on blood eosinophils was limited. In 
Table 3.3 we show the proportion of non-COPD patients with stable eosinophil counts 
and the various stratifications. The correlation for blood eosinophil count, age, gender, 
and smoking status at baseline is shown in Table 3.4. The results did not change 
significantly following the exclusion of patients with prior systemic corticosteroids use. 
 
 
Table 3.2. Proportion of COPD patients with stable eosinophil counts among stratified by gender age, eosinophil counts and smoking 
status at different time points. 
 6 months 9 months 1 year 2 years 4 years 6 years 8 years 
COPD Patients 90% 82% 79% 65% 51% 40% 40% 
 Eosinophil count        
  <2.0% 83% 75% 65% 52% 40% 32% 29% 
  2.0%-3.9% 88% 81% 71% 60% 49% 39% 31% 
  4.0-5.9% 95% 91% 85% 79% 62% 59% 55% 
  ≥6.0% 97% 94% 90% 83% 72% 68% 65% 
 Age        
  40-59 years 90% 85% 80% 68% 51% 50% 44% 
  60-79 years 89% 84% 77% 65% 49% 43% 39% 
  80+ years 85% 79% 73% 59% 42% 38% 31% 
 Gender        
  Females 87% 83% 77% 60% 45% 40% 39% 
  Males 87% 84% 78% 61% 47% 43% 40% 
 Smoking status        
  Yes 90% 83% 75% 63% 51% 41% 40% 
  No 90% 83% 75% 61% 49% 40% 37% 
Abbreviation: COPD=chronic obstructive pulmonary disease 
 
 
 
Table 3.3. Proportion of non-COPD patients with stable eosinophil counts among stratified by gender age, eosinophil counts and 
smoking status at different time points. 
 6 months 9 months 1 year 2 years 4 years 6 years 8 years 
Non-COPD Patients 91% 85% 82% 62% 50% 40% 39% 
 Eosinophil count        
  <2.0% 84% 78% 72% 58% 41% 35% 29% 
  2.0%-3.9% 89% 78% 77% 64% 48% 39% 33% 
  4.0-5.9% 95% 93% 91% 84% 73% 64% 57% 
  ≥6.0% 97% 96% 95% 90% 83% 74% 66% 
 Age        
  40-59 years 92% 89% 84% 72% 58% 49% 45% 
  60-79 years 90% 86% 81% 68% 51% 45% 37% 
  80+ years 88% 83% 76% 61% 43% 36% 31% 
 Gender        
  Females 89% 84% 80% 65% 50% 42% 36% 
  Males 90% 85% 82% 68% 55% 45% 40% 
 Smoking status        
  Yes 91% 85% 83% 69% 53% 45% 40% 
  No 91% 85% 83% 68% 51% 43% 38% 
Abbreviation: COPD=chronic obstructive pulmonary disease 
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Table 3.4. Pearson correlation coeffient for the association between blood eosinophil count, age, gender, and smoking status at 
baseline for COPD and non-COPD patients. 
COPD Eosinophil Count  Age Gender Smoking status 
correlation 0·02 -0·08 -0·04 
P value <0·001 <0·001 <0·001 
Non-COPD Eosinophil Count correlation -0·008 -0·08 -0·009 
P value <0·001 <0·001 <0·001 
 Abbreviation: COPD=chronic obstructive pulmonary disease 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Kaplan Meier curve depicting the stability of blood eosinophil counts in all COPD 
patients and matched controls. 
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Sensitivity analysis 
The long-term stability of blood eosinophil counts was lower in COPD patients versus 
non-COPD (P<0.001) (see supplementary Table S.3.1). The stability of blood 
eosinophil was higher in COPD patients with baseline counts less than 0.34 x 10
9
 
cells/L compared to patients with baseline counts of at least 0.34 x10
9
 cells/L. Also the 
stability of blood eosinophils in COPD was highest in individuals aged 40-59 years 
and decreased with increasing age in both study groups. Both in COPD as well as 
non-COPD, females had significantly higher stability in blood eosinophil counts 
compared to males (P<0.001). There was no difference in stability between current 
smokers and non-smokers among COPD patients. However, among non-COPD 
controls, stability was higher in non-smokers compared to smokers.  
 
DISCUSSION 
 
This is the first population-based study, which shows that the stability of blood 
eosinophil counts was statistically significantly lower in patients with COPD compared 
to non-COPD controls. It was approximately 80% at one year, 60-65% at two years of 
follow-up, and declined progressively thereafter in both groups. Second, it showed 
that stability of blood eosinophil counts is higher with increased baseline levels, while 
advancing age has an opposite effect. Third, it indicated that gender and smoking 
status might have little impact on the stability of blood eosinophils. These data extend 
our understanding of blood eosinophil counts as a potential biomarker in COPD 
management, and has important implications for the follow-up of COPD patients in 
clinical practice and research studies. The results differed slightly in our sensitivity 
analysis; using absolute blood eosinophil thresholds. 
 
  
 
Figure 3.3  Kaplan Meier curves comparing stability of blood eosinophil count in (a) COPD patients and (b) controls by baseline 
eosinophil counts. 
 
a b 
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While traditionally considered a characteristic of asthma, several studies 
have shown eosinophilic inflammation in patients with COPD.
8,19
 Interestingly, there is 
accumulated evidence that blood eosinophilia is a biomarker for response to 
corticosteroid treatment in COPD.
11
 However, while several studies reported cross-
sectional data on eosinophilia in COPD, only a few studies have investigated the 
natural trajectory of blood eosinophil counts in COPD. Pascoe et al, reported a 66% 
prevalence of blood eosinophilia ≥2% in former or current smokers with moderate-to-
severe COPD and a history of exacerbations, among patients participating in a 
pharmacological study.
11
 Using an identical definition, Watz et al,
12
 recently reported a 
prevalence of 54% in former or current smoking patients with severe airflow limitation 
and at least one exacerbation in the previous 12 months. The highest percentage was 
observed in the NHANES cohort,
20
 where 71% of subjects with spirometry-defined 
COPD had blood eosinophilia >2%, compared with 66% of subjects with normal lung 
function. Finally, using a cut-off of ≥3·3%, Vedel-Krogh et al,21 observed that 28% of 
subjects with spirometry defined COPD from a large population sample had elevated 
blood eosinophil counts.  However, longitudinal data on blood eosinophils was not 
available in all of these studies. Using data from the ECLIPSE study, Singh et al.
19
 
investigated the longitudinal changes in blood eosinophil counts in patients with 
moderate-to-severe COPD (mean FEV1 approximately 50%) and non-smoking 
controls with normal lung function, not matched by age. While the baseline prevalence 
of blood eosinophilia ≥2% was not reported, 37% of COPD patients and 36% of 
controls had eosinophil counts persistently ≥2% at all visits, while approximately 14% 
of COPD patients had eosinophil counts persistently <2% and the rest of patients had 
variable counts.  
In the present study, approximately 64% of patients with COPD as well as 
gender, age, and medical practice-matched controls had blood eosinophilia ≥2%, 
suggesting that eosinophilia is not a COPD-specific trait. Moreover, our results 
indicate that stability of eosinophilia is lower in COPD compared to non-COPD. The 
pathophysiology underlying this observation and its clinical relevance remains to be 
established. Also, this is the first study to show the impact of potential confounders on 
the stability of blood eosinophils. 
Our analysis showed that patients with blood eosinophil counts ≥6% had a 
higher stability compared with counts <2% during follow up. We did not identify any 
study that aimed to determine the stability of eosinophil count in healthy populations. 
However, a cohort study which enrolled 410 COPD patients, found that baseline 
eosinophil count was strongly correlated with eosinophil counts after 5 years of follow-
up.
22
 Recently, Disantostefano et al,
20
 showed that old age was associated with blood 
eosinophilia in COPD and non-COPD. However, there are currently no longitudinal 
studies evaluating the impact of age on blood eosinophil counts among patients with 
COPD. Comparing younger and older subjects with asthma, Mathur et al,
23
 showed 
an age-related decline in eosinophil functional activity, but differences in absolute or 
relative eosinophil counts were not reported. The current data indicate that stability of 
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blood eosinophilia decreases with age in both COPD patients as well as matched 
controls. Studies on age-related changes in blood eosinophil counts in healthy 
populations are needed, but currently unavailable. The exact mechanism for the 
differences observed in eosinophil stability by age category in COPD is unknown. 
However, a possible mechanism for decreased stability with age is the decreased 
superoxide anion production and delayed degranulation of eosinophil-derived 
neurotoxin in older patients.
24
 Animal studies in rats suggest a defect in the eosinophil 
accumulation sites and chemotactic activity in older animals.
25
  
 
  
 
Figure 3.4. Kaplan Meier curves comparing stability of blood eosinophil count in (a) COPD patients and (b) controls by age.  
 
 
 
  
 
Figure 3.5. Kaplan Meier curves comparing stability of blood eosinophil count in (a) COPD patients and (b) controls by sex.  
 
The current study showed that a statistically significant difference exists in 
the stability blood eosinophil counts between males and females, and by smoking 
status. Although the stability of blood eosinophil counts did not differ by smoking 
a b 
a b 
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status for absolute blood eosinophil counts. The clinical relevance of these findings is 
yet to be explored.  
The use of data from a large number of COPD patients in primary care, the 
inclusion of matched controls and the long follow-up period are major strengths of the 
current study. This is the first study that showed the stability of blood eosinophil 
counts over a 10-year period, making our findings robust. Moreover, this is the first 
study that employed a unique approach (time-to-event) in the determination of blood 
eosinophil stability. However, this study also has notable limitations. Although the 
positive predictive value of identifying patients with COPD in the CPRD is 90%, lung 
function data were unavailable. Thus, it was not possible to investigate the stability of 
blood eosinophilia in the various GOLD stages of COPD. Secondly, we used 2% and 
0.34 x 10
9
 cells/L cut-off to define stability of blood eosinophil counts in our study, 
while some studies have considered different cut-offs. Also, it is impossible to rule out 
the inclusion of patients with reversible airflow limitation in the study. Finally, we did 
not include patients that were younger than 40 years in our study.  
Blood eosinophil counts are increasingly recognised as an important 
biomarker for predicting response to ICS therapy in COPD patients, with better 
response observed among patients with elevated counts. The current study confirms 
that blood eosinophilia is common in COPD and matched controls and suggests that 
this is not a COPD-specific trait as the proportion of subjects with blood eosinophilia 
was comparable in both COPD and non-COPD controls. Also, when determining 
blood eosinophil counts and the frequency of follow-up in clinical practice or 
pharmacological studies, it is important to take into account the impact of age and 
baseline levels on the long-term stability of blood eosinophil counts, with the impact of 
gender and smoking found to be less pronounced. While this is the largest study to 
date investigating how blood eosinophil counts changes with time, the relationship 
with (different types of) exacerbations and their recovery remains to be established.  
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Figure 3.6. Kaplan Meier curves comparing stability of blood eosinophil count in (a) COPD patients and (b) controls by smoking status 
at baseline. 
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Table  S.3.1. Proportion of COPD patient with stable eosinophil counts among stratified by gender age, eosinophil counts and smoking status at 
different time points.  
 
6  
months 
9 
months 
1 
year 
2 
years 
4 
years 
6 
years 
8 
years 
COPD patients 85% 82% 75% 62% 49% 42% 35% 
    Absolute blood eosinophil count (cells/L) 
       
      <0.34 x 10
9
 cells/L 95% 93% 90% 86% 80% 77% 75% 
      ≥0.34 x 10
9
 cells/L 80% 70% 63% 45% 30% 23% 18% 
    Age 
       
       40-59 years 95% 93% 85% 83% 76% 71% 67% 
       60-79 years  93% 90% 80% 79% 70% 65% 60% 
       80+ years 91% 89% 77% 73% 66% 61% 58% 
    Sex 
       
      Females 94% 92% 89% 81% 75% 70% 68% 
      Males 92% 89% 85% 75% 65% 61% 57% 
    Smoking status 
       
      Yes 95% 90% 88% 81% 72% 69% 62% 
      No 95% 90% 88% 79% 72% 69% 62% 
Non-COPD controls 96% 93% 91% 85% 77% 73% 69% 
   Absolute blood eosinophil count (cells/L) 
       
      <0.34 x 10
9
 cells/L 97% 95% 94% 90% 85% 79% 77% 
      ≥0.34 x 10
9
 cells/L 83% 75% 79% 50% 33% 23% 19% 
    Age 
       
       40-59 years 97% 95% 92% 88% 82% 78% 75% 
       60-79 years 96% 94% 91% 85% 77% 71% 69% 
       80+ years 94% 91% 88% 81% 73% 68% 65% 
    Sex 
       
      Females 97% 95% 93% 89% 81% 77% 73% 
      Males 95% 92% 90% 83% 73% 68% 64% 
    Smoking status 
       
      Yes 93% 91% 89% 83% 73% 68% 65% 
      No 95% 93% 91% 88% 80% 74% 71% 
Abbreviation: COPD=chronic obstructive pulmonary disease. 
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ABSTRACT  
 
Background: The Evaluation of Chronic obstructive pulmonary disease (COPD) 
Longitudinally to Identify Surrogate End-points (ECLIPSE) study identified C-reactive 
protein (CRP) as a key biomarker in systemic inflammation among patients with 
COPD; reports have suggested that inhaled corticosteroids (ICS) attenuate CRP 
levels. Therefore, the aim of this study was to evaluate the risk of moderate-to-severe 
exacerbations, severe exacerbations and all-cause mortality among patients with 
COPD currently exposed to ICS stratified by CRP levels compared to never ICS users 
with low CRP levels in a large general practice setting. 
 
Methods: In this population-based cohort study from 1 January 2005 to 31 January 
2014, we used data from the Clinical Practice Research Datalink (CPRD) in the 
United Kingdom. We included subjects age 40 or more who had a diagnosis of 
COPD. ICS exposure was determined based on the time since the most recent 
prescription, and classified as current (1-30 days), recent (31-60 days), past (>60 
days) or never users. We evaluated the risk of moderate-to-severe exacerbations, 
severe exacerbations and all-cause mortality among ICS users stratified by CRP 
levels, using Cox regression analysis adjusting for confounders (SAS 9.4). Current 
and never users of ICS were further stratified by CRP measurements into categories 
(category 1 (0-3 mg/L), category 2 (4-7 mg/L) and category 3 (≥8 mg/L). The 
reference category included never ICS users with low CRP levels (0-3 mg/L). We 
conducted a sensitivity analysis, using a CRP threshold of ≥20 mg/L instead of (≥8 
mg/L. 
 
Results: We included 17,722 subjects diagnosed with COPD who met the inclusion 
criteria. Among current or never ICS with elevated CRP levels we found no 
significantly reduced risk of moderate-to-severe or severe exacerbations compared to 
never ICS users with CRP levels of 0-3 mg/L. For patients currently exposed to ICS 
with CRP levels ≥8 mg/L there was no reduced risk of moderate-to-severe (adjusted 
hazard ratio [adj. HR] 0.99; 95% confidence interval [CI] 0.76-1.31) or severe 
exacerbations (adj.HR 1.52; 95% CI: 0.71-3.27). Similarly, there was no decreased 
risk of moderate-to-severe or severe exacerbations among never ICS users with CRP 
levels ≥8 mg/L. However, we found an increased risk of all-cause mortality among 
COPD patients with CRP levels ≥8 mg/L currently exposed to ICS with (adj.HR 2.38; 
95% CI: 1.81-3.13) and never ICS users (adj.HR 2.81; 95% CI: 2.20-3.58) compared 
to never ICS users with CRP levels of 0-3 mg/L. 
 
Conclusions: We did not find a reduced risk of moderate and/or severe COPD 
exacerbations among COPD patients with varying CRP levels currently exposed to 
ICS. However, we found an increased risk of all-cause mortality among patients with 
elevated (≥8 mg/L) CRP levels irrespective of ICS use. 
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INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality worldwide
1
 and is projected to be the third leading cause of death by the 
year 2030.
2
 Due to the heterogeneity of COPD, there is a growing interest in 
biomarkers and their potential to guide therapy among sub-groups of patients with 
COPD.
3
 Inhaled corticosteroids (ICS) are additionally used to suppress inflammation 
and reduce exacerbation risk in patients unresponsive to bronchodilators. Hurst and 
colleagues assessed 36 biomarkers with the potential for diagnosis and management 
of COPD, one of which was C-reactive protein (CRP).
4
 CRP is an acute-phase protein 
synthesised predominantly by the hepatocytes and acts by binding to receptors of the 
phagocytes and impacting on apoptosis and necrosis.
5
 The ECLIPSE study illustrated 
that after 3 years of follow-up, all-cause mortality and exacerbation frequency was 
higher in persistently inflamed COPD patients (as measured by an increase in various 
biomarkers including CRP) compared to non-inflamed patients.
6
 COPD is not an 
isolated condition with pathological mechanisms specifically localised in the lungs, but 
a heterogeneous disease with chronic inflammatory processes in various tissues 
accompanied by changes in various biomarkers.
3
 
Reports from clinical studies have suggested that ICS attenuate CRP levels 
among patients with moderate to severe COPD
7–9
 and elevated CRP levels have 
been linked with increased risk of severe exacerbations and mortality.
10,11
 The 
Copenhagen City Heart Study followed COPD patients, a small proportion of whom 
were exposed to ICS over a period of 8 years, and reported that patients with 
elevated CRP levels in combination with other biomarkers were at increased risk of 
severe exacerbations.
12
 A randomised controlled trial (RCT) that enrolled more than 
6,000 COPD patients over a 3-year period found that ICS exposure reduced COPD 
exacerbations but not all-cause mortality.
13
  
Furthermore, meta-analysis of 15 studies showed that high baseline CRP 
was associated with a higher risk of mortality among COPD patients.
11
 The use of ICS 
has been reported to significantly reduce CRP levels,
7–9
 hence we speculate that this 
attenuation of CRP will result in decreased risk of exacerbations and mortality. 
Biomarker guided therapy has the potential to help reduce the risk of fractures and 
pneumonia associated with ICS exposure by identifying patients groups more likely to 
benefit from ICS treatment.
3
 No longitudinal study has yet evaluated the role of CRP 
in guiding ICS therapy among patients with COPD in a large general practice setting.  
Therefore, the aim of this study was to evaluate the risk of moderate-to-severe 
exacerbations, severe exacerbations and all-cause mortality among patients with 
COPD currently exposed to ICS and never ICS users stratified by CRP categories 
compared to never ICS users with the lowest CRP categories. 
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METHODS  
 
Data source 
Data for this study were obtained from the Clinical Practice Research Datalink 
(CPRD). CPRD holds computerised medical records of 674 primary care practices in 
the United Kingdom. The database provides detailed information on drug 
prescriptions, clinical events, demographics, specialist referrals, and hospital 
admissions.
14
 In addition, laboratory test results are available, including biomarker 
information. Data collection began in January 1987 and over 11 million persons are 
currently included.
15
 This database has been used in various studies on COPD.
16–18
 
Approval for this study was obtained from the Independent Scientific Adversary 
Committee (ISAC) of the Medicines and Healthcare product Regulatory Authority  
(protocol no: 18_323R). 
 
Study population 
For this study we selected all newly diagnosed COPD subjects aged 40 years and 
older as recorded by a first read code during our study period 1 January 2005 (after 
the introduction of Quality Outcome Framework (QOF)) to the 31 January 2014. 
Subjects were followed from the date of their COPD diagnosis (index date) until the 
end of data collection, date of death, and end of study or when the outcome of interest 
occurred, whichever came first. Subjects needed to have at least one CRP 
measurement before the index date to be included in the study. Subjects with a 
history of asthma at baseline were excluded. Subjects with acute exacerbations of 
COPD or oral glucocorticoid use within 30 days prior to index date were excluded. 
 
Exposure 
Each patient’s follow-up time was divided into fixed periods of 90 days. Exposure to 
ICS was determined time-dependently during follow-up. Prior to the start of each 
interval, ICS exposure was determined based on the time since the most recent 
prescription, and classified as current (1-30 days), recent (31-60 days), past (>60 
days) or never use. Never users of ICS comprised of patients without ICS exposure 
during follow-up. Subjects could move between exposure groups over time. Our 
exposure groups of interest included current (subjects exposed to ICS within the first 
30 days to the start of an interval) and never users (subjects with no ICS use within an 
interval). Current and never users of ICS were further stratified by the most recent 
CRP measurements, with the CRP levels classified into categories (category 1 (0-3 
mg/L), category 2 (4-7 mg/L) and category 3 (≥8 mg/L). We derived CRP categories 
by splitting the CRP distribution at the 33.3
th
 and 66.7
th
 centiles using the PROC 
univariate procedure (SAS 9.4) (SAS Institute, Cary, NC). 
We employed a 12 months look-back period to determine CRP levels during 
follow-up; this choice was based on the mechanistic plausibility for ICS to attenuate 
CRP over this time period, hence we also provided a missing CRP category.
9
 Patients 
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with missing CRP measurements were classified into a separate category. When two 
or more CRP measurements were recorded on the same date, the mean CRP value 
was calculated. We used the term “elevated CRP” levels to refer to CRP levels >3 
mg/L in this work. 
 
Outcome 
The primary outcome of interest was a moderate-to-severe exacerbation, which was 
defined using validated definitions (H312200, H3y1.00) for acute exacerbations of 
COPD from the clinical and referral files.
19,20
 The secondary outcome was a severe 
exacerbation, defined as a COPD-related hospitalisation/accident and emergency visit 
using read codes (8H2R.00, 66Yi.00) from either the clinical or referral files or the 
read codes  (H312200, H3y1.00) for acute exacerbations from the referral file. The 
primary and secondary outcomes were not fully mutually exclusive. We also 
evaluated the risk of all-cause mortality. Referral files contain referral details recorded 
by general practitioners (GPs) while the clinical file contains all medical data entered 
by the GP.
21
    
 
Covariates  
Potential confounders were assessed time-dependently with the exception of gender, 
smoking status, alcohol use, and body mass index, which were determined at 
baseline. The following covariates were considered as potential confounders, and 
identified at the start of each interval: a history of congestive heart failure, ischemic 
heart disease, anxiety, chronic liver disease, cancer excluding non-melanoma skin 
cancer, stroke, rheumatoid arthritis, diabetes mellitus, hypertension, inflammatory 
bowel disease, solid organ transplant, atopic dermatitis, renal dialysis, human 
immunodeficiency virus or osteoporosis. In addition, the use of the following drugs 
within 6 months prior to the start of an interval were considered as potential 
confounders: antihistamines, proton pump inhibitors, antipsychotics, or 
antidepressants.
22–25
 We statistically adjusted our analyses for proxy indicators of the 
severity of obstructive airway disease, as previously defined as the use of short- and 
long-acting beta-agonists, short- and long-acting anti-muscarinic agents, xanthine 
derivatives or oral corticosteroids.
26,27
 In addition, the use of antibiotics for COPD 
exacerbations in the month prior to an interval was considered as a potential 
confounder.
28
 
 
Statistical analysis 
We evaluated the risk of moderate-to-severe exacerbations, severe exacerbations 
and all-cause mortality stratified by ICS use and CRP levels using Cox regression 
analysis (SAS 9.4) (SAS Institute, Cary, NC). Current and never ICS users were 
stratified by CRP levels. Categories were made to reduce the impact of outlying 
values and to account for the positively skewed distribution of CRP. The reference 
category for this study included patients who were never exposed to ICS with the 
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lowest CRP levels (0-3 mg/L). Furthermore, we compared the risk of study outcomes 
between never users in category 2 (4-7 mg/L) and current ICS users in category 2 (4-
7 mg/L), never ICS users in category 3 (≥8 mg/L) and current ICS users category 3 
(≥8 mg/L) using Wald test and we only reported any significant differences the groups 
in our fully-adjusted analyses p-values less than 0.05. Potential confounders were 
included in the final model if they changed the beta-coefficient for the association 
between current ICS and never use and the outcome of interest by at least 5% or 
when consensus about inclusion existed within the team of researchers, supported by 
clinical evidence from literature.   
 
Sensitivity analysis 
Further analysis repeated the abovementioned analyses but broke down the highest 
CRP level category into patients with a serum CRP level 8-19 mg/L and those with 
values ≥20 mg/L. We chose this threshold because we felt that it may better reflect 
the acute phase inflammatory process.
29
  
 
 
                         Figure 4.1. Flow chart showing the selection of eligible patients. 
 
 
 
COPD Patients:
213,561
COPD Patients:
115,216
COPD Patients:
29,361
COPD Patients:
19,446
COPD Patients:
17,724
COPD Patients:
17,722
Index date before January 2005
n=98,345
Patients without CRP measurements
before index
n=85,855
History of asthma
n=9,915
Oral corticosteroids 30 days prior
n=1,722
Acute exacerbations 30 days prior
n=2
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RESULTS  
 
We identified 213,561 patients with COPD and 17,722 met the inclusion criteria 
(Figure 4.1). Table 4.1 shows the baseline characteristics of all COPD patients. At 
baseline 5,162 COPD patients were exposed to ICS and 12,560 were not. Over half 
of the ICS users were females, with a mean age of 69.1 years. At baseline, the mean 
CRP levels were 12.9 (±29.0) mg/L for ICS users with COPD and 12.4 (±30.0) mg/L 
COPD patients who had not used ICS. About 29.3% of ICS users were obese versus 
24.1% of ICS naïve subjects, 35.6 % of ICS users were current smokers compared to 
45.0% among subjects not exposed to ICS.  
 
Moderate-to-severe and severe exacerbations 
 Table 4.2 shows that risk of moderate-to-severe exacerbations was not different 
between COPD patients who were current ICS users with CRP levels of 0-3 mg/L 
compared to never ICS users with low CRP serum (0-3 mg/L, adjusted hazard [adj.] 
ratio [HR] 0.95; 95% confidence interval [CI] 0.70-1.27 (4-7 mg/L or ≥8 mg/L). Wald 
tests showed that the risk of moderate-to-severe COPD exacerbations was not 
different between ICS users and never users with COPD. Regardless of ICS exposure 
status, risk of moderate-to-severe COPD exacerbations was not statistically different 
between different CRP categories (0-3 mg/L vs. 4-7 mg/L vs. or ≥8 mg/L). Table 4.3 
shows that these findings were largely similar for the risk of severe COPD 
exacerbations.  
 
All-Cause Mortality 
All-cause mortality among COPD patients with low CRP levels (0-3 mg/L) was not 
different between current ICS users and never ICS users, adj. HR please add (Table 
4.4). This finding was consistent when ICS use was compared with never use in other 
CRP categories  (4-7 mg/L or ≥8 mg/L). However,  we found an approximately three-
fold of  all-cause mortality among patients with CRP levels ≥8 mg/L compared to 
COPD patients with low CRP serum levels (0-3 mg/L), adj.HR 2.81; 95% CI: 2.20-
3.58 for ICS naïve COPD patients.  
 
Sensitivity analysis 
In the sensitivity analysis, never or current use of ICS among COPD patients with 
CRP levels of ≥20 mg/L was not associated with a significant reduction in the risk of 
moderate-to-severe or severe COPD exacerbations compared to never ICS users 
with low CRP serum levels (0-3 mg/L, Tables S.4.1 and S.4.2). But we found that risk 
of all-cause mortality among COPD patients with CRP levels ≥20 mg/L was 3.5-4-fold 
increased among ICS and ICS naïve patients, e.g. adj.HR 4.03; 95% CI: 3.11-5.22 
among never users of ICS) compared never users with no elevated CRP (Table 
S.4.3). 
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Table 4.1. Baseline characteristics of COPD patients.  
  ICS users
a
 
 
ICS naïve
a
 
 
n= 5,162 % n=12,560 % 
Females 2,688 52.1 5,981 47.6 
Mean age (years, SD) 69.1 11.7 68.2 11.0 
Mean follow-up (years, SD) 3.0 2.2 3.0 2.2 
Age category (years)     
  40-59 1,069 20.7 2,766 22.0 
  60-79 3,030 58.7 7,659 61.0 
  80+ 1,063 20.6 2,135 17.0 
BMI (kg/m
2
) in the past 6 months     
   Underweight (BMI< 18.5 kg/m
2
) 264 5.1 797 6.3 
   Normal weight (BMI 18.5-24.9 kg/ m
2
) 1,640 31.8 4,498 35.8 
   Overweight (BMI 25.0-30.0 kg/ m
2
) 1,596 30.9 3,905 31.1 
   Obese (BMI > 30.0 kg/ m
2
) 1,512 29.3 3,029 24.1 
   Missing 150 2.9 331 2.6 
Mean CRP level (mg/L, SD) 12.9 29.0 12.4 30.0 
Smoking status at index date     
  Never 737 14.3 1,211 9.6 
  Current 1,839 35.6 5,656 45.0 
  Former  2,581 50.0 5,688 45.3 
  Missing 5 0.1 5 0.1 
Drug use (in the past 6 months)     
  SABAs 3,375 65.4 4,168 32.2 
  LABAs 2,304 44.6 388 3.1 
  SAMAs 500 9.7 619 4.9 
  LAMAs 1,010 19.6 673 5.4 
  Xanthine derivatives 43 0.8 12 0.1 
 Antipsychotics 63 1.2 133 1.1 
History of co-morbidities      
   Cardiovascular disease  1,232 23.9 2,610 20.8 
  Diabetes Mellitus 726 14.1 1439 11.5 
  Anxiety 953 18.5 2,187 17.4 
  Osteoporosis 443 8.6 943 7.5 
  Any cancer (except non-melanoma skin cancer) 922 17.9 2,186 17.4 
 Chronic liver disease 16 0.3 62 0.5 
Abbreviations: SD, standard deviation; COPD, chronic obstructive pulmonary disease; BMI, body mass index; CRP, C-reactive protein; 
SABAs, short-acting beta-2 agonists; LABAs, long-acting beta-2 agonists; SAMAs, short-acting muscarinic antagonists; ICS, inhaled 
corticosteroids; LAMAs, long-acting muscarinic antagonists; n, number; %, percentage 
a
ICS status was determined prior to start of follow-up as ICS users were patients with an ICS prescription ever before and naïve patients 
as all patients without a record of ICS ever before. 
 
 
DISCUSSION  
 
In this study, the risk of moderate and/or severe COPD exacerbations or all-cause 
mortality was comparable between ICS users and non-users, irrespective of CRP 
levels. Regardless of ICS exposure status, risk of moderate- and/or severe COPD 
exacerbations was not different between different CRP categories (0-3 mg/L vs. 4-7 
mg/L vs. or ≥8 mg/L), whereas all-cause mortality was approximately three-fold 
increased among patients with CRP levels ≥8 mg/L as compared to COPD patients 
with low (0-3 mg/L) CRP serum levels. 
Exacerbations of COPD are important drivers of COPD-related hospitalisations and 
mortality.
30
 Very few researchers have evaluated the role of CRP in guiding ICS use in 
the improvement of moderate-to-severe or severe exacerbations. In a large 
population-based prospective study that included over 6,000 COPD patients, 
Thomsen et al,
31
 reported that patients with elevated CRP levels, fibrinogen, and 
leucocyte counts had increased risk of exacerbations. However, when the 
investigators evaluated each elevated biomarker separately (including CRP), they 
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found no significantly increased risk of frequent exacerbations, in line with our 
findings. 
 
Table 4.2. Risk of moderate-to-severe exacerbations among never and current ICS user stratified by CRP levels. 
 Moderate-to-severe 
n=2,781
b
 
IR 
(/1000PY) 
Age and sex adjusted 
 HR 
(95% CI) 
Adjusted 
 HR 
(95% CI)
a
 
 
ICS use     
 Never 1,080 47.4   
By CRP levels(mg/L)     
     0-3 132 54.9 Reference Reference 
     4-7 97 49.1 0.90 (0.69-1.17)
c
 0.88 (0.68-1.14) 
     ≥8 151 64.7 1.19 (0.94-1.51)
d
 1.11 (0.88-1.40) 
     Missing CRP 700 43.5 0.80 (0.66-0.96) 0.83 (0.69-1.00) 
 Current 772 95.6   
  By CRP levels(mg/L)     
     0-3 72 91.3 1.65 (1.24-2.19) 0.95 (0.70-1.27) 
     4-7 56 82.4 1.50 (1.10-2.05)
 c
 0.83 (0.60-1.14) 
     ≥8 93 103.9 1.92 (1.47-2.50)
 d
 0.99 (0.76-1.31) 
     Missing CRP 551 96.5 1.77 (1.46-2.14) 1.01 (0.82 -1.24) 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; PY, 
person-years. 
a
Adjusted for age, sex, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, recent ICS use, past ICS use, use of antipsychotics, antidepressants, atopic dermatitis, use of oxygen, short-acting beta-2 
agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives 
and oral corticosteroid 6 months prior and use of antibiotics 1 month prior. 
Recent ICS users had 285 moderate-to-severe exacerbations; Past ICS users had 644 moderate-to-severe exacerbations 
b
2,781 moderate-to-severe exacerbations were recorded among 17,722 patients with COPD. 
c
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
d
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
 
It is important to note that the authors stated that the use of ICS was “relatively rare” 
among the patients enrolled and might have affected their findings (with only 3% of 
the study population was exposed to ICS at baseline).
31
 In our study, we noted an 
increased risk of moderate and/or severe exacerbations when we adjusted only for 
age and sex, following adjustments for all possible confounders the risk disappeared. 
This is the first study to specifically evaluate the risk of moderate-to-severe, severe 
exacerbations and all-cause mortality among COPD patients currently exposed to ICS 
stratified by CRP levels. A randomised controlled trial conducted across 11 centers 
among 289 COPD patients treated with ICS with or without LABA, found no reduction 
in CRP levels although serum protein D levels decreased, suggesting that ICS 
treatment affects lung-specific biomarkers rather than systemic inflammatory 
markers.
8
 Furthermore, ECLIPSE investigators found that elevated levels of CRP, 
fibrinogen and leukocyte counts were associated with the occurrence of 
exacerbations in the first year in univariate analyses.
32
 However, the effect 
disappeared following multivariate adjustments except for leucocyte counts. 
Approximately 30% of patients with COPD exacerbations have been reported to have 
normal CRP levels,
33
 which questions the validity of CRP as a robust biomarker. 
Furthermore, De Torres et al,
34
 reported that current exposure to glucocorticoids did 
not influence CRP levels, contrary to previous reports.
7
 Consistent with our study, 
there was a huge variation in CRP levels across the mean, suggesting that CRP 
cannot be used as a clinical diagnostic tool.
35
 The exact mechanism by which ICS 
interact with CRP in COPD remains unclear. However, interleukin 6, a potent 
regulator of CRP generation known to be present in high concentrations in the serum 
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and expiratory condensates of patients with COPD, can be down-regulated by 
corticosteroids.
36
 
 
Table 4.3. Risk of severe exacerbations among never and current ICS user stratified by CRP levels. 
 Severe exacerbations 
n=367
b
 
IR 
(/1000PY) 
Age and sex adjusted 
HR 
(95% CI) 
Adjusted 
HR 
(95% CI)
a
 
 
ICS use     
 Never 123 5.1   
  By CRP levels(mg/L)     
     0-3 13 5.2 Reference Reference 
     4-7 12 5.8 1.11 (0.51-2.43)
c
 1.08( 0.49-2.37) 
     ≥8 17 6.9 1.34 (0.65-2.76)
d
 1.24 (0.60-2.56) 
     Missing CRP 81 4.8 0.91 (0.51-1.63)   0.95 ( 0.53-1.70) 
 Current 110 11.0   
By CRP levels(mg/L)     
     0-3 7 7.3 1.35 (0.54-3.38) 0.83 (0.32-2.13) 
     4-7 12 14.4 2.64 (1.21-5.79
 c
 1.60 (0.71-3.60) 
     ≥8 16 14.3  2.64 (1.27-5.50)
d
 1.52 (0.71-3.27) 
     Missing CRP 75 10.6 1.96 (1.09-3.54) 1.22 (0.65-2.28) 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; PY, 
person-years. 
a
Adjusted for age, sex, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, diabetes mellitus, 
ischemic heart disease, osteoporosis, recent ICS use, past ICS use, use of proton-pump inhibitors, antidepressants, oxygen, 
antipsychotics, statins, short-acting beta-2 agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting 
muscarinic antagonists, xanthine derivatives and oral corticosteroids in the 6 months prior and use of antibiotics specific for COPD 1 
month prior. 
Recent ICS users had 39 severe exacerbations; Past ICS users had 95 severe exacerbations 
b
367 severe exacerbations were recorded among 17,722 patients with COPD. 
c
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
d
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
 
All-cause mortality is an important end-point, which is seldom assessed 
among COPD patients mostly due to the short duration of patient follow-up in most 
studies. In our study, we found an increased risk of all-cause mortality among COPD 
patients with elevated CRP levels (8 mg/L) compared to patients with low CRP levels. 
Consistent with our finding, the Lung Heart Study which enrolled over 4,800 patients 
with mild to moderate COPD stratified into CRP quartiles reported that patients with 
elevated CRP levels were at increased risk of all-cause mortality.
37
 Similarly, a cohort 
study of 1,302 patients with airflow limitation with a median follow-up of 8-years in 
Denmark, reported a greater risk of COPD deaths among patients with elevated CRP 
levels compared to patients with lower CRP levels.
12
 However, a randomised double-
blind multi-centre study which enrolled 218 patients with stable COPD, found that 
elevated CRP levels did not increase the risk of all-cause mortality.
34
 This might be 
due to the low statistical power of their study. More recently, a meta-analysis and 
systematic review of 15 studies, which included 11,180 COPD patients, found that 
higher baseline CRP was associated with a higher risk of mortality.
11
 Cardiovascular 
events and cancers accounted for most deaths.
11,38
 With no clear CRP cut-off, 
researchers have called for the adoption of a clearly defined threshold for clinical and 
observational studies, in order to truly reveal the potential role of CRP in COPD 
management.
39
  
The heterogeneity of systemic inflammation has been recognised in patients 
with COPD.  These include high heterogeneity in serum CRP, fibrinogen, and TNF, 
which are largely attributed to host or disease-related factors.
40
 Increased CRP levels 
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have been reported in obese patients and epidemiological data shows an age-related 
increase in inflammatory biomarkers.
40
 In a general population, a dose-related effect 
has been reported between cigarette smoking and increased levels of CRP and 
fibrinogen
41,42
 and CRP levels remained elevated for close to two decades after 
smoking cessation.
43
 
 
Table 4.4. Risk of all-cause mortality among never and current ICS user stratified by CRP levels. 
 All-cause mortality 
n=2,839
b
 
IR 
(/1000PY) 
Age and sex adjusted 
HR 
(95% CI) 
Adjusted 
HR 
(95% CI)
a
 
 
ICS use     
 Never 1,138 47.0   
  By CRP levels(mg/L)     
     0-3 84 33.6 Reference Reference 
     4-7 84 40.5 1.17 (0.86-1.58) 1.21 (0.89-1.63) 
     ≥8 291 117.3 3.11 (2.44-3.96) 2.81 (2.20-3.58) 
     Missing CRP 679 39.6 1.10 (0.88-1.38) 1.16 (0.93-1.46) 
 Current 639 62.4   
By CRP levels(mg/L)     
     0-3 37 37.9 1.08 (0.74-1.59) 0.81 (0.55-1.20) 
     4-7 35 41.2 1.18 (0.80-1.76) 0.90 (0.60-1.34) 
     ≥8 163 142.5 3.59 (2.75-4.67) 2.38 (1.81-3.13) 
     Missing CRP 404 55.6 1.55 (1.22-1.96) 1.15 (0.90-1.47) 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; PY, 
person-years. 
a
Adjusted for age, sex, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, atopic dermatitis, diabetes mellitus, cancer, recent ICS use, past ICS use, use of oxygen, statins, short-acting beta-2 
agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives 
and oral corticosteroid use in the 6 months prior and use of antibiotics specific for COPD 1 month prior. 
Recent ICS users had 264 deaths; Past ICS users had 798 deaths 
b
2,839 deaths were recorded among 17,722 patients with COPD. 
 
Although better understanding of the effects of confounders on CRP levels 
exist, its stability and variability remain critical to its relevance as a guide for 
therapeutic interventions in COPD. The ECLIPSE study reported CRP as the least 
stable biomarker assessed, with only 21% of patients having a 3-months 
measurement within 25% of baseline values.
44
 Furthermore, CRP is known to have a 
half-life of CRP in plasma of 19 hours and the National Health and Nutrition 
Examination Survey (NHANES) observed significant short-term variability 
(approximately 2.5 weeks) in CRP levels, particularly at high values.
45
 This makes 
CRP a poor biomarker for personalised management of COPD.  
 A major strength of this study was the inclusion of patients from one of the 
world’s largest primary care databases, thereby providing a large population-based 
cohort of COPD patients with CRP measurements followed over time with fair 
recording of all-cause mortality.
46,47
 Second, in our study we used validated definitions 
for moderate and/or severe exacerbations of COPD, using read codes reported to 
have a 96% positive predictive value of identifying acute exacerbations within the 
CPRD.
20
 Nevertheless, we may have missed considerable numbers of exacerbations, 
which may be miscoded e.g. as respiratory tract infections such as pneumonia. Third, 
time-varying classification of exposure to ICS, CRP and covariates allowed us to 
conduct an “on-treatment analysis”, which results in less non-differential 
misclassification of exposure than in an `intention to treat analysis` which ignores ICS 
exposure during follow-up. Lastly, data on confounding factors such as smoking 
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status, BMI, comorbidities, and drugs prescribed were available and as such these 
covariates were adjusted for in our models.  
This study also had limitations. There is a potential for confounding by 
disease severity as we lacked information on patients COPD disease stage. 
Confounding by disease severity is a multifactorial phenomenon that may act in 
different directions.  Although we lacked information on the degree of airflow 
limitations we adjusted for proxies of COPD disease severity. While we excluded 
asthma patients, it was impossible to rule out the inclusion of patients with reversible 
airflow limitation. CRP measurements are not routinely collected as part of the 
diagnosis of COPD; they are most likely requested by the GP in suspicion of bacterial 
infections and might have introduced misclassification bias in our study. We expect 
this bias to be non-differential among COPD patients exposed to ICS and ICS never 
users leading to biased estimate towards the null. While this might have masked the 
true risk of moderate and/or severe exacerbations among patients with elevated CRP 
levels, we found significant associations among patients with elevated CRP levels for 
all-cause mortality, suggesting that our results could not have been affected by this 
bias. Furthermore, because ICS use increases the risk of pneumonia, these patients 
might have a higher CRP levels among the ICS users potentially resulting in 
differential misclassification. This will lead to bias estimates towards or away from the 
null. However, considering the similarities in mean CRP levels between “ever before” 
ICS users and ICS non-using patients, it is less likely that this bias had a huge impact 
on or estimates. We had a significant amount of patients with missing CRP serum 
levels during follow-up; this was due to the choice of a 1-year look-back period for 
CRP assessment. While the choice of this look-back window resulted in missing CRP 
values, this choice was rightly made considering the mechanistic plausibility of ICS to 
attenuate CRP and exacerbations over this time period.
9
 The choice of a longer 
period would have resulted in less missing CRP counts during follow-up but will not be 
plausible in clinical settings. 
In conclusion, we did not find a reduced risk of moderate and/or severe 
COPD exacerbations among COPD patients with varying CRP levels currently 
exposed to ICS. However, we found an increased risk of all-cause mortality among 
patients with elevated (≥8 mg/L) CRP levels irrespective of ICS use. There is 
tremendous enthusiasm and effort to improve precision medicine using biomarkers in 
COPD. While CRP might be a useful biomarker for COPD prognosis, it does not seem 
to have the potential to guide ICS therapy in COPD management.  
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Table S.4.1. Risk of moderate-to-severe exacerbations among never and current ICS users stratified by CRP levels. 
 Moderate-to-severe 
n=2,781
b
 
IR 
(/1000PY) 
Age and sex adjusted  
HR 
(95% CI) 
Adjusted  
HR 
(95% CI)
a
 
 
ICS use     
 Never  1,080 47.4   
  By CRP levels (mg/L)   
    0-3 132 54.9 Reference Reference 
    4-7 97 49.1 0.90 (0.69-1.17)
c
 0.88 (0.68-1.14) 
 8-19 98 67.7 1.24 (0.96-1.61)
d
 1.17 (0.90-1.52) 
 ≥ 20 53 59.7 1.11 (0.81-1.53)
e
 1.01 (0.73-1.39) 
 Missing  700 43.5 0.80 (0.66-0.96) 0.83 (0.69-1.00) 
 Past 644 50.4 0.93 (0.77-1.12) 0.80 (0.66-0.97) 
 Recent 285 79.7 1.47 (1.20-1.81) 0.90 (0.72-1.12) 
 Current 772 95.6   
  By CRP levels (mg/L)   
    0-3 72 91.3 1.65 (1.24-2.19) 0.95 (0.70-1.27) 
 4-7 56 82.4 1.50 (1.10-2.05)
c
 0.83 (0.60-1.14) 
    8-19 53 97.0 1.76 (1.28-2.43)
d
 0.95 (0.68-1.31) 
    ≥20 40 114.8  2.17 (1.53-3.10)
e
 1.07 (0.74-1.54) 
    Missing  551 96.5 1.77 (1.46-2.14) 1.01 (0.83-1.24) 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; PY, 
person-years. 
a
Adjusted for age, sex, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, use of antipsychotic, antidepressants, recent ICS use, past ICS use, atopic dermatitis, use of oxygen, short-acting beta-2 
agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives 
and oral corticosteroid 6 months prior and use of antibiotics 1 month prior. 
b
2,781 moderate-to-severe exacerbations were recorded among 17,722 patients with COPD. 
c
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
d
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
e
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
 
 
Table S.4.2. Risk of severe exacerbations among never and current ICS users stratified by CRP levels. 
 Severe exacerbations 
n=367
b
 
IR 
(/1000PY) 
Age and sex adjusted 
 HR 
(95% CI) 
Adjusted  
HR 
(95% CI)
a
 
 
ICS use     
 Never  123 5.1   
  By CRP levels (mg/L)    
    0-3 13 5.2 Reference Reference 
    4-7 12 5.8 1.11 (0.51-2.43)
c
 1.08 (0.49-2.37) 
    8-19 10 6.5 1.27 (0.56-2.90)
d
 1.22 (0.53-2.78) 
    ≥20 7 7.4 1.45 (0.58-3.63)
e
 1.28 (0.51-3.22) 
    Missing 81 4.8 0.91 (0.51-1.63) 0.95 (0.53-1.70) 
 Past 95 6.5 1.24 (0.70-2.22) 1.12 (0.62-2.01) 
 Recent 39 9.0 1.70 (0.91-3.18) 1.13 (0.59-2.18) 
 Current 110 11.0   
  By CRP levels(mg/L)    
    0-3 7 7.3 1.35 (0.54-3.38) 0.83 (0.32-2.13) 
 4-7 12 14.4   2.64 (1.21-5.79)
c
 1.60 (0.71-3.60) 
    8-19 10 14.8   2.72 (1.19-6.20)
d
 1.61 (0.69-3.78) 
    ≥20 6 13.6   2.53 (0.96-6.65)
e
 1.39 (0.52-3.77) 
    Missing  75 10.6 1.96 (1.09-3.54) 1.22 (0.65-2.28) 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; PY, 
person-years. 
a
Adjusted for age, sex, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, diabetes mellitus, 
ischemic heart disease, osteoporosis, use of proton-pump inhibitors, antidepressants, recent ICS use, past ICS use, oxygen, 
antipsychotics, statins, short-acting beta-2 agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting 
muscarinic antagonists, xanthine derivatives and oral corticosteroids in the 6 months prior and use of antibiotics specific for COPD 1 
month prior. 
b
367 severe exacerbations were recorded among 17,722 patients with COPD. 
c
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
d
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
e
Wald test showed that these categories were statistically significantly different, despite overlapping confidence intervals. 
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Table S.4.3. Risk of all-cause mortality among never and current ICS users stratified by CRP levels 
 All-cause mortality 
n=2,839
b
 
IR 
(/1000PY) 
Age and sex adjusted  
HR 
(95% CI) 
Adjusted 
 HR 
(95% CI)
a
 
 
ICS use     
Never 1,138 47.0   
  By CRP levels(mg/L)    
     0-3 84 33.6 Reference Reference 
     4-7 84 40.5 1.17 (0.86-1.58) 1.21 (0.89-1.64) 
     8-19 106 69.0 1.89 (1.42-2.52) 1.84 (1.38-2.45) 
     ≥20 185 196.0 4.93 (3.81-6.38) 4.03 (3.11-5.22) 
  Missing 679 39.6 1.10 (0.88-1.38) 1.17 (0.93-1.47) 
Past 798 53.9 1.46 (1.16-1.82) 1.43 (1.14-1.79) 
Recent 264 60.0 1.68 (1.32-2.15) 1.44 (1.12-1.84) 
Current 639 62.4   
   By CRP levels(mg/L)    
     0-3 37 37.9 1.08 (0.74-1.59) 0.88 (0.59-1.29) 
     4-7 35 41.2 1.18 (0.80-1.76) 0.97 (0.65-1.44) 
     8-19 66 95.3 2.54 (1.84-3.50) 2.02 (1.46-2.80) 
     ≥20 97 214.6 5.00 (3.73-6.70) 3.17 (2.36-4.27) 
     Missing 404 55.6 1.55 (1.22-1.96) 1.24 (0.98-1.57) 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; PY, 
person-years. 
a
Adjusted for age, sex, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, atopic dermatitis, diabetes mellitus, cancer, use of oxygen, statins, recent ICS use, past ICS use, short-acting beta-2 
agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives 
and oral corticosteroid use in the 6 months prior and use of antibiotics specific for COPD 1 month prior. 
b
2,839 deaths were recorded among 17,722 patients with COPD. 
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ABSTRACT  
 
Background: It remains unclear whether eosinophilia is useful in guiding inhaled 
corticosteroid (ICS) therapy in chronic obstructive pulmonary disease (COPD) 
patients. The goal of this study was to evaluate the risk of acute exacerbations, 
COPD-related hospitalisations/accident and emergency (AE) visits and all-cause 
mortality with various levels of eosinophil counts among COPD patients using ICS. 
 
Methods: A cohort study was conducted using the United Kingdom (UK) Clinical 
Practice Research Datalink. Patients were aged ≥40 years and had COPD 
(n=32,693). Current users of ICS were stratified by relative and absolute eosinophil 
counts to determine the risk of outcomes with blood eosinophilia using Cox regression 
analysis. 
 
Results: Among COPD patients, current use of ICS was not associated with a 
reduced risk of acute COPD exacerbations, COPD-related hospitalisations/AE visits 
and all-cause mortality. Stratification of ICS use by absolute or relative eosinophil 
counts did not result in significant differences in risk of COPD exacerbations or 
hospitalisations/AE visits. However, all-cause mortality was reduced by 12-24% 
among patients with eosinophilia.  
 
Conclusions: COPD–related acute exacerbations or hospitalisations/AE visits were 
not reduced with eosinophilia among users of ICS with COPD. However, all-cause 
mortality was reduced by 12%-24%. These findings are potentially important and 
require further evaluation in prospective studies. 
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INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality worldwide and is defined by the presence of chronic respiratory symptoms 
and persistent airflow limitation.
1
 While bronchodilators are the cornerstone of 
pharmacological management of COPD, patients with frequent exacerbations are 
often additionally treated with inhaled corticosteroids (ICS).
2
 Exacerbations play a 
central role in the pathophysiology of COPD as they are related to lung function 
decline, poor health status and increased mortality.
3
 While non-response to ICS 
therapy is common,
4
 potential side effects of ICS include fractures and pneumonia.  
Clinical data have suggested that blood eosinophil count, which is present in 
up to 40% of COPD patients,
5
 is a promising biomarker of response to ICS in patients 
with COPD.
6–9
 Eosinophilic airway inflammation has been associated with an 
increased risk of exacerbations, and patients with eosinophilic inflammation 
responded better to ICS therapy than non-eosinophilic patients.
6,10
 Pascoe and 
colleagues,
6
 performed a post-hoc analysis of data from two replicate, randomised, 
double blind trials with duration of 12 months. In the analysis, vilanterol 25μg was 
compared with 25μg vilanterol plus 50μg, 100μg, or 200μg fluticasone furoate in 
patients with moderate-to-severe COPD. They observed that 68% of COPD patients 
had peripheral blood eosinophilia. Importantly, across all doses of ICS, fluticasone 
furoate and vilanterol reduced exacerbations by 29% compared with vilanterol alone 
in patients with eosinophil counts ≥ 2%, and by 10% in patients with eosinophil counts 
<2%. Analysis of data from the FLAME trial, showed no significant reduction in 
exacerbation among COPD patients exposed to salmeterol/fluticasone compared to 
indacaterol/gycopyrronium at blood eosinophil levels of 150-300 cells/µL versus 300 
cells/µL.
8
 In this study, we use the word “eosinophilia” to mean elevated blood 
eosinophil counts based on our defined cut-offs. 
However, studies with real-world evidence are currently limited and are 
needed to identify patients who will benefit from ICS use. Therefore, the aim of this 
study was to evaluate the risk of acute exacerbations, COPD-related 
hospitalisations/accident and emergency (AE) visits and all-cause mortality, with 
various levels of eosinophil counts among COPD patients using ICS. 
 
METHODS  
 
Data source 
This study was conducted with data obtained from the Clinical Practice Research 
Datalink (CPRD). It provides detailed information on drug prescriptions, clinical 
events, demographics, specialist referrals, hospital admissions, and electronic lab link 
data of patients from 674 general practices, who are representative for 7% of the total 
British population.
11,12
 Data collection started on 1 January 2005, corresponding to the 
introduction of the Quality and Outcomes Framework (QOF) in April 2004, which 
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improved routine recording of various diseases, including COPD.
13
 Routinely collected 
historical data was available, dating back to 1987. Previous studies with the CPRD 
have shown a high level of validity of recording of COPD,
11
 and COPD 
exacerbations.
14
 CPRD has previously been used to study COPD.
15–17
 The 
independent scientific advisory committee of Medicines and Healthcare products 
Regulatory Agency (MHRA) database research approved the study protocol (No: 
17_065R). 
 
Study population 
We selected all patients aged ≥40 years with a diagnosis of COPD, as recorded by a 
first read code during valid data collection from 1 January 2005 through 31 January 
2014. We excluded all patients with a diagnosis of COPD as recorded by validated 
read codes before 1 January 2005. Patients were followed from the date of their 
COPD diagnosis (index date) until the end of data collection, date of death, end of 
study (31 January 2014) or when the outcome of interest occurred, whichever came 
first. The primary outcome of interest was an acute exacerbation of COPD, using 
validated read codes for acute exacerbations of COPD with 96% positive predictive 
value (PPV) in identifying acute exacerbations in the CPRD.
18
 Secondary outcomes 
were hospitalisation/AE visit for COPD and all-cause mortality.  Only patients with 
blood eosinophil counts measured during study period were included. Blood 
eosinophil count closest to index date (i.e. start of follow-up) was used in our 
analyses. Relatively stable blood eosinophil counts have been reported among COPD 
patients over time within the UK population, irrespective of exposure to systemic 
glucocorticoids or other factors.
19,20
 We excluded patients with a history of asthma, 
those with COPD exacerbations, those with oral corticosteroids in the past month or 
those with ICS use in the past year. 
 
Exposure 
Exposure to ICS was determined time-dependently during follow-up. Each patient’s 
follow-up time was divided into fixed periods of 90 days, starting at index date. Prior to 
the start of each interval, ICS exposure was determined based on the date of the 
prescription, and classified as current, recent, past or never use (patient without ICS 
exposure). Current users had received their most recent ICS prescription within the 30 
days prior to the start of an interval, recent users were those with their most recent 
ICS prescription between 31 and 60 days prior, and past users were issued their most 
recent ICS prescription more than 60 days ago. Never users were those with no prior 
or current exposure to ICS at the start of an interval. At index date all patients were 
classified as never or current users, and could then move between exposure groups 
over time – meaning that e.g. past and recent users could become current users 
again when a new ICS prescription was issued. Current ICS users were stratified by 
serum counts of blood eosinophil at baseline and classified as low (<2.0%), moderate 
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(≥2.0 to 3.9%), high (4.0% to 5.9%) or very high (≥6.0%). We also stratified by 
absolute blood eosinophil count (<0.34 x 10
9
 cells/L versus ≥0.34 x 109 cells/L). We  
 
 
 
                         Figure 5.1: Flow chart showing the selection of eligible patients. 
 
 
 
chose this analysis approach because of its reliability, in adequately assessing 
exposure status and covariates, which is essential to the validity of our results.
21
 
 
Covariates  
Potential confounders were assessed time-dependently; with the exception of gender, 
smoking status, alcohol use, and body mass index, which were determined at 
baseline. The following covariates were considered as potential confounders, and 
COPD Patients:
213,561
COPD Patients:
115,256
COPD Patients:
77,862
COPD Patients:
43,484
COPD Patients:
36,136
COPD Patients:
32,903
COPD Patients:
32,693
COPD Patients:
32,910
Index date before January 2005
n=98,305
Patients without absolute blood 
eosinophils and total WBC recording
n=37,394
ICS use 1 year prior
n=34,378
History of asthma
n=7,348
Oral corticosteroid use 
30 days prior
n=3,226
Acute exacerbations 30 days prior
n=7
Patients with missing data
n=210
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identified at the start of each 90-day interval: a history of congestive heart failure, 
anaemia, chronic liver disease, allergic rhinitis, all malignancies except non-
melanoma skin cancer, ischaemic heart disease, stroke, rheumatoid arthritis, diabetes 
mellitus, hypertension, pulmonary fibrosis, osteoporosis, and anxiety. Additionally, the 
use of antihistamines, oxygen, proton-pump inhibitors, antipsychotics, 
antidepressants, or statins were identified in the past 6 months.
22–26
 We adjusted for 
proxy indicators of the severity of obstructive airway disease, as previously defined as 
dispensed prescriptions of, short and long-acting beta-agonists, short and long-acting 
muscarinic antagonists, xanthine derivatives and oral corticosteroids.
27,28
 
 
Statistical analysis 
We evaluated the risk of study outcomes stratified by ICS use, gender, and age using 
Cox regression analysis SAS 9.4 PHREG procedure (SAS Institute, Cary, NC). 
Current ICS use was further, stratified by blood eosinophil counts. The difference 
between each eosinophil count strata was tested using Wald’s test for relative and 
absolute blood eosinophil counts. To avoid immortal time bias, all patients were 
classified as never users until the first ICS prescription after the index date, and all 
exposure categories of ICS use were incorporated into the statistical model time-
dependently. We ran separate models for age, gender, absolute and relative counts 
avoiding collinearity between absolute and relative eosinophil counts. Kaplan-Meier 
curves were plotted using the life table procedure. Potential confounders were 
included in the final models if they independently changed the β-coefficient for current 
ICS exposure by at least 5%, or when consensus existed within the team of 
researchers. 
 
RESULTS  
 
We identified 213,561 patients with COPD, of whom 32,693 met the inclusion criteria 
(Figure 5.1). Table 5.1 shows the baseline characteristics of COPD patients, who 
were predominantly elderly males. At baseline, the mean blood eosinophil count was 
3.1% (± 2.7%) and 64.1% had a relative blood eosinophil count ≥2.0%. More than half 
of all patients were either overweight (31.9%) or obese (25.8%), and a considerable 
proportion of COPD patients suffered from ischemic heart disease (15.4%). 
 
Acute COPD exacerbations 
Current use of ICS was not associated with a significant reduction in risk of acute 
exacerbations (adjusted hazard ratio [adj.HR] 1.15; 95% confidence interval [CI] 1.09-
1.21), Table 5.2 The risk of acute COPD exacerbations was not significantly lower 
among current ICS users with relative eosinophil counts ≥2%, as compared to current 
users with relative counts <2%. This was similar when comparing absolute blood 
eosinophil counts ≥0.34 x 109 cells/L with counts <0.34 x 109 cells/L. There was no 
difference in risk of acute exacerbations between all relative and absolute eosinophil 
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categories.  Figure 5.2a shows KM analysis. When stratified by age and gender, no 
significant association with the risk of acute exacerbations was observed, using males 
or those aged 40-59 as the reference (Table 5.2). 
 
Table 5.1. Baseline characteristics of COPD patients.  
    
 
 
n=32,693 % 
Females 14,551 44.5 
Mean age (years, SD) 68.4 10.8 
Mean Follow-up time (years, SD) 3·1 2·2 
Age category (years) 
  
  40-59 6,902 21.1 
  60-79 20,350 62.3 
  80+ 5,441 16.76 
BMI (kg/m
2
) in the past 6 months 
  
 Underweight (BMI < 18.5 kg/m
2
) 1,704 5.2 
 Normal weight (BMI 18.5-24.9 kg/ m
2
) 11,286 34.5 
 Overweight (BMI 25.0-30.0kg/ m
2
) 10,412 31.9 
 Obese (BMI > 30.0 kg/ m
2
) 8,437 25.8 
 Missing 854 2.6 
Mean relative eosinophil count (%, SD) 3·1 2·7 
Relative blood eosinophil count  
  
 Low (<2.0%) 11,756 36.0 
 Moderate (≥2.0% - 3.9%) 13,059 39.9 
 High (4.0% - 5.9%) 5,110 15.6 
 Very High (≥ 6.0%) 2,768 8.5 
Absolute blood eosinophil count  
  
 <0.34 x 10
9
 cells/L 26,828 82.1 
 ≥0.34 x 10
9
 cells/L 5,865 17.9 
Smoking status at index date 
  
 Never 3,285 10.1 
 Current 14,522 44.4 
 Former  14,849 45.4 
 Missing 37 0.1 
Drug use (in the past 6 months) 
  
 SABAs 15,307 46.8 
 LABAs 2,724 8.3 
 SAMAs 2,451 7.5 
 LAMAs 4,432 13.6 
 Xanthine derivatives 97 0.3 
 Antipsychotics 352 1.1 
History of co-morbidities  
  
 Diabetes Mellitus 4,027 12.3 
 Anxiety 4,865 14.8 
 Osteoporosis 1,872 5.7 
 Malignancies excluding non-melanoma skin cancer 4,867 14.9 
 Chronic liver disease 110 0.3 
 Ischaemic heart disease 5,027 15.4 
Abbreviations: SD, standard deviation; COPD, chronic obstructive pulmonary disease; BMI, body mass index; SABAs, short-acting 
beta-2 agonists; LABAs, long-acting beta-2 agonists; SAMAs, short-acting muscarinic antagonists; LAMAs, long-acting muscarinic 
antagonists; ICS, inhaled corticosteroids. 
 
COPD-related hospitalisations/accident and emergency visits 
Current use of ICS was associated with a 1.2-fold increased risk of COPD-related 
hospitalisations/AE visits (adj.HR 1.17; 95% CI: 1.04-1.32). Similar to acute COPD 
exacerbations, stratification by absolute or relative blood eosinophil count did not 
result in a significant difference in risk of COPD-related hospitalisations/AE visits). We 
also found no difference in risk when we tested the difference in risk between 
absolute and relative blood eosinophil counts.  Figure 5.2b shows the KM life table 
analysis curves. We did not identify an increased risk of hospitalisations with current 
female ICS users compared to current male ICS users (adj.HR 0.98; 95% CI 0.77-
1.11, Table 5.3), and there were no differences in the risk of hospitalisations with 
increasing age groups (Table 5.3). 
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Table 5.2 Risk of acute COPD exacerbations with current use of ICS, stratified by blood eosinophil counts, gender and age. 
  
Exacerbations IR Age and gender adjusted 
HR 
(95% CI) 
Adjusted HR 
(95% CI)
a
 n=14,523
d
 (/1000 PY) 
ICS use 
    
 Never  8,744 128.8 Reference Reference 
 Past 2,538 137.7 0.99 (0.99-1.04) 0.94 (0.90-0.99) 
 Recent 882 188.7 1.38 (1.28-1.47) 1.11 (1.03-1.19) 
 Current 2,359 208.6 1.49 (1.41-1.55) 1. 15 (1.09-1.21) 
   By relative blood eosinophil count 
  
      Low (<2.0%) 838 207.5 Reference Reference 
      Moderate (≥2.0%-3.9%) 943 211.4 1.01 (0.92-1.11) 1.03 (0.93-1.13) 
      High (4.0%-5.9%) 373 214.6 1.03 (0.91-1.16) 1.04(0.92-1.17) 
      Very High (≥6.0%) 205 191.4 0.93 (0.79-1.08) 0.95(0.81-1.11) 
   By absolute blood eosinophil count 
  
       <0.34 x 10
9
 cells/L 1,907 208.5 Reference Reference 
       ≥0.34 x 10
9
 cells/L 452 209 1.00 (0.90-1.11) 0.99 (0.89-1.09) 
   By gender 
    
       Males 1,348 211.3 Reference Reference
b
 
       Female  1,011 205.2 0.95 (0.88-1.04) 0.97 (0.89-1.05) 
    By age categories 
    
        40-59 years 561 214.2 Reference Reference
c
 
        60-79 years 1,539 212.5 1.01 (0.92-1.11) 1.03 (0.93-1.13) 
        80+ year 259 179.3 0.89 (0.77-1.03) 0.99 (0.85-1.14) 
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, 
confidence interval; PY, person-years. 
a
adjusted for age, gender, smoking status, alcohol use, BMI, a history of heart failure, diabetes mellitus, chronic liver disease, 
pulmonary fibrosis, ischaemic heart disease, osteoporosis, anxiety, hypertension, anaemia, and the use of antipsychotics, statins, 
oxygen, proton-pump inhibitors, antidepressants, or antipsychotics, long-acting beta-2 agonist, short-acting beta-2 agonist, short-
acting muscarinic agent, long-acting muscarinic antagonist, xanthine derivatives and oral corticosteroid use 6 months prior to the start 
of an interval. 
b
adjusted for all confounders under (a) except gender. 
c
adjusted for all confounders under (a) except  age. 
d
14,523exacerbations were recorded among 32,693 patients with COPD. 
Note: We evaluated the risk of study outcomes stratified by ICS use, gender, and age using Cox regression analysis. 
 
 
All-Cause Mortality 
Current use of ICS was associated with a statistically significantly increased risk of all-
cause mortality (adj.HR 1.20; 95% CI 1.12-1.29) compared to never ICS users, 
sTable 4. In contrast to the previous outcomes, when current ICS users were stratified 
by relative blood eosinophil counts, we observed a decreased risk of all-cause 
mortality among patients with increased eosinophil counts as compared to those with 
low (<2%) eosinophil counts. We found a difference in risk of all-cause mortality 
between patients with low and moderate relative eosinophil counts (p=0.001). No 
difference was found with absolute blood eosinophil counts. The KM curve shows 
differences in the proportion of patients with COPD who survived, stratified by relative 
blood eosinophil counts (Figure 5.2c). Stratification to by absolute blood eosinophil 
count did not show a significant association with all-cause mortality adj HR 0.92; 95% 
CI (0.79-1.06) for patients with absolute eosinophil counts ≥0.34 x 109 cells/L versus 
counts <0.34 x 10
9
 cells/L. Female users of ICS had a 21% decreased risk of all-
cause mortality (adj.HR 0.79; 95% CI 0.69-0.88) compared to males, and we found an 
increased risk of all-cause mortality with age (Table 5.4). 
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Table 5.3. Risk of COPD hospitalisations/AE visits with current use of ICS by blood  eosinophil counts, gender and age. 
  
COPD 
Hospitalisations/ 
AE visits 
n= 1,987
d
 
IR 
Age and gender adjusted 
 HR 
 (95% CI) 
Adjusted HR 
(95% CI) 
a
 
(/1000 
PY) 
ICS use 
    
 Never  973 11.9 Reference Reference 
 Past 366 14.1 1.05 (0.93-1.19) 0.98 (0.87-1.11) 
 Recent 166 21.6 1.55 (1.31-1.82) 1.11 (0.93-1.31) 
 Current 482 24.5 1.71 (1.53-1.91) 1.17 (1.04-1.32) 
   By relative blood eosinophil count 
        Low (<2.0%) 176 25.7 Reference Reference 
      Moderate (≥2.0%-3.9%) 183 23.5 0.91 (0.73-1.11) 0.93(0.75 -1.14) 
      High (4.0%-5.9%) 78 25.1 0.96 (0.73-1.26) 0.99 (0.76-1.29) 
      Very High (≥6.0%) 45 23.9 0.93 (0.67-1.29) 0.97 (0.69-1.35) 
   By absolute blood eosinophil count 
         <0.34 x 109 cells/L 395 25.0 Reference Reference 
       ≥0.34 x 10
9
 cells/L 87 22.5 0.89 (0.71-1.13) 0.89 (0.70-1.12) 
   By gender 
           Males 258 23.5 Reference Referenceb 
       Female  224 25.9 1.09 (0.91-1.31) 0.98 (0.77-1.11) 
    By age categories 
            40-59 years 108 23.4 Reference Referencec 
        60-79 years 326 25.4 1.11 (1.08-1.58) 1.18 (0.94-1.48) 
        80+ year 48 21.8 1.17 (0.73-1.44) 1.29 (0.89-1.85) 
Abbreviations:  COPD, chronic obstructive pulmonary disease; ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, 
confidence interval; PY, person-years; AE, accident and emergency. 
a
adjusted for age, gender, smoking status, alcohol use, BMI, a history of heart failure, diabetes mellitus, chronic liver disease, pulmonary 
fibrosis, ischaemic heart disease, osteoporosis, anxiety, hypertension, anaemia, and the use of antipsychotics, statins, oxygen, proton-
pump inhibitors, antidepressants, antipsychotics, long-acting beta-2 agonist, short-acting beta-2 agonist, short-acting muscarinic agent, 
long-acting muscarinic antagonist, xanthine derivatives and oral corticosteroid use  6 months prior to the start of an interval.  
b
adjusted for all confounders under (a) except gender. 
c
adjusted for all confounders under (a) except  age. 
d
1,987 COPD hospitalisations/AE visits occurred in 32,693 patients with COPD. 
Note:  We evaluated the risk of hospitalisation/AE visits for COPD stratified by ICS use, gender, and age using Cox regression analysis. 
 
DISCUSSION  
We found no reduced risk of COPD-related acute exacerbations or 
hospitalisations/AE visits among patients with blood eosinophilia in COPD patients 
using ICS. However, all-cause mortality was reduced among current ICS users with 
blood eosinophilia compared to current ICS users with low relative blood eosinophil 
count. However, this effect could not be detected with absolute eosinophil counts. 
 
ICS use and risk of exacerbations or COPD-related hospitalisations/AE visits 
As compared to never users, current users of ICS had a significantly 
increased risk of exacerbations or COPD-related hospitalisations/AE visits, although 
the risk between recent and current users was comparable. Similarly, Melo et al found 
an increased risk of first exacerbation among COPD patients currently exposed to 
ICS.
27
 Since ICS are prescribed in order to prevent these events, confounding by 
disease severity may explain this, in particular because the association is also present 
among ICS users who have recently stopped taking the drugs (recent users). 
Furthermore, recent and current users of ICS in our study might represent a different 
phenotype of COPD patients, maybe the so-called frequent exacerbators.
29
 Although 
a multicentre 4-year double blind study in COPD patients also reported an increased 
risk of first COPD exacerbation in patients exposed to any ICS compared to patients 
not exposed to ICS.
30
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Table 5.4. Risk of all-cause mortality with current use of ICS by baseline blood eosinophil counts, gender and age. 
  
All-cause 
mortality 
n= 6,181
 d
 
IR Age and gender adjusted 
 HR  
(95% CI) 
Adjusted HR 
(95% CI)
a
 
(/1000 
PY) 
ICS use 
    
 Never  3,160 38.3 Reference Reference 
 Past 1,343 49.8 1.32 (1.23-1.39) 1.25 (1.17-1.33) 
 Recent 484 59.7 1.67(1.52-1.84) 1.36 (1.23-1.49) 
 Current 1,194 57.4 1.56 (1.46-1.67) 1.20 (1.12-1.29) 
   By relative blood eosinophil count 
  
      Low (<2.0%) 477 65.5 Reference Reference 
      Moderate (≥2.0%-3.9%) 435 52.9 0.81 (0.71-0.92) 0.88 (0.77-0.99) 
      High (4.0%-5.9%) 168 51.2 0.73 (0.61-0.87) 0.79 (0.66-0.94) 
      Very High (≥6.0%) 114 56.7 0.71 (0.58-0.87) 0.76 (0.62-0.93) 
   By absolute blood eosinophil count 
  
       <0.34 x 10
9
 cells/L 959 57.4 Reference Reference 
       ≥0.34 x 10
9
 cells/L 235 57.1 0.90 (0.78-1.04) 0.92 (0.79-1.06) 
   By gender 
    
       Males 712 60.9 Reference Reference
b
 
       Female  482 52.8 0.81 (0.72-0.91) 0.79 (0.69-0.86) 
    By age categories 
    
        40-59 years 88 17.9 Reference Reference
c
 
        60-79 years 729 53.6 2.97 (2.38-3.70) 2.38 (1.89-3.00) 
        80+ year 377 164.5 9.31 (7.31-11.74) 5.07 (3.96-6.49) 
Abbreviations:  COPD, chronic obstructive pulmonary disease; ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, 
confidence interval; PY, person-years. 
a
adjusted for age, gender, smoking status, alcohol use, BMI, heart failure, atrial fibrillation, diabetes, anxiety, chronic liver disease, all 
cancers except non-melanoma skin cancer, stroke, antipsychotics, long-acting beta-2 agonist, short-acting beta-2 agonist, short-acting 
muscarinic agent, long-acting muscarinic antagonist, xanthine derivatives and oral corticosteroid use 6 months prior to the start of an 
interval.   
b
adjusted for all confounders under (a) except gender. 
c
adjusted for all confounders under (a) except age. 
d
6,181 patients died after follow-up of 32,693 patients with COPD. 
Note: We evaluated the risk of all-cause mortality stratified by ICS use, gender, and age using Cox regression analysis. 
Impact of blood eosinophil counts on exacerbations and COPD-related 
hospitalisations/AE visits 
Our findings are partially in line with previous research. While traditionally 
considered a characteristic of asthma, several studies have reported eosinophilic 
inflammation in patients with COPD.
31,32
 Pascoe and colleagues,
6
 concluded that 
COPD patients treated with ICS with higher blood eosinophil counts had reduced 
exacerbations compared to those with low blood eosinophil counts. While our 
observational study results are in contrast to this it is important to note we excluded 
patients with a history of asthma while Pascoe and co-workers only exclude active 
asthma patients and included patients with one or more exacerbations in previous 
year.
33
 The FLAME trial evaluated the time to the first exacerbation in COPD patients 
exposed to indacaterol/gycopyrronium compared to salmeterol/fluticasone and found 
no significant risk reduction in exacerbations among patients with blood eosinophil 
levels of 150 up to 300 cells/µL, versus 300 cells/µL or more.
8
 When comparing our 
results to both previous studies, an important distinction was the comparator group, 
which may explain differences in results. Our findings were consistent with post-hoc 
analyses from the ISOLDE trial.
34
 It showed no difference in the time-to-first 
exacerbation in patients with high or low eosinophil counts. It is important to note that 
our study also employed the time-to-first exacerbation approach. Similar to our study, 
three randomised clinical trials that studied blood eosinophils and ICS/long-acting 
bronchodilator reported no statistically significant effects for time to first 
moderate/severe exacerbation in patients with relative eosinophils counts ≥2% versus 
counts <2%.
35
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Impact of blood eosinophil counts on all-cause mortality 
Our findings are in agreement with a study which evaluated the 3-year survival using 
relative eosinophil count cut-off of ≥2%, which showed that COPD patients with higher 
blood eosinophil counts had a significantly decreased 3-year mortality compared to 
COPD patients with blood eosinophil counts <2% exposed to ICS.
36
 However a 
randomised, double-blind, placebo-controlled study by Barnes and co-workers,
34
 
using subjects from the ISOLDE study, found no difference in the risk of deaths in 
COPD patients exposed to ICS with  different eosinophil counts. Similarly, a clinical 
study involving 303 patients with COPD found that elevated blood eosinophil counts 
(≥200, 300, 400 cells/µL) were not associated with mortality when compared with 
patients with decreased eosinophil counts.
37
  
In recent years, various researchers have questioned the use of the 2% cut-
off adopted by various studies to determine effective response to ICS in patients with 
COPD, others have argued in favour of the use of absolute blood eosinophil counts in 
making clinically beneficial decisions for patients with COPD.
5,38,39
 As absolute counts 
are less affected by total white blood cell count.
8
 Vedel-Krogh et al suggested that 
0.34 x 10
9
 cells/L cut-off was appropriate in detecting COPD exacerbations because 
this cut-off was associated with increased risk of moderate and severe exacerbations 
in patients with COPD in population-based settings.
5
 The exact mechanism underlying 
the presumed changes in COPD-related exacerbations in patients with varying 
baseline blood eosinophil counts remains unclear.
6,7
 However, it might be due to the 
non-T helper2 eosinophilic inflammation in COPD, induced by the epithelial innate 
lymphoid cell type 2 pathways. Innate lymphoid cell type 2 has been recognised in 
relation to the pathogenesis in severe non-allergic eosinophilic asthma.
40
  
Strengths and limitations 
A major strength of this study was the use of data from one of the world’s 
largest primary care databases, thereby providing a very large population-based 
cohort of COPD patients with eosinophil measurements. Second, we used a validated 
definition for an acute exacerbation of COPD, using read codes which were reported 
to show a 96% PPV of identifying an acute exacerbation within the CPRD.
18
 
Nevertheless, we may have missed a considerable amount of exacerbations that may 
be miscoded e.g. as respiratory tract infections or pneumonia. Third, Classification of 
exposure to ICS and covariates time-dependently during follow-up allowed us to 
conduct an “on-treatment analysis”, which results in less non-differential 
misclassification of exposure than in an `intention to treat analysis` which ignores ICS 
exposure during follow-up. Fourth, we eliminated patients with a history of asthma to 
avoid patients with reversible airflow limitation from our study. Lastly, we had 
information on important confounding factors such as smoking status, BMI and other 
comorbidities and drug use. Despite numerous strengths, this study also had 
limitations. In addition to those already mentioned, there is a potential for residual 
confounding as we lacked information on the disease severity and previous 
exacerbations. Although the positive predictive value of identifying patients with 
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COPD in the CPRD is 90%,
11
 lung function data were unavailable. While we excluded 
asthma patients, it was impossible to rule out the inclusion of patients with reversible 
airflow limitation.
41
 We lacked information on cause-specific mortality; as such we 
could not perform detailed analysis on the cause of death. Eosinophil counts are not 
been routinely collected as part of diagnosis of COPD patients, and thus, the patient 
population in this study may not be representative of all COPD patients. Moreover, 
this could have masked a true association between eosinophil counts and various 
outcomes. ICS inhalers are known to last for 25 to 100 days depending on the active 
ingredient and the dose prescribed by the GP,
42
 this might have led to non-differential 
misclassification of ICS exposure, masking the true effect (bias towards the null) 
leading to insignificant findings. Without this potential distortion, the risk of acute 
exacerbations or hospitalisation/AE visits might have been lower for patients with 
elevated blood eosinophil counts. However, we detected a significant risk of all-cause 
mortality irrespective of blood eosinophil counts, we do not believe that our results are 
influenced by the potential of a non-differential misclassification. 
In conclusion, among COPD patients, we did not find a reduced risk of 
COPD-related acute exacerbations or hospitalisations/AE visits among patients with 
blood eosinophilia in COPD patients using ICS. However, all-cause mortality was 
reduced among current ICS users with blood eosinophilia compared to current ICS 
users with low relative blood eosinophil count. However, this effect could not be 
detected with the absolute eosinophil counts. There is an increasing body of evidence 
linking blood eosinophil counts to clinically relevant outcomes in patients with COPD. 
As such, these findings are potentially important and require further evaluation in 
prospective studies. 
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Figure 5.2. Kaplan Meier curve showing a) Proportion of patients without exacerbations with current ICS users stratified by blood 
eosinophil counts. b) Proportion of patients without COPD hospitalisations / accident and emergency visits among current ICS 
users stratified by blood eosinophil counts.  c) Proportion of patients who survived among current ICS users stratified by relative 
blood eosinophil counts. 
c 
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ABSTRACT  
Background: Although recently introduced in the pharmacological treatment 
algorithm of chronic obstructive pulmonary disease (COPD), there is a need for more 
data supporting the use of blood eosinophil counts as a biomarker to guide inhaled 
corticosteroids (ICS) therapy. The aim of this study was to evaluate the risk of 
moderate and/or severe exacerbations and all-cause mortality in a large primary care 
population after withdrawal of ICS compared to continued users stratified by elevated 
blood eosinophil counts. 
 
Methods: In this population-based cohort study, we used data from the Clinical 
Practice Research Datalink (CPRD) in the United Kingdom. We included subjects’ 
age 40 or more who had a diagnosis of COPD. We excluded subjects with a history of 
asthma, pulmonary fibrosis, cardiac arrhythmia and bronchiectasis, COPD 
exacerbations occurring within 6 weeks prior to index date, or with myocardial 
infarction within 3 months prior to index date. Continuous users were subjects who 
received their most recent ICS prescription within 3 months before the start of an 
interval. ICS withdrawals were those who discontinued ICS for more than 3 months. 
We evaluated the risk of moderate and/or severe exacerbations and all-cause 
mortality among subjects with various blood eosinophil thresholds who withdrew from 
ICS compared to continuous ICS users with elevated blood eosinophil levels using 
Cox regression analysis adjusted for potential confounders. 
 
Results: We identified 48,157 subjects diagnosed with COPD between 1 January 
2005 to 31 January 2014. Withdrawal of ICS was not associated with an increased 
risk of moderate-to-severe exacerbations among subjects with absolute blood 
eosinophil counts ≥0.34 x 109 cells/L (adjusted hazard ratio [adj. HR] 0.72; 95% 
confidence interval [CI] 0.63-0.81) or relative counts ≥ 4.0% (adj.HR 0.72; 95% CI: 
0.66-0.78). Similarly, withdrawal of ICS was not associated with an increased risk of 
severe exacerbations among subjects with absolute blood eosinophil ≥0.34 x 109 
cells/L (adj.HR 0.82; 95% CI: 0.61-1.10) or relative blood eosinophil counts ≥ 4.0% 
(adj.HR 0.80; 95% CI: 0.61-1.04). No increased risk of all-cause mortality was 
observed among subjects who withdrew from ICS irrespective of elevated absolute or 
relative blood eosinophil counts.  
 
Interpretation: In a real-world primary care population, we did not observe an 
increased risk of moderate and/or severe COPD exacerbations or all-cause mortality 
among subjects with eosinophilia who withdrew their use of ICS.  
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INTRODUCTION  
 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality worldwide and is defined by the presence of chronic respiratory symptoms 
and persistent airflow limitation
1
. Exacerbations play a central role in the 
pathophysiology of COPD as they are related to lung function decline, poor health 
status and increased mortality.
2
 While bronchodilators are the cornerstone of 
pharmacological management of COPD, patients with frequent exacerbations are 
often additionally treated with inhaled corticosteroids (ICS).
3
 While non-response to 
ICS therapy is common,
4
 potential side effects of ICS include fractures and 
pneumonia.
3
 
Clinical data have suggested that elevated blood eosinophil counts, which is 
present in up to 40% of COPD patients,
5
 is a promising biomarker of response to 
ICS.
6–9
 Eosinophilic airway inflammation has been associated with an increased risk 
of exacerbations, and patients with eosinophilic inflammation responded better to ICS 
therapy than non-eosinophilic patients.
6,10
 The role of eosinophils in guiding ICS 
therapy is a growing area of research. Pascoe and colleagues,
6
 performed a post-hoc 
analysis of data and found that across all doses of ICS, fluticasone furoate and 
vilanterol reduced exacerbations by 29% compared with vilanterol alone in patients 
with eosinophil counts ≥2%, and by 10% in patients with eosinophil counts <2%. 
Analysis of data from the Withdrawal of Inhaled Steroids during Optimized 
Bronchodilator Management (WISDOM) trial showed a reduction of the rate of 
moderate and severe exacerbations in patients with relative eosinophil counts of 4% 
or more, or absolute eosinophil counts of 300 cells/µL or higher when ICS was 
continued compared to patients with the same eosinophil counts who tapered off ICS 
use. Therefore, it has been suggested that withdrawal of ICS in patients with 
eosinophil counts ≥4% and a history of exacerbations may increase the risk of COPD 
exacerbations.
7
 Although the Global Initiative for Obstructive Lung Disease (GOLD) 
recently introduced blood eosinophils in the pharmacological treatment algorithm of 
the disease,
11
 long-term effects of blood eosinophil-guided ICS withdrawal are 
currently unexplored and data in patients treated in real-life clinical setting are 
scarce.
12
 In this study, we use the word “eosinophilia” to refer to elevated blood 
eosinophil count based on our defined thresholds. 
Therefore, the aim of this study was to evaluate the risk of moderate and/or 
severe exacerbations and all-cause mortality in a large primary care population in the 
United Kingdom (UK) after withdrawal of ICS compared to continued use of ICS 
among COPD subjects stratified by elevated relative or absolute eosinophil counts.  A 
priori, we hypothesized that ICS withdrawal is associated with increased risk of 
exacerbations and mortality in subjects with blood eosinophilia.  
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METHODS  
 
Data source 
This study was conducted with data obtained from the Clinical Practice Research 
Datalink (CPRD), providing detailed information on drug prescriptions, clinical events, 
demographics, specialist referrals, hospital admissions, and electronic lab link data of 
subjects from 674 general practices, who are representative for 7% of the total British 
population.
13,14
 Data collection started on 1 January 2005, corresponding to the 
introduction of the Quality and Outcomes Framework (QOF) in April 2004, which 
improved routine recording of various diseases, including COPD.
15
 Routinely collected 
historical data was available, dating back to 1987. Previous studies with the CPRD 
have shown a high level of validity of recording of COPD,
13
 and COPD 
exacerbations.
16
 The independent scientific advisory committee (ISAC) for Medicines 
and Healthcare products Regulatory Authority (MHRA) database research approved 
the study protocol (No: 18_036R). 
 
Study population 
We selected subjects aged 40 years and older with a diagnosis of COPD recorded by 
a read code during valid data collection (1 January 2005 to 31 January 2014). 
Subjects were followed from the date of COPD diagnosis (index date) until their dates 
of transfer out of the database, the end of the study period (31 January 2014), death, 
or until the outcome of interest occurred, whichever occurred first. Only subjects with 
at least one blood eosinophil measurement were included. We excluded subjects with 
a history of asthma, pulmonary fibrosis, cardiac arrhythmia and bronchiectasis, COPD 
exacerbations occurring within 6 weeks prior to index date, or with a myocardial 
infarction within 3 months prior to index date. 
 
Outcomes and Exposure 
The primary outcome of interest was moderate-to-severe exacerbations of COPD. 
The secondary outcomes included severe exacerbations and all-cause mortality. 
Details about operational definitions of moderate-to-severe exacerbations and severe 
exacerbations of COPD using the clinical and referral files
17
 are listed in the 
supplementary Table S.6.1. Exposure to ICS was determined time-dependently 
during follow-up. Each patient’s follow-up time was divided into fixed intervals of 90 
days, starting at index date. Prior to the start of each interval, ICS exposure was 
determined based on the most recent date ICS prescription, and classified as current, 
past or never use (subjects without ICS prescriptions). For this study, current ICS 
users were defined as continuous users; these were subjects who received their most 
recent ICS prescription within 3 months before the start of an interval. Past users 
were those who withdrew from ICS for more than 3 months. While in the Study to 
Understand the Safety and Efficacy of ICS Withdrawal from Triple Therapy in COPD 
(SUNSET) trial ICS withdrawal effects were seen after 4 weeks, the early effects were 
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comparable with the longer-term effects, suggesting that a different time interval, for 
example, 1 month versus the current 3 months period, would not result in different 
results regarding these outcomes.
18
 Moreover, as exacerbations and mortality were 
the primary outcomes in our study, we believe that discontinuation of ICS beyond 3 
months is more appropriate. Also in the SUNSET trial, exacerbations were evaluated 
after 26 weeks. This threshold (3 months) has be found to be robust in evaluating the 
risk of exacerbations in patients withdrawn from ICS use.
7,9
 During follow-up subjects 
could move between different exposure categories. Continuous ICS users and those 
who had withdrawn ICS use were stratified by absolute eosinophil count  (using 0.34 x 
10
9
 cells/L as a cut-off value) or relative eosinophil counts (using 4% as a cut-off 
value).
7
  
 
 
 
                         Figure 6.1. Flow chart showing the selection of eligible patients. 
 
 
COPD Patients:
115,216
COPD Patients:
77,730
COPD Patients:
51,229
COPD Patients:
50,964
COPD Patients:
50,839
COPD Patients:
50,673
COPD Patients:
48,157
COPD Patients:
50,839
Patients without absolute blood 
eosinophils and total WBC recording
n=37,486
History of pulmonary fibrosis
n=265
History of asthma
n=26,501
History of cardiac arrythmias
n=125
History of brochiectasis
n=0
Myocardial infarction 3months prior to
index
n=166
Moderate-to-severe exacerbations 
6 weeks  prior to index
n=2,516
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Covariates  
Potential confounders were assessed time-dependently with the exception of gender, 
smoking status, alcohol use, and body mass index, which were determined at 
baseline. The following covariates were considered as potential confounders, and 
identified at the start of each interval: a history of congestive heart failure, ischemic 
heart disease, anxiety, chronic liver disease, cancer excluding non-melanoma skin 
cancer, stroke, rheumatoid arthritis, diabetes mellitus, hypertension, inflammatory 
bowel disease, solid organ transplant, atopic dermatitis, renal dialysis, human 
immunodeficiency virus or osteoporosis. In addition, the use of the following drugs 
within 6 months prior to the start of an interval were considered as potential 
confounders: antihistamines, proton pump inhibitors, antipsychotics, or 
antidepressants.
19–22
 We statistically adjusted our analyses for proxy indicators of the 
severity of obstructive airway disease, as previously defined as the use of short- and 
long-acting beta-agonists, short- and long-acting anti-muscarinic agents, xanthine 
derivatives or oral corticosteroids.
23,24
 
 
Statistical analysis 
We evaluated the risk of moderate-to-severe exacerbations, severe exacerbations 
and all-cause mortality among subjects with elevated eosinophil counts who withdrew 
from ICS versus continuous ICS users with elevated blood eosinophil counts using 
Cox regression analysis SAS 9.4 (SAS Institute, Cary, NC). The difference between 
each blood eosinophil count stratum was tested using Wald’s test. To avoid immortal 
time bias, never ICS users were incorporated into the statistical model. We assessed 
the presence of risk factors by reviewing subjects’ records prior to each 90-day 
interval. Our initial analysis was adjusted for age and sex. All potential confounders 
were tested and adjusted for in the final model if they changed the beta-coefficient for 
continuous ICS exposure by at least 5% or when consensus about inclusion existed 
within the team of researchers, supported by clinical evidence from literature, or 
both.   
 
Sensitivity analyses 
Two sensitivity analyses were conducted. In the first analyses we stratified ICS users 
(continuous use and withdrawal groups) by absolute eosinophil count cuff-off  (0.15 x 
10
9
 cells/L, 0.40 x 10
9
 cells/L) and relative eosinophil cut-off (2.0% or 6.0%) 
7
(See 
supplementary Table S.6.2-S.6.7). Secondly, for moderate-to-severe exacerbations 
as an outcome, we censored subjects on any hospitalisations/AE visit unrelated to 
COPD for absolute eosinophil count or relative eosinophil counts cut-off defined in our 
primary analysis (Table 6.5). 
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RESULTS  
 
213,561 subjects with COPD were identified, of whom 48,157 met the inclusion 
criteria (Figure 6.1). Table 6.1 shows the baseline characteristics of the COPD cohort, 
which consisted of 46% females, with a mean age of 68.4 ± 10.9 years. Most subjects 
were current (43%) or former smokers (47%). At baseline, elevated blood eosinophil 
counts (defined as absolute blood eosinophil counts ≥0.34 x 109 cells/L) were present 
in 18% (n=8,671) of all subjects. The overall population was either overweight (32%) 
or obese (34%) and 12% suffered from diabetes mellitus. About 28% had been 
prescribed any ICS (alone or in fixed combinations) at baseline. 
 
Table 6.1. Baseline characteristics of COPD patients. 
   Blood eosinophil counts 
  
Total 
n=48,157 
 
 
% 
 
<0.34 x10
9
cells/L
 
n=39,486 
 
 
% 
 
≥0.34 x10
9
cells/L
 
n=8,671 
 
 
% 
Females 22,081 45.9 19,042 48.2 3,039 35.0 
Mean age (years, SD) 68.4 10.9 68.3 10.9 68.6 10.8 
Age category (years)       
  40-59 10,175 21.1 8,406 21.3 1,769 20.4 
  60-79 29,942 62.2 2,4481 62.0 5,461 63.0 
  80+ 8,040 16.7 6,599 16.7 1,441 16.6 
BMI at index date (kg/m
2
)       
Underweight (BMI < 18.5 kg/m
2
) 2,418 5.0 2,068 5.2 350 4.0 
Normal weight (BMI 18.5-24.9 kg/m
2
) 16,225 33.7 13,414 34.0 2,811 32.4 
Overweight (BMI 25.0-30.0 kg/m
2
) 15,503 32.2 12,583 31.9 2,920 33.7 
Obese (BMI > 30.0 kg/m
2
) 12,696 26.4 10,359 26.2 2,337 27.0 
Missing BMI 1,315 2.7 1,062 2.7 253 2.9 
Smoking status        
Never 4,998 10.4 4,114 10.4 884 10.2 
Current 20,528 42.6 16,922 42.9 3,606 41.6 
Former  22,585 46.9 18,411 46.6 4,174 48.1 
Missing 46 0.1 39 0.1 7 0.1 
Drug use (in the past 6 months)       
 SABAs 27,091 56.3 22,022 55.8 5,069 58.5 
 LABAs 4,297 8.9 3,459 8.8 838 9.7 
 SAMAs 4,004 8.3 3,262 8.3 742 8.6 
 LAMAs 8,563 17.8 7,041 17.8 1,522 17.6 
 ICS 13,441 27.9 10,972 27.8 2,469 28.5 
 Xanthine derivatives 359 0.7 281 0.7 78 0.9 
 Antipsychotics 555 1.2 463 1.2 92 1.1 
History of co-morbidities        
   Cardiovascular disease  10,196 21.2 8,253 20.9 1,943 22.4 
 Diabetes Mellitus 5,945 12.3 4,716 11.9 1,229 14.2 
 Anxiety 7,142 14.8 5,974 15.1 1,150 13.3 
 Osteoporosis 2,951 6.1 2,512 6.4 439 5.1 
 Any cancer (except non-melanoma 
skin cancer) 
7,196 14.9 5,935 15.0 1,261 14.5 
 Chronic liver disease 147 0.3 118 0.3 29 0.3 
Abbreviations: Abbreviations: SD, standard deviation; COPD, chronic obstructive pulmonary disease; BMI, body mass index; SABAs, 
short-acting beta-2 agonists; LABAs, long-acting beta-2 agonists; SAMAs, short-acting muscarinic antagonists; LAMAs, long-acting 
muscarinic antagonists; ICS, Inhaled corticosteroids. 
 
Moderate-to-severe exacerbations 
Table 6.2 shows that among COPD subjects with an elevated blood eosinophil count, 
withdrawal of ICS was not associated with an increased risk of moderate-to-severe 
exacerbations as compared to continuous ICS users, yielding adjusted hazard ratios 
[adj. HR] of 0.72; 95% confidence interval [CI] 0.63-0.81 (eosinophilia defined by 
absolute values) and 0.73; 95% CI: 0.66-0.82 (eosinophilia defined by relative 
values). We found a decreased risk of moderate-to-severe exacerbations with low 
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relative or absolute blood eosinophil counts among patients withdrawn from ICS. 
Tables S.6.2 and S.6.5 show that these results were not considerably different when 
we used different absolute or relative threshold values to define eosinophilia among 
subjects who withdrew from ICS. Higher absolute cut-off of ≥0.40 x 109 cells/L yielded 
a fully adj. HR of 0.70; 95% CI: 0.62-0.80 for the risk of moderate-to-severe 
exacerbations, while a lower cut-off value ≥0.15 x 109 cells/L showed (adj.HR 0.74; 
95% CI: 0.69-0.79). Results were not substantially different for higher (≥6%) or lower 
(≥2%) thresholds to define relative eosinophilia. 
 
Table 6.2. Risk of moderate-to-severe exacerbations with ICS use stratified by absolute and relative eosinophil counts among COPD 
patients. 
  
Moderate-to-severe  
n=6,767
c
 
IR 
(/1000PY) 
 
Age and gender adjusted 
HR  
(95% CI) 
Adjusted HR  
(95% CI)
a
 
Absolute eosinophil counts 
    
   Withdrawal from ICS  
    
     <0.34 x 10
9
 cells/L 1,625 49.2  0.55 (0.51-0.60)
 b
   0.72 (0.66-0.78)
 b
 
      ≥0.34 x 10
9
 cells/L               366 49.5           0.57 (0.50-0.64)   0.72 (0.63-0.81) 
  Continuous ICS users 
    
      <0.34 x 10
9
 cells/L 3,85 85.4 0.96 (0.89-1.03)   0.97 (0.91-1.05) 
      ≥0.34 x 10
9
 cells/L                926 87.7           Reference   Reference 
Relative eosinophil counts 
    
   Withdrawal from ICS 
    
      <4.0% 1,511 49.8  0.60 (0.55-0.65)
 b
   0.74 (0.68-0.80) 
b
 
      ≥4.0%               480 47.5           0.58 (0.52-0.64)   0.73 (0.66-0.82) 
     Continuous ICS users 
    
      <4.0% 3,652 86.9 1.04 (0.97-1.11)   1.01 (0.94-1.08) 
      ≥4.0% 1,124 82.2            Reference    Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years. 
a
Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, use of antipsychotics, antidepressants, atopic dermatitis, use of oxygen, short-acting beta-2 agonists, long-acting beta-2 
agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives and oral corticosteroid 6 
months prior to the start of an interval.  
 bWald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use 
with low eosinophil count. 
c
number of never ICS users with moderate-to-severe exacerbations not included. 
 
Severe exacerbations 
We found that withdrawal of ICS was not associated with an increased risk of severe 
exacerbations among subjects with absolute blood eosinophil ≥0.34 x 109 cells/L 
(adj.HR 0.82; 95% CI: 0.61-1.10) compared to continuous ICS users with elevated 
absolute blood eosinophil counts among patients withdrawn from ICS. For relative 
blood eosinophil counts ≥4.0% there was no significant difference in the risk of severe 
exacerbations (adj.HR 0.80; 95% CI: 0.61-1.04) compared to continuous ICS users 
with elevated relative blood eosinophil counts.  
We found no increased risk of severe exacerbations when we used different absolute 
or relative threshold values to define eosinophilia. Absolute cut-off value of ≥0.40 x 
10
9
 cells/L resulted in (adj.HR 0.65; 95% CI: 0.48-0.89), while a lower cut-off value 
≥0.15 x 109 cells/L showed (adj.HR 0.59; 95% CI: 0.50-0.69) Results were similar for 
higher (≥6%) or lower (≥2%) threshold values to define eosinophilia (supplementary 
Tables S.6.3 and S.6.6). 
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Table 6.3. Risk of severe exacerbations with ICS use stratified by absolute and relative eosinophil counts among COPD patients. 
  
Severe exacerbations 
 n=1,177
c
 
IR 
(/1000PY) 
Age and gender adjusted 
HR 
(95% CI) 
Adjusted 
 HR 
(95% CI)
a
 
Absolute eosinophil counts 
    
  Withdrawal of ICS 
    
     <0.34 x 10
9
 cells/L 263 6.9 0.57 (0.47-0.70)
b
 0.79 (0.64-0.97)
b
 
      ≥0.34 x 10
9
 cells/L 63 7.4 0.61(0.46-0.82) 0.82 (0.61-1.10) 
   Continuous ICS users 
    
      <0.34 x 10
9
 cells/L 690 12.4 1.02 (0.86-1.21) 1.03 (0.87-1.23) 
      ≥0.34 x 10
9
 cells/L 161 12.1 Reference Reference 
Relative eosinophil counts 
    
   Withdrawal of ICS 
    
      <4.0% 248 7.1 0.62 (0.52-0.75)
b
 0.82 (0.67-0.99)
b
 
      ≥4.0% 78 6.7 0.59 (0.45-0.77) 0.80 (0.61-1.04) 
  Continuous ICS users 
    
      <4.0% 656 12.6 1.10 (0.94-1.30) 1.06 (0.91-1.25) 
      ≥4.0% 195 11.4 Reference Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years. 
a
Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, diabetes 
mellitus, ischemic heart disease, osteoporosis, use of proton-pump inhibitors, antidepressants, oxygen, antipsychotics, statins, short-
acting beta-2 agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine 
derivatives and oral corticosteroid 6 months prior to the start of an interval. 
 bWald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use 
with low eosinophil count. 
c
number of never ICS users with severe exacerbations not included. 
 
All-cause mortality 
Table 6.4 shows that withdrawal of ICS was not associated with an increased risk of 
all-cause mortality among subjects with absolute blood eosinophil ≥0.34 x 109 cells/L 
(adj.HR 1.08; 95% CI: 0.96-1.22), compared to continuous ICS users with elevated 
absolute blood eosinophil counts. At relative blood eosinophil counts ≥ 4.0% there no 
increased risk of all-cause mortality (adj.HR 1.08; 95% CI: 0.97-1.21) compared to 
continuous ICS users with elevated relative blood eosinophil counts.  
 
Table 6.4.  Risk of all-cause mortality with ICS use stratified by absolute and relative eosinophil counts among COPD patients. 
  
All-cause mortality 
 n=6,008
c
 
IR 
(/1000PY) 
Age and gender adjusted    
HR 
(95% CI) 
Adjusted  
HR 
(95% CI)
a
 
Absolute eosinophil counts 
    
  Withdrawal from ICS 
    
     <0.34 x 10
9
 cells/L 1,763 45.5 0.94 (0.86-1.03)
c
 1.14 (1.04-1.25)
b,c
 
      ≥0.34 x 10
9
 cells/L 415 47.4 0.93 (0.82-1.05) 1.08 (0.96-1.22) 
  Continuous ICS users 
    
      <0.34 x 10
9
 cells/L 3,125 54.3 1.13 (1.04-1.23) 1.14 (1.05-1.23) 
      ≥0.34 x 10
9
 cells/L 705 51.3 Reference Reference 
Relative eosinophil counts 
    
   Withdrawal of ICS 
    
      <4.0% 1,676 47.0 1.08 (0.99-1.17)
b,c
 1.25 (1.15-1.36)
b
 
      ≥4.0% 502 42.4 0.91 (0.81-1.01) 1.08 (0.97-1.21) 
  Continuous ICS users 
    
      <4.0% 2,997 55.8 1.30 (1.20-1.40) 1.25 (1.15-1.35) 
      ≥4.0% 833 47.3 Reference Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years. 
a
Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, atopic dermatitis, diabetes mellitus, cancer, use of oxygen, statins, short-acting beta-2 agonists, long-acting beta-2 agonists, 
short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives and oral corticosteroid use 6 months 
prior to the start of an interval. 
b) Wald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from withdrawal of ICS 
with high eosinophil count. 
b
Wald’s statistics:  Withdrawal of ICS low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use with 
low eosinophil count. 
c
number of never ICS users who died not included. 
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Results were not significantly different when we adopted different absolute or relative 
eosinophil counts (Table S.6.4 and S.6.7). Higher absolute cut-off value of ≥0.40 x 109 
cells/L resulted in no increased risk of all-cause mortality (adj.HR 0.96; 95% CI: 0.85-
1.10) . 
 
Sensitivity analysis 
Table 6.5 shows the second sensitivity analyses for moderate-to-severe 
exacerbations, following censoring for any hospitalisations/AE visit unrelated to COPD 
for absolute or relative blood eosinophil counts the results was similar to Table 6.2. 
 
Table 6.5.   Risk of moderate-to-severe exacerbations with ICS use stratified by absolute and relative eosinophil counts among COPD 
patients censoring at any hospitalisation/AE visit. 
 
Moderate-to-severe 
exacerbations 
 n=6,027
c
 
IR 
(/1000PY) 
Age and gender adjusted 
HR 
(95% CI) 
Adjusted 
HR 
(95% CI)
a
   
Absolute eosinophil counts 
    
   Withdrawal from ICS 
    
     <0.34 x 10
9
 cells/L 1,429 47.8 0.55 (0.51-0.60)
b
 0.71 (0.65-0.78)
b
 
      ≥0.34 x 10
9
 cells/L 328 49.0 0.57 (0.50-0.65) 0.73 (0.64-0.83) 
  Continuous ICS users 
    
      <0.34 x 10
9
 cells/L 3,44 83.4 1.09 (0.30-0.96) 0.98 (0.91-1.06) 
      ≥0.34 x 10
9
 cells/L 830 85.7 Reference Reference 
Relative eosinophil counts 
    
  Withdrawal of ICS 
    
      <4.0% 1,334 48.7 0.60 (0.56-0.66)
b
 0.75 (0.69-0.81)
b
 
      ≥4.0% 423 46.1 0.58 (0.52-0.65) 0.73 (0.65-0.82) 
  Continuous ICS users 
    
      <4.0% 3,270 85.3 1.06 (0.98-1.13) 1.02 (0.95-1.10) 
      ≥4.0% 1,000 79.6 Reference Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years; A/E, 
accident and emergency. 
a
Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, use of antipsychotics, antidepressants, atopic dermatitis, oxygen, short-acting beta-2 agonists, long-acting beta-2 agonists, 
short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives and oral corticosteroid 6 months prior to 
the start of an interval.  
 bWald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use 
with low eosinophil count. 
c
numbers of never ICS user not included. 
 
DISCUSSION  
 
In this study conducted in a real-world primary care population, we did not observe an 
increased risk of moderate and/or severe COPD exacerbations or all-cause mortality 
among patients with relative or absolute peripheral blood eosinophilia after withdrawal 
from ICS, in comparison to continuous users with blood eosinophilia. Opposite to our 
hypothesis, risk of exacerbations was significantly lower in patients withdrawn from 
ICS compared to those with continued use with blood eosinophilia. In addition, no 
increased mortality risk was observed in patients with blood eosinophilia withdrawn 
from ICS compared to continuous ICS users with blood eosinophilia. 
Our results are consistent with the WISDOM trial which found no difference in 
the risk of exacerbations among COPD patients withdrawn from ICS therapy.
25
 
However, a decreased risk of severe exacerbations was seen in some sub-groups in 
our study. More recently, in a Study to Understand Mortality and Morbidity (SUMMIT) 
trial, which enrolled more than 16,000 COPD patients with heightened cardiovascular 
risk, over three-years also found that withdrawal from ICS had no effect on the risk of 
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exacerbations in all groups compared.
26
 Similarly, a meta-analysis of various clinical 
trials exploring the effects of ICS withdrawal among COPD patients without a history 
of asthma, found that overall the withdrawal of ICS did not significantly affect the risk 
of moderate-to-severe exacerbations, although they found that the withdrawal of ICS 
significantly impaired both Forced Expiratory Volume in 1 sec (FEV1) and St George 
Respiratory Questionnaire (SGRQ) score.
27
  
Only a few studies have evaluated the withdrawal of ICS and the risk of 
exacerbations stratified by absolute or relative blood eosinophil counts.
7,18
 In the post-
hoc analysis of data from the WISDOM trial, Watz et al
7
 reported that blood eosinophil 
count ≥4% or ≥300 cells/µL might help identify patients with greater risk of 
exacerbations following ICS withdrawal. Nevertheless, they found no increased risk of 
exacerbations following withdrawal of ICS at eosinophil counts >6.0% consistent with 
our findings.
7
 Furthermore, it is important to note that they only enrolled patients with 
severe to very severe COPD, a history of exacerbations and over 70% of patients 
used ICS before study entry.
7
 COPD patients in CPRD are derived from primary 
practice, a population not enriched for exacerbation risk in which use of 
bronchodilators and ICS use are lower compared to the clinical trials. A recent UK 
population-based cohort study reported that ICS-LABA therapy was more effective 
than LAMA in patients with blood eosinophil counts >4% or >300 cells/µL.
28
 In our 
previous work using COPD patients from the same data source, we found similar 
results for moderate-to-severe and severe exacerbations. However, an important 
difference is the fact that in our previous study only patients with prior history of ICS 
use were included.
29
 Analyses of data from the FLAME trial reported that LABA/LAMA 
combination was superior to LABA/ICS combination in exacerbation reduction for 
relative or absolute blood eosinophil threshold (2%, ≥2%, 3%, <5%, and <150 cells/µL 
subgroups), and at no threshold was LABA/ICS superior to LABA/LAMA.
8
 However, 
the SUNSET trial found that ICS withdrawal led to an increased risk of exacerbations 
among COPD patients with ≥300 cells/µL.18 It is important to note, that unlike our 
study all patients included in the SUNSET trial were on long-term ICS regimens and 
were non-frequent exacerbators (i.e. patients with 0 to 1 exacerbation in the previous 
year). With approximately 29% of COPD patients reported to have 2 or more 
exacerbations 1 year prior in the UK general practice,
30
 it raises questions on the 
generalisability of their findings in a general practice setting. Furthermore, the 
researchers were not convinced that their study could be referred to as a “pure ICS” 
withdrawal study given that patients withdrew to a LABA/LAMA combination, which 
may not be applicable with other therapies.
18
  
All-cause mortality is an important end-point, which is seldom assessed 
among COPD patients partly due to the short duration of patient follow-up in most 
studies. We did not find an increased risk of all-cause mortality among patients who 
withdrew from ICS treatment with elevated absolute or relative blood eosinophil 
counts in our study. There is conflicting evidence on ICS treatments and reduced 
mortality in COPD. Two large trials among patients exposed to a combination of a 
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long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS) the reduction in 
mortality was not statistically significant.
3,31
 However, the INSPIRE trial which included 
severe and very severe COPD patients receiving LABA/ICS experienced fewer 
deaths than those receiving LAMA.
32
 Furthermore, Vestbo et al,
33
 performed a 
stratified pooled analysis of all fatal adverse events comparing ICS-containing versus 
ICS-free treatments in 3 recent 52-week studies among patients with severe to very 
severe COPD at increased risk for exacerbations. They found no statistically 
significant reduction in the risk of developing a fatal event. Furthermore, they found a 
reduced risk of non-respiratory fatal events suggesting that therapy containing an ICS 
may have a direct or indirect effect on chronic diseases that is almost consistently 
associated with mostly severe symptomatic COPD This might be due to 
cardiovascular events, being less likely if the underlying COPD is more stable.
33
  
A major strength of this study was the inclusion of patients from one of the 
world’s largest primary care databases, thereby providing a large population-based 
cohort of COPD patients with eosinophil measurements followed over time. Second, 
in our study we used validated definitions for moderate and/or severe exacerbations 
of COPD, using read codes reported to have a 96% positive predictive value of 
identifying an acute exacerbation within the CPRD.
16
 Nevertheless, we may have 
missed considerable numbers of exacerbations, which may be miscoded e.g. as 
respiratory tract infections such as pneumonia. Third, time-varying classification of 
exposure to ICS and covariates allowed us to conduct an “on-treatment analysis”, 
which results in less non-differential misclassification of exposure than in an `intention 
to treat analysis` which ignores ICS exposure during follow-up as in other studies. 
Lastly, data on confounding factors such as smoking status, BMI, comorbidities, and 
drugs prescribed were available and as such these covariates were adjusted for in our 
models.  
Despite numerous strengths, this study also had limitations. In addition to 
those already mentioned, there is a potential for residual confounding as we lacked 
information on the disease severity and exacerbation history. While we excluded 
asthma patients, it was impossible to rule out the inclusion of patients with reversible 
airflow limitations. Eosinophil counts are not routinely collected as part of diagnosis of 
COPD patients, they are most likely requested by the GP for a purpose and might 
have introduced an information bias in our study. We expect this bias to be non-
differential among COPD patients who withdrew from ICS and those who continued 
ICS therapy leading to bias estimates towards the null. While this might have masked 
the true risk of severe exacerbations among patients with blood eosinophil counts, we 
found significant associations irrespective of the absolute or relative blood eosinophil 
counts for moderate and/or severe exacerbations and mortality, suggesting that our 
results could not have been affected by this bias. Also, there have been concerns on 
the stability of blood eosinophil counts overtime, however blood eosinophil counts 
among COPD patients have been shown to be relatively stable over time.
34,35
 
Confounding by indication is a major concern in observational studies,
23
 because the 
                       Blood eosinophil counts, withdrawal of ICS and risk of COPD exacerbations and mortality in the CPRD   
   
 
  107 
reason for withdrawal or continuation of ICS is often associated with the outcome of 
interest. While the hospital episode statistics (HES) is known to capture most 
hospitalisations in the UK, a low positive predictive value of identifying COPD-related 
hospitalisation using read codes for hospitalisation within the CPRD linked to hospital 
episode statistics (HES) was observed.
36
 Linkage to HES will further limit our overall 
sample size and subsequently our ability to detect any risk this is because only 58% 
of practices have consented to participating in the CPRD linkage scheme.
14
  
In conclusion, this study did not show an increased risk of moderate and/or 
severe COPD exacerbations or all-cause mortality among patients with blood 
eosinophilia who withdrew from ICS therapy. 
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Supplementary Materials 
 
 
Table S.6.1. Read codes and descriptions. 
Read code Medical code Clinical event Read term 
H312200 1446 172705 Acute exacerbation of chronic obstructive airways disease 
H3y1.00 7884 58765 Chron Obstruct Pulmonary dis with exacerbation, unspec 
8H2R.00 11019 13645 Admit COPD emergency 
66Yi.00 46036 956 Multiple COPD emergency hospital admissions 
 
 
 
 
 
 
 
 
 
 
 
 
Table S.6.2.  Risk of moderate-to-severe exacerbations with ICS use stratified by absolute and relative eosinophil counts among 
COPD patients. 
  
Moderate-to-severe 
exacerbations 
IR 
Age and gender adjusted 
HR 
(95% CI) 
Adjusted  
HR 
 (95% CI)
a
  (n=6,767)
c
 (/1000PY) 
Absolute eosinophil's counts       
   Withdrawal of ICS         
      <0.40 x 10
9
 cells/L 1,677 49.4 0.55 (0.51-0.60)
 b
 0.72 (0.66-0.79)
b
 
      ≥0.40 x 10
9
 cells/L 314 48.8 0.56 (0.49-0.63) 0.70 (0.62-0.80) 
  Continuous ICS user 
    
      <0.40 x 10
9
 cells/L 3,97 85.4 0.96 (0.89-1.03) 0.98 (0.91-1.05) 
      ≥0.40 x 10
9
 cells/L 806 87.9 Reference Reference 
Relative eosinophil 
counts     
     Withdrawal of ICS 
    
      <6.0% 1,817 49.3 0.54 (0.49-0.60)
c
 0.67 (0.60-0.74)
b
 
      ≥6.0% 174 48.6 0.54 (0.46-0.65) 0.68 (0.57-0.81) 
     Continuous ICS user 
    
      <6.0% 4,333 85.4 0.94 (0.85-1.03) 0.91 (0.82-1.00) 
      ≥6.0% 443 89.6 Reference Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years. 
a
Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, antipsychotics, antidepressants, atopic dermatitis, use of oxygen, short-acting beta-2 agonists, long-acting beta-2 agonists, 
short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives and oral corticosteroid 6 months prior to 
the start of an interval.  
b
Wald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use 
with low eosinophil count. 
c
numbers of never ICS user with moderate-to-severe exacerbations not included. 
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Table S.6.3.  Risk of severe exacerbations with ICS use stratified by absolute and relative eosinophil counts among COPD patients. 
  
Severe exacerbations 
 n=1,177
c
 
IR 
(/1000PY) 
Age and gender adjusted 
 HR  
(95% CI) 
Adjusted 
 HR 
 (95% CI)
a
 
Absolute eosinophil's counts       
  Withdrawal of ICS       
 
      <0.40 x 10
9
 cells/L 268 6.9 0.57 (0.47-0.71)
b
 0.79 (0.64-0.98)
b
 
      ≥0.40 x 10
9
 cells/L 58 7.8 0.65 (0.48-0.89) 0.87 (0.64-1.19) 
   Continuous ICS user 
    
      <0.40 x 10
9
 cells/L 713 12.4 1.03 (0.86-1.24) 1.05 (0.88-1.26) 
      ≥0.40 x 10
9
 cells/L 138 11.9 Reference Reference 
Relative eosinophil counts 
   
  Withdrawal of ICS 
    
       <6.0% 298 7.0 0.59 (0.46-0.76)
b
 0.78 (0.60-1.01)
b
 
       ≥6.0% 28 6.8 0.58 (0.37-0.89) 0.77 (0.50-1.20) 
  Continuous ICS user 
    
       <6.0% 776 12.3 1.04 (0.82-1.32) 1.01 (0.79-1.28) 
       ≥6.0% 75 11.9 Reference Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years; AE, 
accident and emergency. 
a
Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, diabetes 
mellitus, ischemic heart disease, osteoporosis, use of proton-pump inhibitors, antidepressants, oxygen, antipsychotics, statins, short-
acting beta-2 agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine 
derivatives and oral corticosteroid 6 months prior to the start of an interval. 
b
Wald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use 
with low eosinophil count. 
c
numbers of never ICS user with severe exacerbations not included. 
   
 
 
 
Table S.6.4. Risk of all-cause mortality with ICS use stratified by absolute and relative eosinophil counts among COPD patients. 
  
All-cause mortality 
n=6,008
c
 
IR Age and gender adjusted 
 HR 
 (95% CI) 
Adjusted 
 HR 
(95% CI)
a
 
(/1000PY) 
Absolute eosinophil's counts       
  Withdrawal of ICS 
 
    
 
       <0.40 x 10
9
 cells/L 1,805 45.3 0.94 (0.86-1.03)
b
 1.15 (1.05 -1.26)
b
 
       ≥0.40 x 10
9
 cells/L 373 49.0 0.96 (0.85-1.10) 1.13 (0.99-1.28) 
  Continuous ICS user 
    
       <0. 40 x 10
9
 cells/L 3,220 54.3 1.13 (1.04-1.24) 1.15 (1.05-1.25) 
       ≥0.40 x 10
9
 cells/L 610 51.1 Reference Reference 
Relative eosinophil counts 
    
  Withdrawal of ICS 
    
       <6.0% 1,982 45.8 1.04 (0.93-1.17)
b
 1.27 (1.12-1.43) 
       ≥6.0% 196 46.6 0.93 (0.78-1.11) 1.11 (0.93-1.33) 
  Continuous ICS user 
    
       <6.0% 3,506 54.1 1.24 (1.11-1.39) 1.25 (1.12-1.40) 
       ≥6.0% 324 49.8 Reference Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years. 
a
Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, atopic dermatitis, diabetes mellitus, cancer, use of oxygen, statins, short-acting beta-2 agonists, long-acting beta-2 agonists, 
short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives and oral corticosteroid use 6 months 
prior to the start of an interval. 
b
Wald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use 
with low eosinophil count. 
c
numbers of never ICS user who died not included. 
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Table S.6.5. Risk of moderate-to-severe exacerbations with ICS use stratified by absolute and relative eosinophil counts among 
COPD patients. 
  
Mosderate-to-severe 
exacerbations 
n=6,767
c
 
IR 
(/1000PY) 
Age and gender adjusted 
HR 
(95% CI) 
Adjusted  
HR  
(95% CI)
 a
 
Absolute eosinophil counts 
   
  Withdrawal of ICS 
    
      <0.15 x 10
9
 cells/L 640 47.9 0.56 (0.51-0.61)
b
 0.71 (0.65-0.78)
b
 
      ≥0.15 x 10
9
 cells/L 1,351 50.0 0.59 (0.55-0.63) 0.74 (0.69-0.79) 
  Continuous ICS user 
    
      <0.15 x 10
9
 cells/L 1,617 87.0 1.02 (0.96-1.08) 1.00 (0.94-1.06) 
      ≥0.15 x 10
9
 cells/L 3,159 85.2 Reference Reference 
Relative eosinophil counts 
   
   Withdrawal of ICS 
    
      <2.0% 701 49.8 0.59 (0.54-0.64)
b
 0.72 (0.67-0.79)
b
 
      ≥2.0% 1,290 49.0 0.59 (0.55-0.63) 0.74 (0.69-0.79) 
  Continuous ICS user 
   
      <2.0% 1,799 89.8 1.07 (1.01-1.13) 1.02 (0.96-1.08) 
      ≥2.0% 2,977         83.6 Reference Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years. 
a
Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, antipsychotics, antidepressants, atopic dermatitis, use of oxygen, short-acting beta-2 agonists, long-acting beta-2 agonists, 
short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives and oral corticosteroid 6 months prior to 
the start of an interval.  
b
Wald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use 
with low eosinophil count. 
c
number of never ICS users with moderate-to-severe exacerbations not included. 
 
 
 
Table S.6.6.  Risk of severe exacerbations with ICS use stratified by absolute and relative eosinophil counts among COPD patients. 
  
Severe exacerbations 
 n=1,177
c
 
IR 
(/1000PY) 
Age and gender adjusted 
 HR  
(95% CI) 
Adjusted  
HR 
(95% CI)
a
 
Absolute eosinophil counts 
   
  Withdrawal of ICS   
   
      <0.15 x 10
9
 cells/L 115 7.5 0.65 (0.53-0.80)
 b
 0.88 (0.71-1.08)
b
 
      ≥0.15 x 10
9
 cells/L 211 6.8 0.59 (0.50-0.69) 0.79 (0.67-0.93) 
  Continuous ICS user 
    
      <0.15 x 10
9
 cells/L 317 13.8 1.19 (1.04-1.37) 1.17 (1.02-1.35) 
      ≥0.15 x 10
9
 cells/L 534 11.6 Reference Reference 
Relative eosinophil counts 
   
     Withdrawal of ICS 
    
      <2.0% 125 7.7 0.69 (0.57-0.85)
 b
 0.89 (0.73-1.09)
b
 
      ≥2.0% 201 6.6 0.59 (0.50-0.70) 0.80 (0.67-0.95) 
     Continuous ICS user 
    
      <2.0% 355 14.3 1.28 (1.11-1.46) 1.20 (1.05-1.38) 
      ≥2.0% 496 11.2 Reference Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years; AE, 
accident and emergency. 
a
Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, diabetes 
mellitus, ischemic heart disease, osteoporosis, use of proton-pump inhibitors, antidepressants, oxygen, antipsychotics, statins, short-
acting beta-2 agonists, long-acting beta-2 agonists, short-acting muscarinic antagonists, long-acting muscarinic antagonists,  xanthine 
derivatives  and oral corticosteroid 6 months prior to the start of an interval. 
 bWald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use 
with low eosinophil count. 
c
number of never ICS users with severe exacerbations not included. 
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Table S.6.7. Risk of all-cause mortality with ICS use stratified by absolute and relative eosinophil counts among COPD patients. 
  
All-cause mortality 
n=6,008
d
 
IR 
(/1000PY) 
Age and gender adjusted HR 
(95% CI) 
Adjusted  
HR 
(95% CI)
a
 
Absolute eosinophil counts     
   Withdrawal of ICS 
 
      
      <0.15 x 10
9
 cells/L 825 52.8 1.06 (0.97-1.14)
b,c
 1.23 (1.13-1.33) 
      ≥0.15 x 10
9
 cells/L 1,353 42.5 0.88 (0.82-0.94) 1.05 (0.98-1.13) 
  Continuous ICS user 
    
      <0.15 x 10
9
 cells/L 1,526 64.4 1.31 (1.23-1.40) 1.27 (1.19-1.35) 
      ≥0.15 x 10
9
 cells/L 2,304 48.4 Reference Reference 
Relative eosinophil counts 
   
     Withdrawal of ICS 
    
      <2.0% 892 54.0 1.16 (1.07-1.25)
b,c
 1.30 (1.20-1.41)
b
 
      ≥2.0% 1,286 41.6 0.89 (0.83-0.95) 1.06 (0.99-1.14) 
     Continuous ICS user 
    
      <2.0% 1,692 65.8 1.44 (1.35-1.53) 1.34 (1.26-1.43) 
      ≥2.0% 2,138 46.9 Reference Reference 
Abbreviations: ICS, Inhaled corticosteroids; IR, incidence rate; HR, hazard ratio; CI, confidence interval; PY, person-years. 
a)
 Adjusted for age, gender, smoking status, body mass index, alcohol use, history of heart failure, chronic liver disease, ischemic heart 
disease, atopic dermatitis, diabetes mellitus, cancer, use of oxygen, statins, short-acting beta-2 agonists, long-acting beta-2 agonists, 
short-acting muscarinic antagonists, long-acting muscarinic antagonists, xanthine derivatives and oral corticosteroid use 6 months 
prior to the start of an interval. 
b)
 Wald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from withdrawal of ICS 
with high eosinophil count. 
c
Wald’s statistics:  Withdrawal of ICS with low eosinophil counts statistically significantly different (P<0.05) from continuous ICS use 
with low eosinophil count. 
d
number of never ICS users who died not included. 
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ABSTRACT  
 
Introduction: Chronic obstructive pulmonary disease (COPD) is characterised by 
persistent airflow obstruction and respiratory symptoms. While short-course systemic 
glucocorticoids (GCs) are prescribed in patients with acute COPD exacerbations, little 
is known of the risk of fractures with intermittent exposure to high-dose GC and the 
effect of proxies of disease severity.  
 
Method: A case-control study was conducted using the Danish National Hospital 
Discharge Registry (NHDR) between January 1996 to December 2011. Conditional 
logistics regression models were used to derive adjusted odds ratios (OR) risk of 
fractures in subjects with COPD stratified by intermittent high-dose, and proxies of 
disease severity. 
 
Results: A total of 635,536 cases and the same number of controls were identified 
(mean age 67.5 ±13.8, 65% female). COPD patients with intermittent use of high 
average daily dose oral glucocorticoids did not have an increased risk of any, 
osteoporotic, hip or clinically symptomatic vertebral fracture compared to non-COPD 
patients (adj. OR 0.65; 95% CI: 0.50-0.86, 0.70; 95% CI: 0.70-0.99, 1.17; 95% CI: 
0.59-2.32, 1.98; 95% CI: 0.59-6.65 respectively). We identified an elevated risk of 
osteoporotic fracture among patients who visited the emergency unit (adj.OR 1.47; 
95% CI 1.20-1.79) or were hospitalised in the past year for COPD (adj.OR 1.76; 95% 
CI 1.66-1.85). Current GC use among COPD patients was associated with an 
increased risk of osteoporotic, hip and clinically symptomatic vertebral fractures 
compared to patients without COPD. 
 
Conclusions: Intermittent high-dose GCs was not associated with an increased risk 
of any, osteoporotic, hip or clinically symptomatic vertebral fractures in patients with 
COPD. Current GC use was however associated with an increased risk of hip and 
clinically symptomatic vertebral fractures. Therefore, emphasis on prophylactic 
treatment of fractures may not be essential in patients with COPD receiving 
intermittent dose of GCs, whereas this should be considered for high-dose long-term 
users with advanced COPD disease stage, postmenopausal women and men over 40 
years. 
 
 
 
 
 
 
                         Use of high-dose intermittent systemic glucocorticoids and the risk of fractures in patients with COPD   
 117 
INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is characterised by persistent airflow 
obstruction and respiratory symptoms. It is projected to be the third leading cause of 
morbidity and mortality by 2030.
1,2
 Pharmacologic management of stable COPD 
consists of short- and long-acting bronchodilators, as well as inhaled and oral 
glucocorticoids (GCs).
3
 In patients with acute COPD exacerbations, short courses of 
systemic GCs are prescribed in order to reduce exacerbations, shorten recovery time 
and reduce the length of hospital stay.
3
 Although not recommended by current 
international guidelines, a proportion of COPD patients are chronically treated with 
low-dose oral GCs.
4
 
The detrimental effects of GCs on bone mineral density (BMD), resulting in 
an increased (hip or vertebral) fracture risk, are well established.
5–9
 While elevated 
fracture risk may be caused by several factors related to disease severity which 
negatively influences bone structure, fracture risk remains elevated in patients using 
oral GCs even after adjustment for proxy indicators of disease severity.
10–12
 
Consequently, GC use is included in risk prediction tools such as FRAX,
8
 and 
international clinical guidelines on the prevention of GC-induced osteoporosis.
13
  
Fracture risk associated with oral GC use increases rapidly, particularly during the first 
3 months of treatment, and is partially independent of a decreased BMD.
14
 The 
increase in fracture risk is directly, and linearly, related to the daily, and possibly also 
to cumulative, dose of oral GCs; yet the relative relationship between the two is not 
consistent.
5–7,15
 Thus clinicians suggest the use of intermittent dosing of GCs to 
mitigate and manage GC-induced adverse effects, such as fractures.
16
 De Vries et al. 
evaluated the risk of fracture with intermittent use of high-dose oral GC and found a 
small increased risk of osteoporotic fractures among patients with various disease 
conditions requiring GC use.
7
 They defined intermittent high dose exposure as daily 
dose ≥ 15mg and cumulative dose exposure ≤1g (for instance 30 mg prednisolone 
equivalents per day for 2-4 weeks).  
While the risk of fracture in patients with obstructive airways disease exposed 
to intermittent high-dose oral GC was examined by de Vries et al in a large British 
population, little is known of this risk in COPD patients in other settings. Therefore the 
objective of the present study was to investigate the effects of intermittent high-dose 
glucocorticoid use on fracture risk in patients with COPD, the impact of proxy 
indicators of disease severity and the effect of dose, compared to patients without 
COPD.  
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METHODS  
 
Design and source population 
A population-based case-control study was conducted using healthcare records from 
the Danish National databases. In Denmark, separate registers of computerized 
medical records on all contacts to hospitals and drug prescriptions can be linked for 
the entire population (approximately 5.5 million inhabitants). The register was founded 
in 1977 and covers all inpatients contacts from 1977 to 1994, and from 1995 onwards 
also includes all outpatient visits to hospitals, outpatient clinics, and emergency 
rooms. After discharge, the physician enters the reason for the contact according to 
the International Classification of Diseased (ICD) system. The register has a 
nationwide coverage of public health facilities with an almost 100% completeness of 
recordings and a high precision of diagnoses
17,18
, particularly for fracture diagnoses.
6
  
The Danish Medicines Agency keeps a nationwide prescription database, the 
Register of Medicinal Product Statistics, with information on prescriptions for 
refundable drugs. The database includes information on the patient’s civil registry 
number, the type and amount of drug prescribed in accordance to the Anatomical 
Therapeutic Chemical (ATC) classification system
2
 and the date when the prescription 
was filled by the patient. This permits an evaluation of the average daily dose and 
cumulative exposure. All registers can be interconnected through the use of the civil 
registry number that is assigned to all Danes.
19
  
 
Study population / outcome 
Cases were identified as patients aged 45 years and older who had sustained a 
fracture between January 1996 and December 2011. Fractures considered included a 
fracture of the hip (ICD10 code S72.0-S72.2), clinical symptomatic vertebrae (S12, 
S22.0-S22.1, S32.0-S32.2, S32.7, S32.8, T08), osteoporotic (defined as a fracture of 
the hip, clinical symptomatic vertebrae, radius/ulna [S52] or humerus [S42.2-S42.4] 
according to the World Health Organisation’s (WHO) definition.20 Any fracture was 
determined by the following International Classification of Diseases and Related 
Health Problems (ICD)-10 codes: S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, 
T02, T08, T10 and T12. For each case, one control patient (who had not sustained a 
fracture) was matched by gender and year of birth using incidence-density sampling.
21
 
The date of the first fracture defined the index date for cases, and controls were 
assigned the index date of their matched cases.  
 
Exposure  
Presence of COPD before the index date was defined based on ICD-10 code J43 or 
J44. Individuals without an ICD-10 code for COPD were categorized as non-COPD 
patients and used as the reference category in all analyses. Furthermore, among 
COPD patients we evaluated oral glucocorticoid (GC) use before the index date. 
Based on the time since the most recent GC dispensing from the index date patients 
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were classified as current (1-91 days), recent (92-182), past (183-364 days) or distant 
(over 364 days) users. For each current user, the cumulative and average daily GC 
exposure was estimated. The average daily dose was calculated by dividing the 
cumulative GC exposure by the treatment time (i.e. the time between the first GC 
dispensing and the index date). Intermittent high-dose of GC was defined as daily 
dose ≥15mg and cumulative exposure <1g.7 This roughly corresponds to 30mg 
prednisolone per day for 2-4 weeks. It is recommended that patients with COPD 
receive 30-40 mg of prednisolone for 7-14 days and no longer that in the event of an 
exacerbation.
3
 The cumulative dose was calculated by adding up all previous GC 
dispensing using the defined daily dosages (DDDs). The average daily dose was 
calculated by dividing the cumulative GC exposure by the treatment time (i.e. the time 
between the first GC dispensing and the index date). GC exposure was expressed as 
oral prednisolone equivalents. 
 
Confounders 
We considered the following potential confounders before the index date: history of 
fracture, rheumatoid arthritis, inflammatory bowel disease (IBD), secondary 
osteoporosis (type 1 diabetes, hyperthyroidism, hypogonadism and renal failure), 
dementia, type 2 diabetes mellitus, cerebrovascular disease, pneumonia, 
malignancies (excluding non-melanoma skin cancer) and gout. These potential 
confounders have been related to fractures and COPD in previous studies.
11,22
 Other 
potential confounders included a dispensing in the six months before the index date of 
the following drugs: inhaled cromoglycates, xanthine derivatives, bisphosphonates, 
vitamin D, calcium, raloxifene, strontium, denosumab, calcitonin, parathyroid 
hormone, hormone replacement therapy, antipsychotics, antidepressants, 
hypnotics/anxiolytics, anticonvulsants, anti-parkinson drugs, antihypertensive drugs 
and proton pump inhibitors. Proxy indicators of respiratory disease severity variables 
included a dispensing of inhaled corticosteroids, long-acting beta-2 agonists, short-
acting beta-2 agonists, long-acting anticholinergics, short-acting anticholinergics, 
roflumilast, oxygen and the number of accident and emergency registrations or 
hospitalisations for COPD in the previous year.
11
  
 
Statistical analysis 
Conditional logistic regression was used to estimate odds ratios (ORs) for fracture risk 
(SAS 9.3 (SAS Institute, Cary, NC)). Final regression models were determined by 
stepwise backward elimination using a significance level of 0.05. Patients without 
COPD were the reference category. Analyses were stratified by intermittent GC 
exposure, proxies of disease severity and average daily and cumulative dose 
exposure for specific fracture sites. Proxies of disease severity considered include 
hospitalisation and emergency visits for COPD in previous year. All results were 
presented as OR with corresponding 95% confidence intervals (CIs). 
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RESULTS  
The study population consisted of 635,536 cases and the same number of controls. 
Baseline characteristics of the study participants are shown in Table 7.1. The mean 
age at index date was 67.5 ±13.8 and 65% were female. Approximately 18% of the 
cases (n = 113,553) and 15% of the controls (n = 97,460) used GCs in the six months 
before the index date. There was a history of fracture among 24.4% of the cases and 
8% of the controls. A higher proportion of cases had used anticonvulsants, hypnotics, 
anxiolytics, and antidepressants in the six months prior to index date. There were 
38,013 (6%) patients with COPD among the cases and 28,490 (4.5%) among 
controls.  
 
Table 7.1 Baseline Characteristics. 
      Cases        Controls 
  n=635,536 % n=635,536 % 
Male sex 224,182 35.3 224,182 35.3 
Mean age at index date (years, SD) 67.5 13.8 67.5 13.8 
   45-60 220,166 34.6 220,158 34.6 
   60-74 194,647 30.6 194,664 30.6 
   75+ 220,723 34.7 220,714 34.7 
History of co-morbidities      
   Fracture  154,923 24.4 49,742 7.8 
   COPD   38,013 5.9 28,490 4.5 
   Pneumonia  21,106 3.3 15,771 2.5 
   Rheumatoid arthritis 12,245 1.9 9,133 1.4 
   Inflammatory bowel disease 12,962 2.0 10,005 1.6 
   Secondary osteoporosis 32,275 5.1 25,041 3.9 
   Type 1 diabetes mellitus 13,897 2.2 8,439 1.3 
   Type II diabetes mellitus 31,252 4.9 25,535 4.0 
   Hyperthyroidism 13,934 2.2 13,614 2.1 
   Hypogonadism 612 0.1 408 0.1 
   Renal failure 5,570 0.9 3,496 0.6 
   Dementia 16,572 2.6 9,251 1.5 
   Cerebrovascular disease 54,999 8.7 41,511 6.5 
   Malignancies (excl. non-melanoma skin cancer) 71,393 11.2 62,780 9.9 
Drug use within six months before index date 
   Oral glucocorticoids 113,553 17.9 97,460 15.3 
   Inhaled corticosteroids 215,50 3.4 19,236 3.0 
   Inhaled bronchodilators  44,096 6.9 37,105 5.8 
   Xanthine derivatives 5,427 0.9 4,653 0.7 
   Bisphosphonates 16,941 2.7 10,211 1.6 
   Vitamin D 740 0.1 627 0.1 
   Calcium 8,535 1.3 5,777 0.9 
    Raloxifene 747 0.1 493 0.1 
    Hormone replacement therapy 45,381 7.1 55,626 8.8 
   Antipsychotics 31,258 4.9 20,080 3.2 
   Antidepressants 89,941 14.2 53,689 8.5 
   Hypnotics/anxiolytics 72,682 11.4 54,384 8.6 
   Anticonvulsants 21,443 3.4 10,456 1.7 
   Anti-Parkinson drugs 7,030 1.11 3,987 0.6 
   Antihypertensive drugs 228,310 35.9 227,776 35.8 
   Proton pump inhibitors 56,646 8.9 41,382 6.5 
COPD related Emergency visit in past year 588 0.1 302 0.1 
COPD related Hospitalisation in past year 9,658 1.5 4,252 0.7 
Abbreviations: SD: standard deviation; COPD: chronic obstructive pulmonary disease. 
 
 
 
Table 7.2 presents the adjusted fracture risk among COPD patients currently 
exposed to oral glucocorticoid, compared with patients without COPD. COPD patients 
with intermittent use of high average daily dose oral glucocorticoids did not have an 
increased risk of any, osteoporotic, hip or clinically symptomatic vertebral fracture 
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compared to patients without COPD (adj. OR 0.65; 95% CI: 0.50-0.86, 0.70; 95% CI: 
0.70-0.99, 1.17; 95% CI: 0.59-2.32, 1.98; 95% CI: 0.59-6.65 respectively).   
However, the risk of osteoporotic fractures was significantly increased among 
long-term heavy users receiving a cumulative dose between 1 and 4.9 grams (adj.OR: 
1.46; 95% CI: 1.07-1.20), and the risk of hip fracture increased among COPD patients 
with cumulative dose of 5.0-9.9 g (adj.OR: 2.88; 95% CI: 1.27-6.57). As a proxy for 
disease severity, we further stratified COPD patients by patients with an emergency 
visit or hospitalisation for COPD in the year prior to fracture (Table 7.3).  We identified 
an elevated risk of osteoporotic fracture among patients who visited the emergency 
unit (adj.OR 1.47; 95% CI 1.20-1.79) or were hospitalised in the past year for COPD 
(adj.OR 1.76; 95% CI 1.66-1.85), as compared to patients without COPD (Table 7.3). 
Similarly the risk of hip fracture was elevated in hospitalised patients (adj.OR: 2.47; 
95% CI: 2.26-2.70) and those who visited the emergency unit (adj.OR: 2.13; 95% CI: 
1.49-3.04) in the past year, compared to non-COPD patients. The risk of clinically 
symptomatic vertebral fractures showed a 3-fold increase among COPD patients 
 
Table 7.2. Adjusted risk fractures among COPD patients compared to patients without COPD stratified by current GC use. 
 Any Fracture 
Adj. OR
a,b 
(95% CI) 
Osteoporotic fracture 
Adj. OR
a,b 
(95% CI) 
Hip Fracture 
Adj. OR
a,b 
(95% CI) 
Clinical Symptomatic Vertebral 
Adj. OR
a,b 
(95% CI) 
No COPD  Reference)  Reference  Reference  Reference 
COPD 1.06 (1.04-1.08) 1.03 (1.00-1.06)  1.08 (1.03-1.13) 1.31 (1.20-1.44) 
  By GC exposure     
    Current use 1.01 (0.96-1.06) 1.12 (1.05-1.20) 1.23(1.10-1.37) 1.87(1.52-2.31) 
      By average daily dose ≥15 mg/day (oral prednisolone equivalents) 
        <1 gram 0.65 (0.50-0.86) 0.70 (0.49-0.99) 1.17 (0.59-2.32) 1.98 (0.59-6.65) 
        1.0-4.9 g 1.14 (0.90-1.43) 1.46 (1.07-2.00) 1.61 (0.95-2.73) 2.43 (0.95-6.22) 
        5.0-9.9 g 1.36 (0.97-1.89) 1.40 (0.91-2.16) 2.88 (1.27-6.57) 0.93 (0.35-2.44) 
        ≥ 10 g 1.07 (0.84-1.36) 1.19 (0.85-1.65) 1.59 (0.89-2.87) 1.25 (0.52-3.00) 
Abbreviations: OR:  odds ratio; GC:  glucocorticoid; COPD: chronic obstructive pulmonary disease; CI: confidence interval. 
Current GC use:  most recent GC dispensing with 1-91 days before index date. 
a
Values are the adjusted odds ratios (95% confidence interval) 
b
adjusted for: prior fracture, history of pneumonia, inhaled corticosteroids, inhaled bronchodilators, antidepressants, 
hypnotics/anxiolytics, proton pump inhibitors, emergency visit for COPD, hospitalisation for COPD, never, distant, past, and recent use 
of oral GCs. 
 
following hospitalisation and emergency visit in the past year when compared to 
patients without COPD. We also noticed an increased risk of any fracture in patients 
with emergency visits or hospitalisation for COPD. 
The individual breakdown of average daily dose and cumulative dose by 
fracture type among COPD patients, compared to non-COPD patients, is provided in 
Table 7.4. Current GC use among COPD patients was associated with an increased 
risk of osteoporotic (adj.OR: 1.12; 95% CI: 1.05-1.20), hip (adj.OR: 1.23; 95% CI: 
1.10-1.37) and clinically symptomatic vertebral fractures (adj.OR: 1.87; 95% CI: 1.52-
2.31) as compared to patients without COPD except risk for any fracture. The risk of 
hip and clinically symptomatic vertebral fractures increased with increasing average 
daily doses, with patients exposed to 7.5-15 mg/day having the greatest risk. 
Cumulative dose of 5.0-9.9g was associated with an increased risk of clinically 
symptomatic vertebral fractures (adj.OR: 2.26; 95% CI: 1.52-3.35).  
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Table 7.3. Adjusted risk of fracture among COPD patients stratified by proxies of disease severity compared to patients without COPD. 
  
Any Fracture 
Adj. OR
a,b 
(95% CI) 
Osteoporotic fracture 
Adj. OR
a,b 
(95% CI) 
Hip Fracture 
Adj. OR
a,b 
(95% CI) 
Clinical Symptomatic 
Vertebral 
Adj. OR
a,b 
(95% CI) 
No COPD  Reference)  Reference  Reference  Reference 
COPD 1.05 (1.03-1.07) 1.03 (1.00-1.06) 1.08 (1.03-1.13) 1.31(1.20-1.44) 
  Proxy indicators of disease 
    Emergency visit in past year for COPD 
      No 1.05 (1.03-1.07) 1.03 (1.00-1.06) 1.08 (1.03-1.13) 1.31 (1.20-1.44) 
      Yes 1.47 (1.27-1.71) 1.47 (1.20-1.79) 2.13 (1.49-3.04) 3.15 (1.64-6.07) 
    Hospitalisation in past year for COPD 
      No 1.07 (1.05-1.10) 1.06 (1.03-1.08) 1.11 (1.06-1.17) 1.35 (1.23-1.48) 
      Yes 1.66 (1.60-1.73) 1.76 (1.66-1.85) 2.47 (2.26-2.70) 3.08 (2.57-3.69) 
Abbreviations: OR:  odds ratio; GC:  glucocorticoid; COPD: chronic obstructive pulmonary disease; CI: confidence interval. 
Current GC use:  most recent GC dispensing with 1-91 days before index date. 
a
values are the adjusted odds ratios (95% confidence interval)  
b
Adjusted for previous fracture, history of pneumonia, inflammatory bowel disease, cerebrovascular disease, inhaled corticosteroids, 
inhaled bronchodilators, antidepressants, hypnotics/anxiolytics, proton pump inhibitors, hospitalisations for COPD, emergency visits for 
COPD, and previous use of oral GCs.  
 
Table 7.4. Adjusted risk of fracture among COPD patients compared to patients without COPD stratified by average daily and 
cumulative exposure. 
  
Any Fracture 
Adj. OR
a,b 
(95% CI) 
Osteoporotic fracture 
Adj. OR
a,b 
(95% CI) 
Hip Fracture 
Adj. OR
a,b 
(95% CI) 
Clinical Symptomatic 
Vertebral 
Adj. OR
a,b 
(95% CI) 
No COPD Reference) Reference Reference Reference 
COPD 1.06 (1.04-1.08) 1.03 (1.00-1.06) 1.08 (1.03-1.13) 1.31 (1.20-1.44) 
   By GC exposure 
    
     Current use 1.01 (0.96-1.06) 1.12 (1.05-1.20) 1.23(1.10-1.37) 1.87(1.52-2.31) 
       By average daily dose (oral prednisolone equivalents) 
          <7.5   mg/day 0.98 (0.92-1.04) 1.08 (0.99-1.17) 1.16 (1.01-1.34) 1.53 (1.18-1.99) 
          7.5-15 mg/day 1.08 (0.99-1.17) 1.20 (1.07-1.34) 1.23 (1.02-1.47) 2.98 (2.05-4.33) 
≥15 mg/day 1.01 (0.89-1.15) 1.15 (0.96-1.37) 1.66 (1.21-2.28) 1.55 (0.94-2.54) 
       By cumulative dose (oral prednisolone equivalents) 
<1.0 g 0.87 (0.77-0.99) 1.01 (0.86-1.18) 1.19 (0.89-1.59) 1.96 (1.10-3.46) 
1.0-4.9 g 0.96 (0.89-1.04) 1.09 (0.98-1.22) 1.21 (1.01-1.45) 1.60 (1.15-2.24) 
5.0-9.9 g 1.11 (1.00-1.22) 1.15 (1.02-1.31) 1.23 (0.99-1.53) 2.26 (1.52-3.35) 
≥ 10 g 1.06 (0.98-1.15) 1.18 (1.06-1.31) 1.26 (1.06-1.51) 1.87 (1.33-2.64) 
 Abbreviations: OR:  odds ratio; GC:  glucocorticoid; COPD: chronic obstructive pulmonary disease; CI: confidence interval. 
Current GC use:  most recent GC dispensing with 1-91 days before index date.  
a
values are the adjusted odds ratios (95% confidence interval) 
b
Adjusted for previous fracture, history of pneumonia, inhaled corticosteroids, inhaled bronchodilators, antidepressants, 
hypnotics/anxiolytics, proton pump inhibitors, hospitalisations for COPD, emergency visits for COPD, and previous use of oral GCs.  
 
DISCUSSION  
 
In the current study, we found that exposure to intermittent high-dose glucocorticoid 
was not associated with an increased risk of any, osteoporotic, hip and clinically 
symptomatic vertebral fracture in COPD patients compared to patients without COPD. 
Furthermore, we showed that proxies of disease severity (hospitalisation and 
emergency visit for COPD in the past year) were associated with an increased risk of 
any, osteoporotic, hip and clinically symptomatic vertebral fractures among patients 
with COPD compared to patients without COPD.  
This study extends previous knowledge from large population-based 
studies.
5,6
 A cohort study by de Vries et al,
7
 showed that intermittent high-dose of 
glucocorticoid among patients with various diseases requiring GC use was associated 
with a small increased risk of osteoporotic and vertebral fractures, but no increased 
risk of hip fractures. In their study, intermittent use of GC was defined as daily dose ≥ 
15mg and cumulative exposure ≤ 1g similar to our study. However, they employed a 
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cohort study design adjusting for covariates time-dependently. This might explain the 
absence of the small increased risk of osteoporotic and vertebral fractures with 
intermittent exposure in our study. Another study among patients with COPD found no 
increased risk of vertebral fracture with intermittent use of systemic GC.
23
 The 
investigators defined intermittent use of GC as exposure to prednisolone for an 
average of 4 months during the patient’s lifetime and the study population was 
comprised of men over 50 years. Additionally, intermittent use of GCs (daily dose ≥ 
10mg and cumulative dose ≤ 1g) did not change the BMD in patients with COPD,24 
this might explain our result. However, COPD patients exposed to continuous GC use 
were 2.4 times more likely to have one or more vertebral fractures.
23
  
In our study, we defined emergency visits and hospitalisations for COPD in 
the past year as proxies for disease severity. Patients with COPD who were 
hospitalised or who visited the emergency unit in the past year had an increased risk 
of hip, osteoporotic and clinically symptomatic vertebral fractures. The severity of the 
disease may influence the dose and duration of GC administered.
9
 However, severity 
of pulmonary disease was shown to be inversely proportional to BMD.
11
 Our findings 
are in line with a population-based case-control study of Danish patients with fractures 
exposed to corticosteroids (n=124,655), reporting that overall fracture risk increased 
with the number of days in which COPD patients were hospitalised.
14
 While 
hospitalisation was identified as an important proxy for disease severity, the duration 
of disease has been found not to correlate with fracture risk, as it does not reflect 
severity of disease 
14
. Adjustment for disease severity is limited in fracture studies 
5,25,26
. In our study, we adjusted the primary analysis for proxies of disease severity. 
Furthermore, studies have identified the importance of disease severity on fracture 
risk in patients exposed to GC. Consequently, adequate adjustments should be made 
when studying the risk of fractures in COPD patients.
11
 
The present results are in line with a previous observational study, which 
evaluated cumulative/daily dose and the risk of fractures using the CPRD. The 
researchers found an increased risk of hip and vertebral fractures with higher daily 
doses of oral corticosteroids compared to patients using lower doses.
10
 Our findings 
are also supported by a large case-control study that reported an increased risk of hip 
fractures with increasing average daily dose.
10
 Vestergaard et al,
14
 also reported a 
dose-dependent increased risk of fractures, with the greatest risk of hip fractures 
observed at a dose of ≥ 7.5 mg/day. Their study was carried out in a subset of our 
population. In our study, an increased risk of osteoporotic, clinically symptomatic 
vertebral and hip fractures was observed at a dose of 7.5 to 15 mg/day compared to 
patients without COPD. The perceived increased risk of hip and osteoporotic fracture 
with increasing cumulative dose seems to disappear after adjustment for various 
confounders. However, the risk of GC related fractures was reported to be strongly 
associated with daily dose than with cumulative dose.
6,27
 This may be due to 
misclassification of exposures to GC as participant’s exposures were ascertained by 
interviews and prone to recall bias. Researchers have emphasised the importance of 
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daily dose monitoring in patients exposed to GC, as the risk of fracture have been 
seen to return towards baseline following termination of GC therapy irrespective of 
cumulative dose.
6
 
Several mechanisms have been suggested for the possible relationship 
between COPD and fracture. GC use has been associated to the reduction in bone 
mineral density and increased fracture risk, which include inhibition of steroid 
synthesis and inhibition over reduced calcium absorption from the gut and increased 
loss of osteoclast, osteoblast, insulin-like growth factor and collagen.
28,29
 It has been 
suggested that factors associated with COPD itself may contribute to loss of bone 
mineral density.
30,31
 Similarly, low dietary calcium is correlated with low BMD and 
increases fracture risk.
25
 However, the risk of fracture among patients receiving oral 
GCs is somewhat independent of decreased bone mineral density.
7
 Damage to the 
micro-architecture of the trabecular bone has been attributed to deformities of the 
vertebrae.
32
 Furthermore, it is been reported that cumulative exposure to GCs 
correlates with the degree of the trabecular network of bones.
33
 Furthermore, smoking 
remains a major risk for COPD and may induce osteoporosis via various mechanism 
which includes the alteration of metabolism of calciotropic hormone; dysregulation in 
the production, metabolism, and binding of estradiol, altered metabolism of adrenal 
cortical hormone and bone angiogenesis.
34
  
The main strength of our study was the large sample size among cases and 
controls. This was possible because our study was conducted using the Danish 
National database with roughly 5 million anonymised patient records from across 
Denmark.
17
 We considered hospitalisation and emergency visit in the past year as 
proxies for disease severity.
14
 Although we adjusted our analyses for these proxies 
this might not have completely corrected for the severity of the disease. Our 
limitations included the lack of information on smoking, alcohol use, inflammatory 
markers, muscle mass or strength and BMD as such we could not adjust for these 
potential confounders in our analysis. There is also the problem of diagnosis of 
vertebral fracture, which is mostly done by clinical and radiological assessment, as 
such asymptomatic vertebral fractures are most likely to go undetected.
6
 We could not 
independently confirm the predictive values of cases diagnosed with fractures by the 
general practitioner. Although a high positive predictive value (93%) of diagnosis of 
fractures has been reported in the Danish database.
26
 This limits the possibility of 
non-differential misclassification. As with most observational studies, we could not 
rule out the possibility of misclassification of exposure to GCs. Information on 
potential treatment received prior to entry into the Danish national database was also 
not available. We also lacked information on the severity of COPD as such there may 
be confounding by indication.
9
  
In conclusion, intermittent high-dose GC was not associated with an 
increased risk of any, osteoporotic, hip or clinically significant vertebral fractures in 
patients with COPD. Current GC use, however, was associated with an increased risk 
of hip and clinically symptomatic vertebral fracture. It is important to also note that 
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COPD alone increases the risk of fracture compared to those without COPD, 
especially among patients with history of hospitalisation or emergency room visit for 
COPD. Therefore, emphasis on prophylactic treatment of fractures may not be 
essential in patients with COPD receiving intermittent dose of GCs, whereas this 
should be considered for high-dose long-term users with advanced COPD disease 
stage, postmenopausal women and men over 40 years. 
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INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality worldwide and is defined by the presence of chronic respiratory symptoms 
and persistent airflow limitation.
1
 Although bronchodilators are central to the 
pharmacological management of COPD, patients with recurrent exacerbations are 
often additionally treated with inhaled corticosteroids (ICS).
2
 Exacerbations play a 
central role in the pathophysiology of COPD as they are linked to lung function 
decline, poor health status, and increased mortality.
3
 Corticosteroid use has been 
associated with increased risk of pneumonia and fractures.
4,5
 There is growing 
interest in precision medicine using biomarkers in COPD.
6
  
Biomarkers such as blood eosinophils and C-reactive proteins (CRP) have 
been identified as important markers of inflammation in COPD. Clinical data suggest 
that elevated blood eosinophil counts, which is present in up to 40% of COPD 
patients,
7
 is a promising biomarker of response to ICS.
8–11
 Elevated blood eosinophil 
counts have been associated with an increased risk of exacerbations, and patients 
with eosinophilic inflammation responded better to ICS therapy than non-eosinophilic 
patients.
8,12
 The exact mechanism by which ICS reduces exacerbation among 
eosinophilic patients remains unclear.
9
 Evaluation of COPD Longitudinally to Identify 
Surrogate End-points (ECLIPSE) investigators identified several biomarkers including 
CRP, believed to be an important biomarker among COPD patients. ICS has been 
reported to attenuate CRP levels. This dissertation investigates the role of blood 
eosinophil and CRP in COPD management and examines the trends in exacerbations 
and the risk of fractures with systemic corticosteroid use. 
 
BIOMARKERS AND INHALED CORTICOSTEROID USE IN COPD 
 
Recently, there has been a focus on the use of biomarkers to help guide management 
of COPD patients with the aim of improving COPD-related outcomes such as 
exacerbations. Accumulating evidence indicates that COPD patients with elevated 
blood eosinophil counts respond better to ICS therapy.
8,9
 However, if blood 
eosinophils are to be useful in the clinical management of COPD, it is important to 
address certain concerns which includes; the correlation of eosinophils in various 
tissues, the stability of blood eosinophil counts over-time, clinically relevant cut-offs of 
blood eosinophils, role blood eosinophils and ICS in the reduction of COPD-related 
exacerbations. It has been established that up to 40% of patients with stable COPD 
have elevated blood eosinophil counts
13
 with reported positive correlation between 
blood and sputum counts.
14–16
 Although the strength of the correlation between blood 
and sputum eosinophilia is still been debated.
17
 Various studies have sought to 
establish the repeatability and reproducibility of blood eosinophil measurements in 
COPD patients with varying results.
18,19
 Previous studies have focused primarily on 
measurements of blood eosinophil counts among small numbers of patients, with 
short durations of follow-up durations typically spanning few weeks, deemed to be 
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inadequate in understanding the long-term stability of blood eosinophils. There is a 
consensus among researchers and clinicians that for blood eosinophil counts to be 
central in ICS management, the long-term stability of blood eosinophil counts needed 
to be determined among COPD patients in clinical populations. Therefore the aim of 
Chapter 3 was to determine the stability of blood eosinophil counts among patients 
with COPD and the impact of sex, age, smoking and baseline counts. Following our 
investigations, we found that the stability of blood eosinophils among COPD patients 
was approximately 90% at 6 months, 82% at 2 years of follow-up and declined 
progressively irrespective of comorbidities or drug exposures. Furthermore, patients 
with baseline blood eosinophil counts ≥ 6% showed higher stability, age and sex also 
had a significant impact on blood eosinophil counts.
20
 While several studies reported 
cross-sectional data on eosinophilia in COPD, none have investigated the stability of 
blood eosinophil counts among COPD patients using longitudinal data. Pascoe et al,
8
 
reported 66% prevalence of blood eosinophilia ≥2% in former or current smokers with 
moderate-to-severe COPD and a history of exacerbation. Using identical cut-offs to 
later, Watz et al,
9
 reported a prevalence of 54% in former or current smokers with 
severe airflow limitation and at least one exacerbation in the previous 12 months 
These findings extends our understanding of blood eosinophil as a potential 
biomarker in COPD management. 
Post-hoc analyses of RCTs suggest that patients with elevated blood 
eosinophil counts  (≥2%) were more likely to benefit from ICS treatments.8 Thereafter, 
a significant number of post-hoc analyses of RCTs have been conducted to evaluate 
the effect of ICS on exacerbation risk reduction among COPD patients with elevated 
blood eosinophil counts adopting various relative blood eosinophil thresholds, with 
conflicting findings.
21–23
 These findings not only raised questions on the exact relative 
blood eosinophil thresholds which could best predict the beneficial effects of ICS 
therapy on exacerbation risk reduction but also whether relative blood eosinophil 
counts were useful as a guide to targeted treatments in clinical settings. A meta-
analysis assessing whether relative blood eosinophil counts of ≥2% was effective in 
guiding ICS therapy found that the use of relative blood eosinophil thresholds ≥2% 
was insufficient in identifying patients who might potentially benefit from ICS 
treatment.
24
 Researchers have since reported that the use of absolute blood 
eosinophil counts was more robust in predicting the risk of exacerbations compared to 
relative counts,
25,26
 thus shifting the focus of investigators towards the potential of 
absolute blood eosinophil counts as a guide for ICS therapy in COPD. Thus, in 
Chapter 5 we evaluated the role of absolute or relative blood eosinophil counts in 
ICS-guided therapy in a large population-based COPD cohort. We found no reduced 
risk of COPD-related acute exacerbations or hospitalisations/accident and emergency 
(AE) visits among patients with high relative or absolute blood eosinophil counts 
currently exposed to ICS. However, all-cause mortality was reduced among current 
ICS users with elevated relative blood eosinophil counts, although, this effect was no 
detected with absolute blood eosinophil counts.
27
 Other studies have reported the 
Chapter 8  
  
 132 
potential of blood eosinophils to guide ICS therapy among patients with COPD,
8–10
 
with others reporting conflicting results.
27
  
The exact reasons for our findings are unknown, but it is important to note 
that studies exploring blood eosinophil counts as a guide to ICS treatment among 
COPD patients have primarily included only former or current smokers.
8–10,28
 Smoking 
plays a central role in the cascade of events leading to the systemic inflammation in 
COPD. As such this group of patients represent a unique COPD sub-group.
29
 
Researchers also observed that elevated blood eosinophil counts best predicts 
exacerbations in only a sub-group of COPD patients who were ex-smokers.
30
 In our 
study, we excluded patients with a history of asthma to avoid enrolling patients with 
reversible airflow limitation. However, various studies have included patients with a 
history of asthma who are inherently different from COPD patients. Also, patients 
included in prior studies had two or more exacerbations in the previous year and a 
significant proportion of patients were exposed to ICS at baseline. Owing to the 
heterogeneity of COPD, these patients are inherently different from the subjects in our 
study population. One study, which postulated that COPD patients with higher 
baseline blood eosinophil counts would have reduced exacerbation rate in response 
to additional ICS therapy.
8
 Reported differences between treatments within each 
eosinophil count stratum, rather than the differences in response rates between 
strata, hence did not directly test this hypothesis.
31
 Additionally, most studies, which 
reported conflicting findings to our study, have come from post-hoc analyses of 
randomised controlled trials (RCTs). The relatively short duration of follow-up and 
severity of COPD in these post-hoc analyses is a considerable limitation on the 
reported findings.
32
 Investigators have acknowledged that among COPD patients 
without a history of exacerbation as in our study, no data currently suggests that blood 
eosinophil counts will predict ICS response in the future.
8,33
 Thus, our study provides 
valuable information among these patient groups and will need to be replicated in 
prospective studies, including pre-specified RCTs and observational studies. 
Essential to the idea of precision medicine is the understanding of the heterogeneous 
nature of COPD and the need for better management of specific groups.
34
 This thesis 
provides valuable information among newly diagnosed COPD patients in clinical 
settings exposed to ICS, compared to studies focused on patients with advanced 
disease stage, having prior history of exacerbations.
35
 
Furthermore, discontinuation of corticosteroids is of great importance to 
clinicians, this is partly due to the potential adverse reactions resulting from abrupt 
corticosteroid discontinuation and also the documented side effects of continuous ICS 
exposure such as pneumonia and fractures.
36,37
 Post-hoc analyses of data from the 
Withdrawal of Inhaled Steroids during Optimized Bronchodilator 
Management (WISDOM) trial, suggested an increased risk of exacerbations following 
ICS withdrawal among COPD patients with elevated blood eosinophil counts.
9
 Thus, 
we evaluated the risk of moderate-to-severe exacerbations, severe exacerbations and 
all-cause mortality following the withdrawal of ICS compared to continuous ICS users 
among COPD patients stratified by relative and absolute eosinophil counts    
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(Chapter 6). We found no increased risk of moderate and/or severe exacerbations 
among patients who discontinued ICS irrespective of absolute or relative blood 
eosinophil counts. The risk of all-cause mortality among patients who discontinued 
ICS was significantly higher among those with low absolute or relative blood 
eosinophil counts. Furthermore, we did not find patient groups at increased risk of 
moderate and/or severe exacerbations following various sensitivity analyses. Our 
results are comparable with a randomised controlled trial (RCT) which found no 
difference in the risk of severe exacerbations among COPD patients who 
discontinued ICS therapy and those who continued.
38
 However, post-hoc analysis of 
the WISDOM trial suggested that blood eosinophil counts of ≥4% or ≥300 cells/µL 
might help identify patients with greater risk of exacerbations following ICS 
withdrawal.
9
 In line with a previous study, we detected an opposite effect among 
patients with elevated relative blood eosinophil counts.
10
 The exact reasons for the 
disparities in our findings and the post-hoc analyses of the WISDOM trials remain 
uncertain. However, it is important to note that unlike in our study the WISDOM trial 
only enrolled patients with severe to very severe COPD, additionally all patients had a 
history of exacerbation and over 70% of patients in their study were exposed to ICS 
prior to study entry.
9
 A recent trial analysis evaluating the comparative effectiveness 
of ICS treatments showed that inclusion of patients with a history of asthma, prior ICS 
use, and prior exacerbations at randomisation were significant effect-modifiers 
resulting in depletion of susceptible, subsequently influencing exacerbation rates.
39
 
Future studies aimed at improving precision management in COPD would benefit 
from excluding patients with previous or current asthma diagnosis (an important factor 
for fixed airway obstruction), address the withdrawal of ICS at randomisation and 
should stratify patients by their degree of eosinophilia.
35,39
 
The use of a single biomarker to help guide the management of COPD is 
deemed a “one-eyed” approach, thus the use of several biomarkers is believed to 
improve robustness and precision in COPD management.
40
 C-reactive protein (CRP) 
was identified as another biomarker of significant interest in COPD.
41
 Elevated CRP 
levels have been linked with increased risk of exacerbations requiring hospitalisation 
and increased risk of mortality among COPD patients. Reports suggest that ICS 
therapy attenuates CRP levels in COPD.
42–44
 In Chapter 4, we explored the risk of 
moderate-to-severe exacerbations, severe exacerbations and all-cause mortality 
among COPD patients with elevated levels of CRP exposed to ICS compared to 
patients never exposed to ICS without elevated CRP levels. We found no reduced risk 
of moderate and/or severe exacerbations among COPD patients currently exposed to 
ICS with elevated CRP levels. However, we found an increased risk of all-cause 
mortality among patients with elevated CRP levels regardless of ICS exposure. Very 
few researchers have evaluated the role of CRP in guiding ICS therapy aimed at 
improvement of moderate-to-severe or severe exacerbations of COPD. Thomsen et 
al,
45
 reported that patients with elevated CRP levels, fibrinogen, and leucocyte counts 
had increased risk of exacerbations. However, when the investigators evaluated each 
elevated biomarker separately, they found no significantly increased risk of frequent 
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exacerbations with elevated CRP levels alone, (not in combination with other 
biomarkers) which is in line with the results from our study. We noted an increased 
risk of moderate and/or severe exacerbations when we controlled only for age and 
sex. After adjustments for all confounders, the observed risk disappeared. This is the 
first study to specifically evaluate the risk of moderate-to-severe, severe 
exacerbations and all-cause mortality among COPD patients currently exposed to ICS 
stratified by CRP levels. In a double-blind randomized placebo-controlled trial of 
COPD patients across 11 centers, no reduction in CRP levels was observed among 
COPD patients exposed to ICS with or without LABA, although serum protein D levels 
decreased, suggesting that ICS treatment affects lung-specific biomarkers rather than 
systemic inflammatory markers.
43
 Furthermore, the ECLIPSE investigators reported 
that elevated levels of CRP, fibrinogen and leukocyte counts were associated with the 
occurrence of exacerbations in the first year in a univariate analysis.
46
 However, the 
effect disappeared in the elevated CRP group following multivariate adjustments. A 
meta-analysis of 15 randomised and non-randomised studies, found that elevated 
CRP levels were associated with higher mortality rates among COPD patients with 
varying degree of ICS exposure at baseline.
47
 A lack of consensus on the threshold of 
CRP to be employed in interventions studies have led to the adoption of arbitrary cut-
offs.
40
 In our study, we stratified patients by several CRP cut-offs based on the 
distribution of CRP in our cohort.   
Although ICS has been shown to attenuate the levels of CRP among patients 
with COPD, this reduction might not necessarily mean a reduced risk of 
exacerbations, considering the fact that significant numbers of COPD patients have 
normal CRP levels during exacerbations.
44
 The heterogeneity of systemic 
inflammation has been recognised in patients with COPD. These include a high 
heterogeneity in serum CRP levels and other biomarkers that have been largely 
attributed to individual or disease-related factors.
48
 In general populations, a dose-
related effect has been reported between cigarette smoking and increased levels of 
CRP and fibrinogen.
49,50
 CRP levels remained elevated for close to two decades after 
smoking cessation.
51
 Although improved understanding of the effects of confounders 
on CRP levels exist, stability and variability of CRP remain critical to its relevance as a 
guide for therapeutic interventions in COPD.
52
 The ECLIPSE study reported CRP as 
the least stable biomarker assessed, with only 21% of patients having a 3-months 
measurement within 25% of baseline values.
53
 Furthermore, CRP is known to have a 
half-life in plasma of 19 hours and the National Health and Nutrition Examination 
Survey (NHANES) observed significant short-term variability (approximately 2.5 
weeks) in CRP levels, particularly at high levels.
54
 This, in addition to our findings 
makes CRP a poor biomarker for personalised management of COPD exacerbations.  
 
EXACERBATIONS OF COPD AND THE USE SYSTEMIC CORTICOSTEROIDS  
 
Exacerbation of chronic obstructive pulmonary disease (COPD) is defined as an acute 
episode of increased respiratory symptoms necessitating additional therapy.
3
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Symptoms include; dyspnoea, cough and sputum production and/or purulence. 
Exacerbations significantly affect the quality of life and morbidity of COPD patients
55
 
and is a key driver for hospitalisations and re-admissions, resulting in a high burden of 
disease on the health system.
56
 Consequently, prevention of exacerbations of COPD 
is central to the pharmacologic treatment of the disease and multiple options for drug 
therapy are available.
57
 In the United Kingdom (UK), £253 million is spent yearly on 
COPD management, with more than half of the costs attributed to exacerbations.
58
 
Furthermore, COPD-related mortality has increased from 2004 to 2012 while the 
incidence of COPD decreased and then remained stable over the same period. 
COPD results in over a million bed days and 140,000 hospital admissions each year 
in the UK.
59
 In Chapter 2, we examined the incidence rates of moderate and severe 
exacerbations by age and gender within the UK primary care setting. While several 
studies have evaluated the incidence and prevalence of COPD as a disease, only a 
few studies have considered the trend in exacerbations among COPD patients. Our 
study showed a significant increase in the incidence rates from 2005 to 2013 for the 
primary endpoint, any exacerbations of COPD. For severe exacerbations, incidence 
rates increased from 2008 to 2013. Women had higher incidence rates of any 
exacerbations compared to men throughout the study period but they had similar 
incidence rates of severe exacerbations for COPD from 2005 to 2013. The incidence 
rate of any exacerbations for COPD was higher in patients 80 years and older from 
2005 to 2008, after which this trend was not observed. Fuhrman et al,
60
 examined the 
temporal trends of acute exacerbations and related hospitalisations from 1998 to 2007 
in France, found that admission rates increased significantly, especially among 
females. Although our study reported an increase in severe exacerbations there were 
only slight differences by gender for all years. Another study conducted in Brazil found 
no changes in hospitalisation rates from 1998 to 2009.
61
 The exact reason for the 
observed trends in our study remains unknown. However, it could be linked to various 
factors; while emphasis has been on adherence to treatment guidelines by general 
practitioners (GPs) as a means of mitigating COPD-related exacerbations, a 
significant dissociation has been reported between recommendations of guidelines 
and actual management of COPD patients.
62
 It has been reported that COPD patients 
in the UK were not managed in accordance with recommendations of the Global 
Initiative of Chronic obstructive Lung Disease (GOLD) and the National Institute for 
Health and Care Excellence (NICE), with a substantial amount of patients receiving 
inappropriate treatments.
55
 Despite treatment advances in COPD management, we 
found no objective reduction in exacerbations in our study. In addition to factors 
mentioned earlier, low adherence to therapy,
63
 and improper inhaler technique among 
COPD patients
57
 may have contributed to our findings. Similarly, variations in the 
incidence rates of exacerbations seem to follow the incidence of influenza A in the 
UK, suggesting that this might have had an impact on our results.
64
 
Among patients with acute COPD exacerbations, short courses of systemic 
GCs are prescribed in order to help reduce exacerbations, shorten recovery time and 
shorten the length of hospital stay.
65
 Although not recommended by current 
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international guidelines, a proportion of COPD patients are chronically treated with 
low-dose oral GCs.
66
 The detrimental effects of long-term exposure to systemic 
corticosteroids and the risk of fractures have been well documented.
67–69
 However, 
there is limited information, on intermittent exposure to high-dose systemic 
corticosteroids and fracture risk in population-based settings.
70
 Hence, In Chapter 7, 
we investigated the effects of intermittent high-dose glucocorticoids (GCs) use on 
fracture risk among patients with COPD, the impact of proxies of disease severity and 
the effect of dose. Using a large population-based COPD cohort, we found that 
exposure to intermittent high-dose glucocorticoids was not associated with an 
increased risk of any, osteoporotic, hip and clinically symptomatic vertebral fractures 
among COPD patients compared to patients without COPD. Furthermore, we showed 
that proxies of disease severity (hospitalisations and emergency visits for COPD in 
the past year) were associated with an increased risk of any, osteoporotic, hip and 
clinically symptomatic vertebral fractures among patients with COPD compared to 
patients without COPD.
71
 Our findings are in-line with a large cohort study exploring 
the risk of intermittent-high dose GCs and fracture risk
70
 and expands on other 
population-based studies.
67,68
 Based on our findings, we conclude that emphasis on 
prophylactic treatment of fractures may not be essential in patients with COPD 
receiving intermittent dose of GCs, however, this should be considered among high-
dose long-term users with advanced COPD disease stage, postmenopausal women 
and men over 40 years. 
 
CLINICAL IMPLICATIONS AND FUTURE RESEARCH DIRECTIONS 
 
This thesis investigates the role of blood eosinophil counts and CRP in COPD 
management and examines the trends in COPD-related exacerbations and the risk of 
fractures with systemic corticosteroid use. In the drive towards precision medicine in 
COPD management, this dissertation provided the first population-based evidence on 
the stability of blood eosinophil counts as a biomarker for targeted corticosteroid 
treatment among patients with COPD. We reported relatively stable (variable) blood 
eosinophil counts among COPD patients over time. Our work on the stability of blood 
eosinophil counts broadens the current knowledge of this biomarker among COPD 
patients in general practice and was included in the GOLD 2019 recommendations for 
the management of patients with COPD. However, in a large real-life cohort of COPD 
patients, we did not find evidence supporting the role of blood eosinophil counts as a 
guide to ICS use among patients with COPD. We also found that while CRP might be 
useful in detecting acute infections in COPD, it does not seem to have the potential to 
guide ICS treatment among COPD patients. Currently available evidence on the 
potential for blood eosinophil to guide ICS therapy in COPD has come from post-hoc 
analyses of previous studies. Our findings should be interpreted and adapted by 
clinicians in the light of the patients included in our studies.  Additional evidence on 
the role of biomarkers in COPD management is needed from well-designed 
observational studies and clinical trials to confirm our findings. Owing to the 
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heterogeneity of COPD, It is important that researchers pay particular attention to the 
selection of study participants, patient follow-up, exposure to ICS at study entry, prior 
asthma and exacerbation history.  
Furthermore, this dissertation provides an understanding of the trends of 
moderate and/or severe exacerbations by age and sex among patients with COPD. 
Based on our findings policies and interventions aimed toward reducing exacerbations 
should be especially targeted at women and older patients with COPD. Additionally, it 
is important that clinicians adhere to current treatment guidelines, so as to optimize 
treatment and reduce episodes of exacerbations, as discordance has been found 
between recommendations of guidelines for COPD management and actual clinical 
practice. Considering the negative impacts of COPD-related exacerbations on 
patients and the health system, the trends of exacerbations should be explored in 
other general practice settings. The efficacy and safety of intermittent high-dose 
systemic corticosteroids in COPD management are essential. In this thesis, we found 
no increased risk of fractures among COPD patients, exposed to high-dose 
intermittent GCs in our study. Therefore, clinicians should opt for prophylactic 
treatment of patients receiving long-term high-dose GC or among post-menopausal 
women. Prophylactic treatment of COPD patients receiving high-dose intermittent 
GCs may not be necessary. 
In recent times, there has been extensive research work, geared towards 
understanding the role of biomarkers in the management of COPD among patients 
with severe to very severe disease and prior history of exacerbations. Considering the 
heterogeneous nature of COPD, and the increasing trends of exacerbations among 
newly diagnosed patients. It is therefore imperative that future research is geared 
towards understanding the role of biomarkers in guiding therapy among newly 
diagnosed COPD patients. 
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Summary 
 
Introduction 
Chronic obstructive pulmonary disease (COPD) is a common, preventable and 
treatable disease characterised by relentless respiratory symptoms and airflow 
limitation that is due to airway and/or alveolar aberrations usually triggered by 
significant exposure to noxious gases. Diagnosis of COPD should be considered in 
subjects with respiratory symptoms such as dyspnoea, chronic cough, excessive 
sputum production and history of tobacco use, although occupational and indoor air 
pollution also contributes to the disease onset. Spirometry is employed in COPD 
diagnosis. COPD remains a leading cause of morbidity and mortality worldwide and it 
is projected to be the third leading cause of death worldwide by 2030. Additionally, the 
disease is associated with huge social and economic impacts.  
The natural course of COPD is characterised by acute exacerbations, which 
are defined as the worsening of a patient’s condition beyond normal day-to-day 
variation in symptoms that requires additional pharmacotherapy. Exacerbations of 
COPD have a considerable impact on health status, lung function and exercise 
capacity. The goal of management of patients with COPD is to reduce symptoms, 
improve exercise tolerance, health status and decrease the frequency and severity of 
exacerbations. In the United Kingdom (UK), £253 million is spent yearly on COPD 
management, with over half of the costs attributed to exacerbations. Consequently, 
prevention of exacerbations of COPD is central to the pharmacologic treatment of the 
disease and multiple options for drug therapy are needed.  
Biomarkers such as blood eosinophils and C-reactive proteins (CRP) have 
been identified as important markers of inflammation in COPD. Clinical data suggest 
that elevated blood eosinophil counts, present in up to 40% of COPD patients, is a 
promising biomarker of response to inhaled corticosteroids (ICS). Elevated eosinophil 
counts have been associated with an increased risk of exacerbations, and patients 
with eosinophilic inflammation responded better to ICS therapy than non-eosinophilic 
patients. The Evaluation of COPD Longitudinally to Identify Surrogate End-points 
(ECLIPSE) investigators identified several biomarkers including CRP believed to be 
an important marker in COPD. ICS have been reported to attenuate CRP levels. 
Therefore the current dissertation investigates the role of blood eosinophil and CRP in 
COPD management. We also examined the trends in exacerbations and the risk of 
fractures with systemic corticosteroid use. 
 
Findings 
In Chapter 3 we determine the stability of blood eosinophil counts among patients 
with COPD and the impact of sex, age, smoking and baseline counts. Following our 
investigations, we found that the stability of blood eosinophils among COPD patients 
was approximately 90% at 6 months, 82% at 2 years of follow-up and declined 
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progressively irrespective of comorbidities or drug exposures. Furthermore, patients 
with baseline blood eosinophil counts ≥ 6% showed higher stability, age and sex also 
had significant impact on blood eosinophil counts. This is the first study to have 
investigated the stability trajectory of blood eosinophil counts among COPD patients 
using longitudinal data. This finding extends our understanding of blood eosinophil as 
a potential biomarker in COPD management. 
Post-hoc analyses of RCTs suggest that patients with elevated blood 
eosinophil counts  (≥ 2%) are more likely to benefit from ICS treatments. Thus, in 
Chapter 5 we evaluated the role of absolute or relative blood eosinophil counts in ICS 
guided therapy among patients with COPD in general practice settings. We found no 
reduced risk of COPD-related acute exacerbations or hospitalisations/ accident and 
emergency (AE) visits among patients with high blood eosinophil counts currently 
exposed to ICS. However, all-cause mortality was reduced among current ICS users 
with elevated relative blood eosinophil counts, although this effect was not detected 
with absolute eosinophil counts. While post-hoc analyses of data have reported the 
potential of blood eosinophil counts as a guide for ICS therapy among COPD patients, 
conflicting results abound.  
Furthermore, discontinuation of corticosteroids is of great importance to 
clinicians, this is partly due to the potential adverse reactions resulting from abrupt 
corticosteroid discontinuation and the documented adverse effects of continuous ICS 
exposure such as pneumonia and fractures. Thus, in Chapter 6 we evaluated the risk 
of moderate-to-severe exacerbations, severe exacerbations and all-cause mortality 
following the withdrawal of ICS compared to continuous ICS users among COPD 
patients stratified by elevated relative and absolute eosinophil counts. We found no 
increased risk of moderate and/or severe exacerbations among patients who 
discontinued ICS irrespective of absolute or relative blood eosinophil counts. The risk 
of all-cause mortality among patients who discontinued ICS was significantly higher 
among those with low absolute or relative blood eosinophil counts. We did not find 
patient groups at increased risk of moderate and/or severe exacerbations following 
various sensitivity analyses.  
The use of a single biomarker to help guide the management of COPD is 
deemed a “one-eyed” approach; as such we also evaluated the role of CRP in COPD 
management. Elevated CRP levels have been associated with increased risk of 
exacerbation requiring hospitalisation and increased risk of mortality among COPD 
patients. Reports suggest that ICS therapy attenuates CRP levels in COPD. In 
Chapter 4, we explored the risk of moderate-to-severe exacerbations, severe 
exacerbations and all-cause mortality among COPD patients with elevated levels of 
CRP exposed to ICS compared to patients never exposed to ICS without elevated 
CRP levels. We found no reduced risk of moderate and/or severe exacerbations 
among COPD patients currently exposed to ICS with elevated CRP levels. However, 
we found an increased risk of all-cause mortality among patients with elevated CRP 
levels regardless of ICS exposure. Very few researchers have evaluated the role of 
CRP in guiding ICS use in the improvement of moderate-to-severe or severe 
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exacerbations.  Although ICS has been shown to attenuate the CRP levels among 
patients with COPD, this reduction in CRP levels might not necessarily mean a 
reduced risk of exacerbations, considering the fact that significant numbers of COPD 
patients have normal CRP levels during exacerbations. The heterogeneity of systemic 
inflammation has been recognised in patients with COPD. These include a high 
heterogeneity in serum CRP levels and other biomarkers that have been largely 
attributed to host or disease-related factors.  
Considering the burden, and high cost associated with COPD exacerbations, 
it was essential to understand the trends of exacerbations among COPD patients over 
time. Consequently, in Chapter 2 we examined the incidence rates of moderate and 
severe exacerbations of COPD by age and gender within the UK primary care setting. 
While several studies have evaluated the incidence and prevalence of COPD as a 
disease, only a few studies have considered the trend in exacerbations among COPD 
patients. We found a significant increase in the incidence rates from 2005 to 2013 for 
the primary endpoint, any exacerbations of COPD. For severe exacerbations, 
incidence rates increased from 2008 to 2013. Women had higher incidence rates of 
any exacerbations compared to men throughout the study period but they had similar 
incidence rates of severe exacerbations for COPD from 2005 to 2013. Incidence rates 
of any exacerbations of COPD were higher in patients 80 years and older from 2005 
to 2008, after which this trend was not observed. We found no objective reduction in 
exacerbations in our study. In addition to factors mentioned earlier, low adherence to 
therapy, and improper inhaler technique among COPD patients may have contributed 
to our findings. Similarly, variations in the incidence of exacerbations seem to follow 
the incidence of influenza A in the UK, suggesting that this might have had an impact 
on our results.  
The long-term exposure to systemic corticosteroids and the risk of fractures 
have been well documented. However, In Chapter 7, we investigated the effects of 
intermittent high-dose glucocorticoids (GCs) use and fracture risk among patients with 
COPD, the impact of proxies of disease severity and the effect of dose. Using a large 
population-based COPD cohort, we found that exposure to intermittent high-dose 
glucocorticoids was not associated with an increased risk of any, osteoporotic, hip 
and clinically symptomatic vertebral fractures in COPD patients compared to patients 
without COPD. Furthermore, we showed that proxies of disease severity 
(hospitalisations and emergency visits for COPD in the past year) were associated 
with an increased risk of any, osteoporotic, hip and clinically symptomatic vertebral 
fractures among patients with COPD compared to patients without COPD.  
 
Conclusion 
In chapter 8, we discussed the clinical implications and future perspectives of this 
thesis for researchers and clinicians. COPD is a heterogeneous disease and 
biomarkers play an important role in the disease process.  The exact mechanism by 
which ICS reduces exacerbations among patients with elevated blood eosinophil 
counts remains unclear. However, in view of the findings of this thesis, we conclude 
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that considering the rising trends of COPD exacerbations, among newly diagnosed 
COPD patients. It is important that future research is geared towards understanding 
the role of biomarkers in the management of newly diagnosed COPD patients, taking 
into consideration prior exacerbations, history of asthma, and ICS exposure prior to 
follow-up. 
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Samenvatting 
 
Introductie 
Chronisch obstructieve longziekten (COPD) is een alledaagse aandoening die zowel 
voorkomen, als behandeld kan worden. COPD wordt gekenmerkt door aanhoudende 
symptomen in de luchtwegen en een gelimiteerde luchtstroom. Dit wordt veroorzaakt 
door afwijkingen aan de luchtwegen en/of de longblaasjes, als gevolg van een 
significante blootstelling aan schadelijke gassen. De diagnose van COPD moet 
overwogen worden bij personen met respiratoire symptomen, zoals kortademigheid, 
chronisch hoesten, buitensporige slijmproductie en een historie van roken, hoewel 
luchtvervuiling ook bij kan dragen aan het ontstaan van de aandoening. Bij de 
diagnose van COPD wordt gebruik gemaakt van spirometrie. COPD is de 
belangrijkste oorzaak van morbiditeit en mortaliteit wereldwijd en er wordt geschat dat 
dit in 2030 wereldwijd de derde plek zal innemen als belangrijkste oorzaak. Daarnaast 
is de aandoening geassocieerd met een grote sociale en economische impact.  
Het natuurlijk verloop van COPD wordt gekenmerkt door acute exacerbaties, die 
gedefinieerd zijn als een periode waarin de conditie van de patiënt ernstiger 
verslechtert dan toe te wijzen is aan de gemiddelde dagelijkse variatie. Voor de 
behandeling van deze acute exacerbaties is aanvullende farmacotherapie 
noodzakelijk. COPD-exacerbaties hebben een aanzienlijke impact op de 
gezondheidstoestand, de longfunctie en het vermogen om oefeningen uit te voeren.  
Het doel van de behandeling van patiënten met COPD is om de symptoomlast te 
verlagen, de gezondheidstoestand en het vermogen om oefeningen uit te voeren te 
verbeteren, en de frequentie en de ernst van exacerbaties te verlagen. In het 
Verenigd Koninkrijk (UK) wordt jaarlijks 253 miljoen pond uitgegeven aan de COPD-
behandeling, waarbij meer dan de helft uitgegeven wordt aan de behandeling van 
acute exacerbaties. Om die reden is de preventie van de acute exacerbaties een 
centraal doel binnen de farmacologische behandeling van COPD-patiënten en 
hiervoor zijn verschillende therapieën beschikbaar.  
Biomarkers, zoals bloed eosinofielen en C-reactief proteïne (CRP), zijn reeds 
geïdentificeerd als belangrijke ontstekingsmarkers in COPD. Klinische resultaten laten 
zien dat een verhoogd aantal bloed eosinofielen, aanwezig bij 40% van de COPD-
patiënten, een veelbelovende biomarker is voor de mogelijke respons op 
inhalatiecorticosteroïden. Een verhoogd aantal bloed eosinofielen is geassocieerd 
met een toegenomen risico op exacerbaties, en patiënten met een eosinofiele 
ontsteking reageren beter op een behandeling met inhalatiecorticosteroïden dan 
patiënten zonder verhoogd aantal eosinofielen.  
De onderzoekers van de ECLIPSE-studie (Evaluation of COPD Longitudinally to 
Identify Surrogate End-points) hebben verschillende biomarkers geïdentificeerd, zoals 
CRP, waarvan men verondersteld dat het een belangrijke marker is in COPD-
patiënten. Daarnaast is gerapporteerd dat inhalatiecorticosteroïden in staat zijn om 
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het CRP-niveau te verlagen. Om die reden wordt in dit proefschrift gekeken naar de 
rol van het aantal bloed eosinofielen en CRP binnen de behandeling van COPD-
patiënten. Daarnaast is ook gekeken naar trends binnen het optreden van COPD-
exacerbaties en het fractuurrisico bij systemisch corticosteroïde-gebruik.  
 
Uitkomsten 
In hoofdstuk 3 hebben we gekeken naar de stabiliteit van het aantal bloed 
eosinofielen bij COPD-patiënten en de impact van leeftijd, geslacht, roken en de 
nulmeting. In het onderzoek vonden wij dat de stabiliteit van bloed eosinofielen bij 
COPD-patiënten na zes maanden ongeveer 90% was, en na twee jaar 82%. De 
stabiliteit van bloed eosinofielen nam geleidelijk af in de tijd wat onafhankelijk was van 
de comorbiditeiten of de blootstelling aan geneesmiddelen. Daarnaast hebben 
patiënten met een nulmeting  (van het aantal bloed eosinofielen) groter dan 6% een 
grotere stabiliteit. De leeftijd en het geslacht van de patiënt had daarnaast ook een 
significant effect op het aantal bloed eosinofielen. Dit is de eerste studie waarbij het 
stabiliteitstraject van het aantal bloed eosinofielen is onderzocht bij COPD-patiënten 
waarbij gebruik gemaakt werd van longitudinale data. De uitkomst van deze studie 
vergroot ons begrip over de rol die bloed eosinofielen kan innemen als een potentiële 
biomarker binnen de behandeling van COPD.  
Post-hoc analysen van RCTs suggereren dat patiënten met een verhoogd 
aantal bloed eosinofielen (≥ 2%) waarschijnlijker zijn om een voordeel te ervaren van 
de behandeling met inhalatiecorticosteroïden. Om die reden hebben is in hoofdstuk 
5 gekeken naar de impact van zowel het absolute als het relatieve aantal bloed 
eosinofielen op de behandeling met inhalatiecorticosteroïden. Dit onderzoek werd 
uitgevoerd in de eerste lijn.  Er werd geen verlaagd risico gevonden voor acute 
COPD-exacerbaties, ziekenhuisopnames of het aantal bezoeken aan de 
spoedeisende hulp bij patiënten met een verhoogd aantal bloed eosinofielen die 
behandeld werden met inhalatiecorticosteroïden. Daarentegen was de mortaliteit wel 
lager in de groep met een relatief verhoogd aantal bloed eosinofielen die gebruik 
maakte van inhalatiecorticosteroïde. Dit effect werd niet gezien voor het absoluut 
aantal bloed eosinofielen. Ondanks dat post-hoc analysen laten zien dat er een 
mogelijke rol weggelegd is voor het aantal bloed eosinofielen als richtsnoer voor de 
behandeling met inhalatiecorticosteroïden bij COPD-patiënten, blijven de resultaten 
tegenstrijdig.  
Een ander interessant punt voor artsen is het stoppen van de behandeling 
met corticosteroïden. Dit wordt enerzijds veroorzaakt door de potentiële bijwerkingen 
die op kunnen treden wanneer de behandeling met de corticosteroïden abrupt gestopt 
wordt, maar anderzijds ook de reeds bekende bijwerkingen die op kunnen treden bij 
een continue blootstelling aan corticosteroïden, zoals pneumonie en fracturen. Om 
die reden wordt in hoofdstuk 6 gekeken naar het risico op gematigde – ernstige 
exacerbaties, ernstige exacerbaties en mortaliteit na het stoppen van de behandeling 
met corticosteroïden. De groep patiënten bij wie de behandeling gestopt is wordt 
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vergeleken met een groep patiënten bij wie de behandeling met corticosteroïden is 
voortgezet, waarbij er in de analyse gestratificeerd is voor het relatief en absoluut 
verhoogd aantal bloed eosinofielen. In onze analyse werd geen verhoogd risico 
gevonden op gematigde en/of ernstige exacerbaties bij patiënten bij wie de 
behandeling met corticosteroïden gestopt was. Dit resultaat was onafhankelijk van het 
absolutie of relatieve aantal bloed eosinofielen. Het mortaliteitsrisico was echter 
significant hoger bij patiënten die stopten met de behandeling met corticosteroïden bij 
wie tegelijkertijd sprake was van een laag absoluut of relatief aantal bloed 
eosinofielen. Daarnaast werden er in de verschillende gevoeligheidsanalysen geen 
groepen patiënten gevonden voor wie er sprake was van een verhoogd risico op een 
gematigde en/of ernstige exacerbatie.  
Indien er voor het sturen van de behandeling van COPD patiënten slechts gebruik 
gemaakt wordt van één biomarker, wordt er gesproken over een eenzijdige aanpak. 
Om die reden hebben we de rol van CRP binnen de behandeling van COPD-
patiënten geëvalueerd. Een verhoogd niveau CRP is geassocieerd met een verhoogd 
risico op een exacerbatie die leidt tot een ziekenhuisopname, en mortaliteit bij COPD-
patiënten. Daarnaast suggereert bepaalde literatuur dat het CRP-niveau afneemt door 
de behandeling met corticosteroïden. In hoofdstuk 4 hebben we daarom gekeken 
naar het risico op gematigde – ernstige exacerbaties, ernstige exacerbaties en 
overlijden bij COPD-patiënten met een verhoogd CRP niveau die behandeld werden 
met corticosteroïden. Deze groep patiënten werd vergeleken met COPD-patiënten 
zonder verhoogd CRP-niveau, die daarnaast nooit behandeld zijn met 
corticosteroïden. In dit onderzoek werd geen verlaagd risico gevonden voor 
gematigde en/of ernstige exacerbaties bij COPD-patiënten met een verhoogd CRP-
niveau die behandeld werden met corticosteroïden. Daarentegen vonden we wel een 
verhoogd risico op overlijden bij patiënten met een verhoogd CRP-niveau 
onafhankelijk van de blootstelling aan corticosteroïden. Binnen de literatuur is nog 
maar weinig aandacht besteed aan de mogelijke rol die CRP kan vervullen binnen de 
behandeling van gematigde – ernstige en ernstige exacerbaties. Een verlaging van 
het CRP-niveau als gevolg van een behandeling met corticosteroïden bij COPD-
patiënten hoeft niet direct te leiden tot verlaagd risico op het hebben van een 
exacerbatie. Dit wordt ondersteund door het feit dat er bij een significant aantal COPD 
patiënten sprake is van een normaal CRP-niveau gedurende een exacerbatie. De 
heterogeniteit wat betreft de mate van systemische ontsteking is reeds erkend bij 
patiënten met COPD. Dit omvat ook de hoge mate van heterogeniteit in CRP-niveau 
in het serum en andere biomarkers. Deze heterogeniteit wordt grotendeels toegedicht 
aan gastheer- of aandoening-specifieke factoren.  
Gezien de ziektelast en de hoge kosten die gepaard gaan met COPD 
exacerbaties, was het van essentieel belang om de trends in exacerbaties bij COPD 
patiënten over de tijd te begrijpen. In hoofdstuk 2 hebben we daarom de incidentie 
van gematigde en ernstige COPD exacerbaties onderzocht gespecificeerd voor 
leeftijd en geslacht binnen de eerste lijns zorg in het Verenigd Koninkrijk (UK). Hoewel 
reeds verschillende studies hebben gekeken naar de incidentie en prevalentie van 
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COPD als aandoening, hebben weinig studies zich gericht op de trend van 
exacerbaties bij COPD-patiënten. We vonden een significante toename in de 
incidentie van 2005 tot 2013 voor het primaire eindpunt; elk type exacerbatie. Voor 
ernstige exacerbaties nam de incidentie van 2008 tot 2013 toe. Vrouwen hadden een 
hogere incidentie voor elk type exacerbatie in vergelijking met mannen gedurende de 
gehele studieperiode maar de incidentie van ernstige exacerbaties was vergelijkbaar 
tussen mannen en vrouwen van 2005 tot 2013. De incidentie van elk type exacerbatie 
was ook hoger in patiënten ouder dan 80 jaar van 2005 tot 2008, na 2008 was deze 
trend niet langer zichtbaar. In deze studie werd ook geen objectieve reductie gezien 
van het aantal exacerbaties. Als aanvulling op de factoren die eerder al genoemd zijn, 
kunnen een lage therapietrouw, en een onjuiste inhalatietechniek bij COPD-patiënten 
mogelijk hebben bijgedragen aan onze bevindingen. Evenzo, variaties in de incidentie 
van COPD-exacerbaties lijken de incidentie van influenza A in de UK te volgen, wat 
suggereert dat dit ook mogelijk een impact heeft op onze resultaten.  
De relatie tussen een langdurige blootstelling aan een systemische behandeling met 
corticosteroïden en het risico op een fractuur zijn reeds uitgebreid beschreven. In 
hoofdstuk 7 hebben wij gekeken naar  het effect van een periodieke behandeling 
met een hoge dosering glucocorticosteroïde op het fractuurrisico bij COPD-patiënten. 
Daarnaast is ook gekeken naar de impact van de ziektelast (op basis van afgeleide 
parameters) en het effect van de dosis. Gebruik makend van een groot COPD-cohort 
vonden wij dat blootstelling aan een periodieke behandeling met een hoge dosering 
glucocorticosteroïde niet geassocieerd is met een verhoogd risico op elk type fractuur, 
een fractuur vanwege osteoporose, een heupfractuur, of een klinisch symptomatisch 
wervelfractuur bij COPD patiënten, wanneer deze vergeleken worden met patiënten 
zonder COPD. Daarnaast vonden we dat afgeleide parameters voor de ziektelast 
(ziekenhuisopnames en bezoeken aan de spoedeisende hulp vanwege COPD in het 
laatste jaar) geassocieerd waren met een verhoogd risico op elk type fractuur, een 
fractuur vanwege osteoporose, een heupfractuur, of een klinisch symptomatisch 
wervelfractuur in COPD patiënten wanneer deze vergeleken werden met patiënten 
zonder COPD.  
 
Conclusie 
In hoofdstuk 8 worden de klinische implicaties en het toekomstperspectief op basis 
van dit proefschrift voor onderzoekers en artsen besproken. COPD is een heterogene 
aandoening en biomarkers spelen een belangrijke rol binnen het ziekteproces. Het 
exacte mechanisme waardoor inhalatiecorticosteroïden de kans op een exacerbatie 
verlagen bij patiënten met een verhoogd aantal bloed eosinofielen blijft onduidelijk. 
Echter, op basis van de resultaten gepresenteerd in dit proefschrift concluderen wij 
dat het noodzakelijk is om in de toekomst verder onderzoek te doen naar de rol van 
biomarkers binnen COPD om zo beter te kunnen begrijpen hoe deze ingezet kunnen 
worden binnen de behandeling van nieuwe COPD-patiënten, gelet op het feit dat het 
aantal exacerbaties toeneemt bij nieuwe COPD patiënte.
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Valorisation Addendum 
Valorisation is defined as the process of ensuring the knowledge gained from 
scientific learning and research available or useful for economic or societal utilisation, 
or translating it to competing products, services, processes, and new business.
1
 In 
this section, the societal relevance of this work will be discussed, alongside how this 
dissertation is currently impacting society. 
 
Health Problem 
Chronic obstructive pulmonary disease (COPD) is a common, preventable and 
treatable disease characterised by relentless respiratory symptoms and airflow 
limitation that is due to airway and/or alveolar aberrations usually triggered by 
significant exposure to noxious gases.
2 COPD is a leading cause of morbidity and 
mortality worldwide. Within non-communicable diseases, it was the third leading 
cause of disability-adjusted life years according to the Global Burden of Disease 
Study 2017,
3
 and it is projected to hold an equal position among the leading causes of 
death worldwide in 2030.
4,5
 Additionally, the disease is associated with tremendous 
social and economic impact.
6
 In the European Union, COPD accounts for 38.9 billion 
euros and 52.4 billion dollars in direct and indirect cost in the United States (U.S),
7,8
 
and places a very high burden on health systems.
2
 
The natural course of COPD is characterised by acute events, referred to as 
exacerbations, defined as the acute worsening of a patient’s condition beyond normal 
day-to-day variation in symptoms that requires additional pharmacotherapy.
2
 
Exacerbations of COPD have considerable impact on health status
9
, lung function.
10
 
and exercise capacity.
11
 Furthermore, exacerbations are associated with substantial 
mortality and economic impact. Nearly 60% of all cost of COPD is associated with 
severe acute exacerbations requiring hospital admission.
12
  
A biomarker is defined as a measure of any molecule or material, which 
could be either cells or tissues that reflect a disease process.
13
 The essential roles of 
biomarkers in health includes; enhancing disease diagnosis, monitoring of disease 
prognosis, and guiding therapy, with the aim of improving patient outcomes and 
reducing potential side effects of treatments.
13
 Over the past decade, there has been 
an increased interest in biomarkers such as C-reactive protein (CRP) and blood 
eosinophil counts in COPD.
14–16
 
 
Research Investigations 
In this dissertation, we investigated the long-term stability of blood eosinophils as a 
biomarker among patients with COPD using real-life data from general practice. In a 
detailed analysis, we assessed the stability of this biomarker by age, sex, smoking 
status, and baseline blood eosinophil counts among patients with COPD. In addition, 
we explored the role of blood eosinophil counts as a biomarker for guiding inhaled 
corticosteroids (ICS) therapy in COPD management. Furthermore, we studied the 
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trends of moderate-to-severe and severe exacerbations by age and sex. We also 
determined the potential of creatine reactive protein (CRP) as a biomarker to help 
guide ICS use in COPD management. We employed data from the UK general 
practice setting for most of the research presented in this thesis. We also evaluated 
the management of exacerbations with high-dose intermittent glucocorticoids (GCs) 
and the risk of fractures among COPD patients using data from the Danish 
population. 
 
Main findings 
In contrast to short-term studies, which tried to evaluate the stability of blood 
eosinophil counts among patients with COPD by assessing counts over short hospital 
visits spanning few weeks. In this thesis, we evaluated the long-term stability of blood 
eosinophil counts and the impact of age, sex, smoking status, and baseline eosinophil 
counts. Our study was the first and largest observational study to explore the long-
term stability of blood eosinophil counts among COPD patients. We found that blood 
eosinophil counts stability though lower in COPD patients compared to controls was 
relatively stable in COPD patients. We also showed that age and sex had a significant 
impact on the stability of blood eosinophil counts. Furthermore, we found that blood 
eosinophil counts did not serve as a clinically relevant guide for the initiation or 
withdrawal of ICS among newly diagnosed COPD patients. We also showed that CRP 
was not a reliable biomarker for targeting ICS therapy among COPD patients. 
However, we found an increased risk of all-cause mortality among patients with 
elevated CRP levels regardless of ICS exposure. Furthermore, in this thesis, we 
showed an increased incidence of moderate-to-severe exacerbations among COPD 
patients, especially among women, and this trend is increasing. Lastly, intermittent 
use of high-dose glucocorticoids was not associated with increased risk of fractures 
among COPD patients.  
 
Target population and perspective for future research 
This dissertation is of importance to general practitioners, especially those managing 
newly diagnosed COPD patients, pulmonologists, rheumatologists, respiratory 
researchers, policymakers, and other stakeholders. Short-term studies have tried to 
assess the stability of blood eosinophils as a biomarker in COPD management. 
However, for blood eosinophil counts to play a vital role in COPD management the 
long-term stability of this biomarker among large populations of COPD patients was 
needed to establish its potential. Our findings on the stability of blood eosinophil 
counts provided useful insight into the potential of this biomarker to help guide COPD 
treatment. The study was published in the American Journal of Respiratory and 
Critical care Medicine, and was incorporated into the 2019 Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) recommendations from the management of COPD, 
and played a pivotal role in the recommendations of blood eosinophils as a 
biomarkers in COPD management.
2
 This work has been of relevance to various 
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researchers investigating the role of blood eosinophil counts in COPD management in 
real-world settings and has been cited by numerous sources. 
Post-hoc analyses of data from randomised controlled trials (RCTs) reported 
reduced risk of exacerbations among COPD patients, with elevated blood eosinophil 
counts treated with ICS. While this might be true among patients with advanced 
disease and history of prior exacerbations as reported by post-hoc analyses of RCTs, 
we found no reduced risk of moderate-to-severe or severe exacerbations among 
newly diagnosed COPD patients exposed to ICS. Additionally, we did not observe an 
increased risk of moderate-to-severe exacerbations or severe exacerbations following 
the withdrawal of ICS among newly diagnosed COPD patients with elevated blood 
eosinophil counts. This finding is beneficial to clinicians managing newly diagnosed 
COPD patients in general practice. Future research should, therefore, focus on the 
potential of blood eosinophil as a guide to ICS therapy among newly diagnosed 
COPD patients.  
Only a few studies have assessed the long-term trends of moderate or 
severe exacerbations in general populations, but none has explored this trend among 
COPD patients in the United Kingdom (UK) general practice. Our findings on the 
trends of exacerbations are of importance as it could help target essential 
interventions and policies aimed at reducing the incidence of moderate or severe 
exacerbations especially, among female patients. Furthermore, oral glucocorticoids 
are additionally used in the management of exacerbations among COPD patients. We 
found no increased risk of fractures with exposure to high-dose intermittent GCs. Our 
findings are supported by a previous study, which employed similar definitions for 
intermittent GCs exposure in evaluating fractures risk among COPD patients in the 
general practice.
17
 Therefore, emphasis on prophylactic treatment of fractures by 
clinicians may not be essential in patients with COPD exposed to intermittent dose of 
GCs, whereas this should be considered for high-dose long-term users with advanced 
COPD disease, postmenopausal women, and men over 40 years. 
Furthermore, observational research focused on the potential of biomarkers 
in the personalised management of various diseases can benefit from the 
pharmacoepidemiological approaches employed in this dissertation. Particularly the 
novel approach used in the evaluation of the stability of blood eosinophil counts, 
adopting composite definitions for outcomes, the use of validated definitions for 
exposures and outcomes, time-dependent assessment of biomarkers and medication 
exposures. 
 In conclusion, this thesis provides essential real-life evidence on the stability 
of blood eosinophil counts in large populations of COPD patients, and this finding has 
been incorporated into the 2019 GOLD recommendations. Additionally, it provides 
insights into blood eosinophil counts as a guide to ICS management of COPD 
exacerbations among newly diagnosed patients without prior history of exacerbations, 
ICS use or asthma, which serves as useful information for practitioners charged with 
the management of this group of COPD patients. We hope that the results from this 
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dissertation will help stimulate interventions and policies aimed at addressing the 
rising trend of exacerbations among COPD patients in the UK, especially among 
women. Lastly, clinicians can be confident in the use of high-dose intermittent GCs in 
the management of COPD patients with fewer concerns of any potential risk of 
fractures. 
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